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Abstract
For the most part, diagnostic clinical microbiology still relies on 19th
century ideas and techniques, particularly microscopy and laboratory
culture. In this thesis I investigate the utility of a new approach,
whole-genome sequencing (WGS), to tackle current issues in infectious
disease. I present four studies. The first demonstrates the utility of
WGS in a hospital outbreak of Acinetobacter baumannii. The second
study uses WGS to examine the evolution of drug resistance following
antibiotic treatment. I then explore the use of WGS prospectively dur-
ing an international outbreak of food-borne Escherichia coli infection,
which caused over 50 deaths. The final study compares the perfor-
mance of benchtop sequencers applied to the genome of this outbreak
strain and touches on the issue of whether WGS is ready for routine
use by clinical and public health laboratories. In conclusion, through
this programme of work, I provide ample evidence that whole-genome
sequencing of bacterial pathogens has great potential in clinical and
public health microbiology. However, a number of technical and logis-
tical challenges have yet to be addressed before such approaches can
become routine.
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Chapter 1
Critical review
1.1 Introduction
1.1.1 The first golden age of microbiology
“Progress in science depends upon new techniques, new discoveries
and new ideas, probably in that order.” – Sydney Brenner [1]
1.1.1.1 The microbial world
In the 1670s, when Antonie van Leeuwenhoek turned his home-made microscopes
on water samples and dental plaque, he found himself staring at the wonderful
and varied shapes of his “animalcules”, now classified as protists and bacteria
[2]. Wherever he looked, whether it was at urine or water, muscle tissue or
seminal fluid, he uncovered a microscopic biological world unimagined at this
time. His innovative use of the new technique of microscopy earned him the title
of “founding father of microbiology” [3]. However, the impact of his discoveries
on those dying of infectious diseases remained minimal for two hundred years.
1.1.1.2 Public health and vaccinology
In 1854, when John Snow removed the handle from a water pump on Broad Street,
London, he helped stop an outbreak of cholera, but without really understanding
its cause. Although there had been suggestions that microbes might cause dis-
1
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ease (by Fracastoro and Bassi, amongst others [4]), the generally accepted view
was that miasma, or bad air, was the cause of transmissable diseases. Snow’s
intervention was informed through his pioneering use of a modern-style epidemi-
ology study. He observed and carefully mappped clusters of cases of cholera in
households which drew their water from the Broad Street pump [5]. In remov-
ing the handle and ending the outbreak, he provided strong evidence that it
was water, not air transmitting the cholera. The very same year, Filippo Pacini,
after studying a large cholera outbreak in Padua published his findings of a water-
borne comma-shaped bacillus he called vibrio, identifying it both as the “specific”
cause of cholera as well as demonstrating that it was contagious. However, he
was ignored by the scientific community, with his contribution recognised only
posthumously [6].
1.1.1.3 The birth of medical microbiology
Hansen made the link between rod-shaped bodies in lepromatous nodules and
leprosy in 1873 but, like Pacini, received little initial support for his theory [7].
Instead, Robert Koch did most to popularise the germ theory of disease. Koch
made three major discoveries linking microbes to important human diseases: first,
the link between a sporulating bacillus and anthrax; second, that the tubercule
bacillus caused tuberculosis; and, third, he rediscovered a vibrio as the cause of
cholera, unaware of Pacini’s earlier work. Koch, working with Henle forged a
conceptual framework for evaluating the link between microbes and disease by
the formulation of a set of “postulates”, which could be used to assess whether
a particular agent caused a given disease. Koch, with fellow German Ferdinand
Cohn, also pioneered the growth of pure cultures of bacteria on solid media, a
line of work which eventually culminated in the present-day use of agar.
In parallel with Koch’s studies, Louis Pasteur took on the theory of sponta-
neous generation as an explanation of the origin of microbial life. Pasteur won a
competition sponsored by the French Academy of Sciences, aimed at proving or
disproving spontaneous generation with his elegantly effective flask experiment.
Sadly, space constraints do not permit a detailed description of Pasteur’s many
other major achievements, which include his heat-killing treatment (“pasteurisa-
2
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tion”) and the development of several vaccines effective against bacterial disease,
including chicken cholera.
Pasteur and Koch remain the fathers of medical microbiology, with ideas
that continue to influence and inform modern microbiology. At the turn of the
19th century, microbiologists, armed with microscopy, Koch’s postulates and pure
culture techniques entered the “first golden age of microbiology” [8]. Perkins
remarked that “discovery of the principles... resulted in such a sudden burst
of investigation that it was a lost month in which a new organism was not de-
scribed, catalogued, and laid away”. An astonishing flurry of discoveries followed,
in which the causes of most significant bacterial diseases were determined within
a twenty-year period [8]. These discoveries included Theodor Escherich’s discov-
ery of Bacillus coli, now named Escherichia coli and Frankel’s discovery of the
pneumococcus, subsequently classified as Streptococcus pneumoniae.
Concepts
Bacterial physiology
Methods for cultivation and observation of bacteria
Isolation of bacteria in pure culture
Bacterial nutrition
Bacterial classification based on phenotypes
Medical microbiology
Germ theory of disease
Viruses
Applications
Clinical identification of microbes
Antimicrobial chemotherapy
Vaccines
Industrial fermentation
Table 1.1: The first golden age of microbiology (adapted from Moloy [8])
1.1.1.4 Bacterial classification
Humans have a fundamental desire to classify things. Bacterial classification
rapidly became an obsession for the first generations of medical and environmental
microbiologists, aided by an ever-growing battery of tests and features, including
morphological characteristics, growth under different conditions and ability to
3
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degrade particular substances (Table 1.2).
In 1872, Ferdinand Cohn proposed a basic taxonomy of microbial life based on
morphological criteria, dividing microorganisms into four “tribes” and six genera
(Micrococcus, Bacterium, Bacillus, Vibrio, Spirillum and Spirochaeta) [9].
In medical microbiology, discriminatory tests which could distinguish pathogenic
strains from harmless ones were highly valued, but this led to what would later
be seen as highly unnatural classifications, often based on a single feature. Tests
such as Methyl Red were used to differentiate members of the Enterobacteriaceae,
e.g. E. coli from Enterobacter. Urea hydrolysis was used to discriminate between
E. coli and Proteus in urinary tract infections. The most important test was
Gram’s staining method, which we now know divides organisms based on the
presence of peptidoglycan content in bacterial cell walls [10]. The Gram stain is
often used as the first stage of identification using dichotomous keys, a decision
flow-chart method which follows a series of Boolean (yes/no) choices leading to
a confident identification at the last stage. These keys were, and still are, used
extensively in medical microbiology [11]. These early painstaking efforts on the
classification of bacteria culminated in the first edition of Bergey’s Manual [12],
published in 1923.
1.1.1.5 Numerical taxonomy
By the 1960s, the sheer number of observable phenotypes led Robert Sokal and
Peter Sneath to propose a system of what they called “numerical taxonomy” [13].
This system, based on methods pioneered by Michel Adanson in the early 19th
century, tabulated the results of tests, or “features”, against bacterial isolates.
The method had several innovative elements. One was that each feature should be
considered with equal weight (with care taken not to introduce redundant tests).
Importantly, classification of isolates based on the feature table could be carried
out by computational methods, allowing the system to be used on large numbers
of specimens. Clustering algorithms, such as the neighbour-joining method were
applied to the data. By setting appropriate similarity cut-offs, this system gave
backwards compatibility with the existing taxonomy and provided a frame-work
for new biological insights. Sneath was prescient in predicting that features may
4
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Name Method
Microscopic morphology Cell shape, size, colour
Macroscopic morphology Appearance of colonies
Staining Examples: Gram’s method, Acid-fast reac-
tion
Biochemical assay Catalase/oxidase, sugar fermentation
Analytical Profile Index (API) Commercialised, miniaturised test panels.
Phenotypic reactions case colour change. Re-
sulting pattern looked up in reference book.
Vitek-2 (bioMe´rieux) Plastic card with panel of biochemical tests
Enzyme-linked immunosorbent assay
(ELISA)
Solid-phase enzyme immunoassay
Table 1.2: Tests for identification of bacteria in clinical microbiology
be sourced in the future from molecular data, stating “it may be possible in the
future to re-define it in terms of genes and perhaps nucleotides; this will not effect
the basic concepts of Adansonian methods but may simplify them.” [14]
1.1.2 The second golden age of microbiology
1.1.2.1 Genetics and evolution
Darwin corresponded with Cohn and knew of the work of Pasteur. However, his
theory of evolution had little impact on microbiological thinking for most of the
19th and 20th centuries. The idea that all life, including bacteria were descended
from a common ancestor gained little traction in a medically-dominated anthro-
pocentric viewpoint, in which bacterial species were regarded as fixed entities,
often with the sole purpose of causing disease of humans [15].
In the mid-20th century, the “modern synthesis” of evolution and genetics
brought together ideas from Mendel and Darwin, resulting in a conceptual frame-
work for understanding and testing evolutionary theory in terms of genes. Theo-
dosius Dobzhansky placed Darwin’s ideas in the language of genetics, defining
evolution as “a change in the frequency of an allele within a gene pool” and
later famously stating that “nothing in biology makes sense except in the light of
evolution” [16].
5
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1.1.2.2 Molecular biology
Experimental microbiology had a key role in the birth of molecular biology. De-
oxyribonucleic acid (DNA) was isolated for the first time by Miescher in 1868
from surgical pus. The identification of DNA as the hereditary substance was
due to two key experiments. First, Griffith showed that the S. pneumoniae could
be transformed from a rough to a smooth phenotype by the addition of killed
cells of smooth phenotype [17]. After exhaustively purifying nucleic acid from
the killed cells, Avery subsequently showed it was only this molecule which could
cause transformation [18]. A failed attempt by the prolific Linus Pauling to deter-
mine the structure of DNA preceded Watson and Crick’s double helix structure,
which demonstrated elegantly the chemical basis of DNA replication [19].
Following this discovery, many crucial secrets of life were uncovered: one was
Crick’s “central dogma”–“DNA makes RNA makes protein”, with the flow of
genetic information in one direction. The genetic code was revealed to be a triple
nucleotide system and after much trial-and-error, Nirenberg and Gamow’s “RNA
tie club” assigned an amino acid or function to each of the possible 64 codons.
The most visible product of the second golden age of microbiology was the de-
velopment of molecular cloning, harnessing bacterial gene expression and protein
synthesis to the needs of biotechnology. The discovery of restriction endonucle-
ases, able to cut DNA at specific sequences, twinned with the ability to join
fragments with DNA ligase meant that recombinant DNA molecules could be
created within plasmid vectors and then transformed into E. coli [20–24].
1.1.2.3 Sequencing
Fred Sanger earned his first Nobel Prize in Chemistry for determining the amino
acid sequence of insulin. The first genome to be sequenced was from the RNA
virus bacteriophage MS2 in 1976 [25]. Soon afterwards, three methods of DNA
sequencing were invented in quick succession; Maxam and Gilbert’s method
[26], Sanger and Coulson’s “plus-minus” method [27] and the chain-termination
method now commonly referred to as “Sanger sequencing” [28]. Sanger sequenc-
ing employs a chain termination method using di-deoxynucleotide triphosphates
(ddNTPs), which prevent extension of nascent chains of DNA. By carrying out
6
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Concepts
Bacterial genetics
DNA as genetic material and its structure
Genetic code
Mechanism of gene expression
Regulation of gene expression
Transposons
Bacterial physiology
Membrane transport and electrochemical gradients
Cellular immunology
Applications
Genetic engineering
Nucleic acid and protein sequencing
Microbial classification based upon genotypes
Monoclonal antibodies
Table 1.3: The second golden age of microbiology (adapted from [8])
four separate reactions, each with only one of the four ddNTPs added, and run-
ning the products on a polyacrylamide gel, the sequence of bases can be read.
Sanger’s method used radio-labelling for detection, but now tagging with a fluo-
rescent dye is most commonly used. Plus-minus sequencing was used to sequence
the genome of the DNA phage φX174. However, the chain-termination method
soon proved the quickest and easiest of the three methods and permitted the
sequencing of several landmark genomes – the entire chromosome of human mi-
tochondrial DNA (16.6 kilobase pairs) and bacteriophage λ (49 kb).
1.1.2.4 Molecules as documents of evolutionary history
Comparisons between nucleotide or amino acid sequences of homologous molecules
(those sharing a common ancestor) remains the cornerstone of molecular phylo-
genetics, an approach which has breathed fresh life into Darwin’s idea of common
descent. Before DNA or even peptide sequences became readily available, Zuck-
erkandl and Pauling proposed that the information locked in these molecules
would enable the construction of molecular phylogenies, derived from compar-
isons of homologous sequences from different species [29]. They realised, given
that the genetic code was degenerate (more than one codons often coding for the
7
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same amino acid), that “isosemantic changes” mean that nucleotide sequences
have a higher information content than protein sequences and thus proves a bet-
ter source of phylogenetic information. Furthermore, they speculated that it
might be possible to partition sequence changes into those that had undergone
selection and those that had not.
The Luria and Delbru¨ck experiment showed that mutations arose in the ab-
sence of selection, rather than as a response to selection [30]. Kimura subsequently
proposed that the majority of nucleotide changes were neutral, occurring through
genetic drift and that only a few were fixed by positive selection. This suggested
the existence of a “molecular clock” permitting measurement of evolutionary dis-
tances simply by counting the number of mutations seen between pairs of species.
Clustering algorithms from numerical taxonomy, such as neighbour-joining meth-
ods [31], permitted the phylogenetic reconstruction of evolutionary history in the
form of phylogenetic trees.
Woese showed the ultimate power of these new methods by analysing se-
quences from the small ribosomal DNA subunit, universal in both bacteria and
eukaryotes. Woese made a remarkable discovery; by analysing ribonuclease diges-
tion patterns from 16S rDNA, he found that certain prokaryotes were actually as
closely related to eukaryotes as they were to bacteria. These outliers were often
“extremophiles”, able to withstand extremes of heat, pH or salinity, suggesting
they may have been amongst the earliest forms of life. Woese therefore named
them the “archaebacteria” (now called “archaea”) and proposed that they made
up one of three divisions, along with with bacteria and eukaryotes, in a universal
tree of life [32–34].
Molecular studies have shown that the classical bacterial taxonomy is often
in conflict with phylogenetic data. An example is the taxonomic classification of
E. coli and Shigella. In medical classifications, shigellosis is always caused by the
Shiga-toxin producing Shigella and is distinct from enterohaemorrhagic disease
caused by E. coli O157:H7 (classical EHEC). Molecular phylogenetic analysis has
revealed that in fact Shigella is a member of the B2 phylogroup of E. coli [35,
36], making it more closely related to certain E. coli strains than some other E.
coli are from each other. Therefore, in terms of molecular taxonomy Shigella is
an E. coli (or E. coli are Shigellae). There are examples in other genera, such as
8
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Streptococcus and Neisseria where such extensive recombination has occurred to
make species boundaries blurred or even meaningless.
1.1.3 Bacterial genomics
The publication of the complete genome sequence of Haemophilus influenzae in
1995 ushered in the era of bacterial genomics [37]. The 1.83-megabase chromo-
some was sequenced at an estimated cost of $0.48 per finished base-pair, giving
a total cost of around $900,000 [38].
The process of whole-genome shotgun sequencing pioneered in this study be-
gan with the shearing of genomic DNA into short fragments. These fragments
were then cloned into plasmid vectors and expressed in E. coli to amplify them.
This “clone library” was grown on a solid medium, with individual colonies picked
for sequencing on capillary sequencing machines, which automate the Sanger se-
quencing method. This method proved highly successful and became the stan-
dard method for sequencing bacterial genomes and was later was used to sequence
larger genomes of model organisms: yeast, fruit fly and Homo sapiens [39–41].
By 2000, whole-genome sequencing had yielded complete, published sequences
for over two dozen biologically and medically important microbial species includ-
ing Helicobacter pylori, E. coli K-12, M. tuberculosis and Bacillus subtilis [42].
Technological and logistical innovations such as library construction using robots,
sequencing instruments with increased capacities and the scaling up of workflows
in large sequencing centres, such as the Sanger Centre and the Institute for Ge-
nomic Research (TIGR), meant that, by 2005, at least one complete genome
sequence was available for most bacterial species or pathovars associated with
human disease. The availability of multiple strains of the same species led to
the first comparative genomics projects, which included a comparison between
two strains of H. pylori [43] and pair-wise whole-genome comparisons between
M. tuberculosis H37Rv, a commonly-used laboratory strain and the “Oshkosh”
outbreak strain CDC-1551 [44].
An early “translational” (from the laboratory to the clinic) use of genome
sequencing was “reverse vaccinology”: an approach to the discovery of vaccine
targets that relies on screening whole-genome sequences for potential protective
9
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antigens which are then followed up experimentally [45, 46]. This approach has
recently culminated in the creation of an effective vaccine against the meningo-
coccus [47].
1.1.3.1 Bacterial genome dynamics
If genes provide documents of evolutionary history, bacterial genome sequences
provide phylogenetic encyclopedias. When compared to related strains, genome
sequences often reflect changes in lifestyle or adaptations to particular niches.
A notable finding from comparative genomics studies are examples of extreme
genome reduction. For example, species of Buchnera, phylogenetically closely
related to E. coli, have genomes a fraction of its size [48, 49], having shed many
cellular functions on adopting the endosymbiotic lifestyle. Similarly Mycobac-
terium leprae diverged from the M. tuberculosis complex 36-66 million years ago
[50, 51]. Since then, it has lost over half of its protein-coding potential through
mutations which render genes non-functional, a process termed pseudogenisation,
accompanied by a reduction in genome size and a narrowing of its niche and host
range: M. leprae can only grow in humans, the nine-banded armadillo and the
mouse footpad [52, 53]. Recently, a new leprosy-causing species, M. lepromatosis
was discovered: phylogenetic analysis suggests these two species diverged approx-
imately 10 million years ago [54, 55].
1.1.3.2 Bacterial clonality
Molecular typing methods and genome sequencing have shed light on the popu-
lation genetics of bacterial species. Spratt used the results of multi-locus enzyme
electrophoresis to estimate the rate of change within the genome of a bacterial
species [56]. He recognised that clonality might be disrupted by the action of
recombination to re-organise the genome or replace segments of the genome from
one lineage with those from another. Spratt determined that certain species
are highly monomorphic, for example certain pathovars of Salmonellae, M. lep-
rae, Y. pestis and B. anthracis [57]. Phylogenetic analysis of such important
human pathogens is complicated by the lack of variation; sequencing much less
than the whole-genome will not provide sufficient information for the purposes
10
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Monomorphic
Mycobacterium leprae
Mycobacterium tuberculosis
Salmonella enterica serovar Typhimurium
Bacillus anthracis
Yersinia pestis
Intermediate
Acinetobacter baumannii
Escherichia coli
Polymorphic
Streptococcus spp.
Neisseria spp.
Haemophilus influenzae
Table 1.4: Genetically monomorphic and polymorphic pathogens
of typing and epidemiology. These strains are in contrast to strains with high
genomic plasticity, where significant gene loss and gain as well as chromosomal
rearrangements are seen as a result of recombination. Notable examples are in
the -protobacteria such as Helicobacter and Campylobacter, Neisseriaceae and
Streptococcus (Table 1.4). The extent of recombination within -protobacteria
is so extreme that inter-species comparisons often reveal a total breakdown of
genome synteny (co-linearity along the chromosome) [61, 62].
1.1.4 Clinical microbiology in the 21st century
1.1.4.1 The practice of clinical microbiology
Today, clinical microbiology remains firmly rooted in 19th century techniques,
still relying on microscopy and culture to detect and identify potential pathogens.
Once obtained in pure culture, identification is made possible by a battery of
specific phenotypic assays. Antibiotic sensitivity is assayed by assessing growth
in the presence of antimicrobial agents. While the process of performing multiple
biochemical tests is faciliated by commercially available semi-automated systems
such as Analytical Profile Index (API) and Vitek-2, the principles of diagnostic
11
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microbiology have changed little in over a century.
1.1.4.2 The threat of antibiotic resistance
“It’s time to close the book on infectious diseases, declare the war
against pestilence won, and shift national resources to such chronic
problems as cancer and heart disease.” – William H. Stewart, US
Surgeon General
The number dying from infectious diseases has fallen steadily during the 20th
century [63]. This is largely due to sanitation, vaccination programmes and antibi-
otic therapies, as well as improved nutrition [64]. However, the Surgeon General
was wrong to think that the war against infection would be nearly over in 1970.
Infection is still a leading cause of death world-wide, with an estimated one-third
of the world’s population infected by tuberculosis [65].
For almost every class of clinically useful antibiotic, antibiotic-resistant strains
have been observed within a few years or at most decades after first clinical use
[66]. The emergence of antibiotic resistance in microbes poses a major threat to
our ability to treat infectious disease [67]. Numerous antibiotic-resistant “super-
bugs” have attracted attention, including meticillin-resistant Staphylococcus au-
reus (MRSA), vancomycin-resistant Enterococci and multidrug-resistant Pseu-
domonas aeruginosa. Space does not present a full description of these organisms.
Of particular concern is the emergence of multi-drug resistant Gram-negative bac-
teria including Acinetobacter baumannii, [68].
Antibiotic resistance can arise via a number of molecular mechanisms: muta-
tions affecting target sites of the drug (e.g. rpoB bypass mechanisms, mutations
conferring resistance to rifampicin in M. tuberculosis), antibiotic inactivating or
modification enzymes such as β-lactamases, changes in envelope permeability
and non-specific systems such as drug eﬄux pumps. Antibiotic-resistant de-
terminants are commonly found in plasmids which may be transferred between
species, these include extended-spectrum β-lactamases (ESBLs) and Klebsiella
pneumoniae carbapenemases (KPCs). The recent discovery of a novel metallo-
β-lactamase (NDM-1) which confers carbapenem resistance has been seen in as-
sociation with Klebsiella pneumoniae and E. coli infections [69]. This class is
12
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of particular cause for concern as carbapenems are used as “last-resort” options
against ESBL-producing strains [70]. A “post-antibiotic apocalypse” looms with
some infections potentially becoming resistant to all known antibiotics. Pan-drug
resistant strains of A. baumannii and eXtremely-drug resistant (XDR) and totally
drug-resistant strains of M. tuberculosis have been isolated from patients [71–73].
It is also of concern that there are currently very few antibiotic candidates in the
commercial drug-discovery pipeline [74].
1.1.4.3 Bacterial epidemiology and bacterial typing
The aim of bacterial typing is to distinguish between strains within the same
species. Some typing schemes work with a number of species, whereas some
may be designed for a particular species or subspecies. An ideal bacterial typing
scheme would have a number of desirable properties, including speed, low-cost,
portability (comparable between laboratories [75]) and reproducibility. However,
in the real world, we find a plethora of less-than-ideal schemes. In fact, so many
typing schemes have since been proposed that Mark Achtman once proposed the
term “YATM”‘ (Yet Another Typing Method) as a light-hearted response to the
number of such schemes being published in the Journal of Clinical Microbiology
[76].
Although often seen as an arcane adjunct to diagnostic microbiology, epi-
demiological typing can, if done quickly enough, have an impact on real-world
problems by revealing modes of spread of pathogens and informing choice of in-
tervention strategies (e.g. isolate and decontaminate infectious patients, more
thorough environmental cleaning, improved hand hygiene, better antibiotic stew-
ardship, removing of environmental source).
Many of the molecular typing methods listed in Table 1.5 target sites in the
genome with a high mutation rate, for example microsatellite repeats (VNTR)
and repetitive regions (rep-PCR). This gives the advantage of ready discrimi-
nation between clones and they have been used with much success in bacterial
epidemiology. However many of these methods, however discriminatory, do not
provide information useful for phylogenetic reconstructions, making relatedness
13
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Name Region of genome considered Method employed
Multilocus enzyme elec-
trophoresis (MLEE) [77]
Whole genome Gel electrophoresis
Multilocus VNTR analysis
(MLVA) [78]
Microsatellite/tandem re-
peats
analysis of PCR fragment
size
Multilocus sequence typing
(MLST) [75]
Conserved housekeeping
genes
PCR and sequencing
Pulse-field gel electrophore-
sis (PFGE) [79–81]
genome-wide restriction sites restriction digest and gel
electrophoresis
PCR/multiplex PCR [82] Specific genomic loci PCR and optional sequenc-
ing
rep-PCR [83] repetitive elements, outward
facing primers
PCR and gel electrophoresis
Table 1.5: Examples of molecular techniques for bacterial typing
between isolates with different profiles hard to assess [84]. Techniques such as
MLEE and PFGE, which rely on images produced by gel electrophoresis, are not
easily portable between laboratories.
Multilocus sequence typing (MLST) schemes rely on sequencing a number of
conserved “house-keeping” genes to generate a profile. Each unique sequence is
given an allele number via an on-line database. Each unique combination of alleles
gives a “sequence-type“ (ST). An appropriate set of genes must be identified for
each species under consideration. The success of this scheme relies on choosing
genes that are found in all members of the species and evenly spaced around
the chromosome. Those wishing to share MLST data therefore must agree on
a suitable scheme and use the same set of primers. Multiple schemes may exist
for the same species, there are three competing primer sets for E. coli and two
for A. baumannii, creating potential for confusion [85–87]. MLST has proven a
highly versatile approach, with schemes available for over fifty taxa. It has been
particularly useful in understanding the population structure of recombinogenic
species such as H. influenzae and the pathogenic Neisseria. However, MLST does
not work well for genetically monomorphic species such as M. tuberculosis, where
schemes such as MIRU-VNTR are more discriminatory [88, 89]. Additionally,
MLST schemes permit only a limited view of phylogenetic relatedness through
cluster analysis of single- or double-locus variants (profiles which differ by one or
two alleles and are assumed to be related).
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1.1.5 High-throughput sequencing
The era of high-throughput sequencing began with the release of 454 Life Science’s
GS20 instrument in 2005. Its successor, the GS FLX, was able to produce 200
megabases of sequence each run, enough to sequence several isolates of E. coli
for around $10,000 in sequencing reagents. In 2008, this technology was used to
sequence James Watson’s genome, taking just two months [90, 91] at less than
1% of the cost of the original $3bn human genome project. The first-generation
Solexa Genetic Analyzer produced a gigabase of sequence data when it debuted
in late 2006 [92, 93]. Since then, sequencing throughput has exhibited a hyper-
Moore’s law increase in throughput, with a reciprocal reduction in costs. As of
writing the highest-throughput instrument, the Illumina HiSeq 2500 looks set to
be soon able to generate a terabase (1000 gigabases) of sequence data per run.
There is no sign of this progress slowing. Table 1.6 summarises currently available
high-throughput instruments.
The first generation of high-throughput sequencing technologies differed from
traditional Sanger sequencing in a number of important ways. Firstly, amplifi-
cation of sample relied on the production of “molecular colonies” of clonal DNA
template, without the need for cloning into a biological vector and subsequent
expression in E. coli. These colonies are amplified on beads (454, Ion Torrent)
or on a solid-surface (Solexa) and are sequenced in a massively-parallel fashion,
between a million and a thousand million at a time, depending on the instrument.
The process of reading nucleotides may be light-based: laser-excitation of fluo-
rescently labelled nucleotides (Solexa) or release of photons through the action
of luciferase during nucleotide incorporation (454). The Ion Torrent instrument
relies on the detection of protons released during nucleotide incorporation. This
takes place on a modified silicon chip functioning as a massively-parallel pH me-
ter. Space does not provide a fuller description of the technologies but Metzker
provides a comprehensive snapshot of the situation in 2009 [94].
1.1.5.1 Bioinformatics analysis of high-throughput sequencing data
Analysis of molecular sequence data relies on the process of alignment between
pairs of sequences. High-scoring alignments suggest the presence of homology and
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Technology Year Amplification method Sequencing method Ref
454 (Roche) 2005 Emulsion PCR on beads SBS (flow), fluorescence
detection
[90]
Solexa (Illumina) 2006 Bridge amplification on
solid surface
SBS (reversible block-
ing)
[93]
SOLiD (Life Technolo-
gies)
2008 Emulsion PCR on beads Sequencing by oligonu-
cleotide ligation and de-
tection
[95]
Helicos 2009 Amplification-free Single molecule fluores-
cent sequencing
[96]
Pacific Biosciences 2010 Amplification-free Monitoring of individ-
ual DNA polymerase
molecules in zero-mode
waveguide detectors
[97]
Ion Torrent (Life Tech-
nologies)
2011 Emulsion PCR on beads SBS (flow), detection of
H+ ions on silicon chip
[98]
Table 1.6: High-throughput sequencing platforms and their year of introduction.
SBS: sequencing-by-synthesis.
permit calculation of sequence similarity to be made. The Smith-Waterman and
Needleman-Wunsch methods are well-established as “gold-standard” algorithms
for global and local alignments respectively [99, 100]. However, when faced with
the challenge of aligning millions of reads produced by high-throughput sequenc-
ing instruments to a reference genome, these algorithms were found to be too
computationally expensive to be of practical use [101]. New aligners, optimised
for high-throughput sequencing experiments have been designed for large num-
bers of short reads.
One of the first short-read aligners was Heng Li’s MAQ [102] which was ex-
tremely fast, but had drawbacks, particularly an inability to align individual reads
across insertions or deletions (“indels”). The BWA and Bowtie short-read align-
ers subsequently gained popularity due to their speed, thanks to an optimised
indexing technique called the Burrows-Wheeler transform [103]. Many of the
original algorithms traded sensitivity for speed, to the extent where alignments
were often unreliable. Improvements such as BWA-SW, SSAHA2 and Novoalign
incorporated a fast “seed” step coupled with the slower, more accurate Smith-
Waterman or Needleman-Wunsch algorithms to generate more reliable output
[104, 105]. There is now such a variety of short-read aligners that, echoing Acht-
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man’s YATM, a recently published alignment program was named YOABS (Yet
Other Aligner of Biological Sequences) [106]!
Short-read aligners are deployed in re-sequencing projects, where a high-
quality reference sequence serves as template. When no reference is available,
or when an unbiased method is needed, genome assembly software can be used
to attempt to reconstruct genome sequences de novo. Initially, de novo assem-
bly with reads as short as 20-30 bases was thought to be impossible, as existing
methods, such as the overlap-layout-consensus algorithm, which worked with long
capillary reads and also with 454 sequencing data, did not work for short-read se-
quencing data. However, development of new assembly methods permitted useful
assemblies to be generated from these data, albeit with large numbers of sequence
“gaps”, where repetitive sequences were encountered [107]. The most successful
de novo assembly software now work by constructing de Bruijn graphs of over-
lapping k -mers (short sequence words). Examples of commonly used software
packages include Velvet, SOAPdenovo and ABYSS [108–110].
Once whole-genome assemblies have been generated, “downstream” analysis
often involves annotation of sequences. Typically this involves an initial stage,
where coding sequences are predicted (using software such as Glimmer or GEN-
EMARK, or through homology searches using BLAST [111–113]) and detection
of stable RNA species (tRNAScan-SE, RNAmmer [114, 115]). Subsequently cod-
ing sequences are assigned a tentative function through homology searches of
existing annotation databases, such as the National Center for Biotechnology In-
formation’s non-redundant protein database [116]. This process can be performed
by automated annotation pipelines such as this author’s xBASE-NG [117].
Once annotated, whole-genome assemblies can be viewed through software
such as Artemis, or compared to another genome using Artemis Comparison Tool.
Multiple whole-genome aligners can build an alignment from many genomes.
These alignments can then be used to build whole-genome phylogenies, or to
analyse the core and pan-genome of a species.
The choice of whether to analyse data through a re-sequencing approach or
de novo depends on a number of factors listed in Table 1.7.
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Resequencing approach
Closely-related reference genome available
Detection of single nucleotide polymorphisms (SNPs) Detection of small
indels
Detection of sequence absent from the newly-sequenced strain
de novo assembly approach
No reference sequence or divergent reference sequence
Detection of novel genes or sequence in the newly-sequenced strain
Detection of large-scale genomic rearrangements
Table 1.7: Factors determining choice of sequencing analysis
1.1.5.2 Genomic epidemiology
Whole-genome sequencing has been rapidly adopted as a research tool for molec-
ular evolution studies (Table 1.8).
18
19
Scale Organism Notes Ref
Worldwide S. aureus (ST239) WGS of a historical strain collection demonstrated evolution
of this drug-resistant sequence type over four decades. Also
demonstrated fine-grained discrimination of isolates from differ-
ent wards of a Thai hospital.
[118]
S. pneumoniae (PMEN-1) WGS identified multiple separate events leading to antibiotic
resistance.
[119]
M. leprae Confirmed monomorphic nature of leprosy pathogen and demon-
strated association of SNPs with early human migrations and
trade routes.
[120]
C. difficile WGS of diverse clostridial strains reveals a complex population
structure.
[121, 122]
V. cholerae WGS of isolates from the Haiti epidemic suggest cholera was
imported during the emergency aid response; three waves of
cholera in seventh pandemic.
[123, 124]
Nationwide S. pyogenes Investigated three epidemics in Ontario, Canada; identified
clonal cluster of invasive infections in San Francisco
[125, 126]
L. monocytogenes Demonstrated three distinct strains were involved in nationwide
outbreak of listeriosis food poisoning.
[127]
Salmonella enterica serovar Montevideo Forensic whole-genome analysis helped trace the origin of an
outbreak of food-poisoning. WGS of strains in contaminated
food were phylogenetically closely related to those found in a
meat processing factory in New England.
[128]
B. anthracis Amerithrax investigation helped link anthrax spores sent in the
US postal system to a government researcher. Due to the
monomorphic nature of this pathogen, forensic investigations
relied on presence of low-frequency colonial morphotypes in the
samples.
[129]
S. pneumoniae Genome sequencing demonstrated five instances of vaccine es-
cape recombination in serotype 19A strains.
[130]
Community M. tuberculosis Network-based analysis of putative transmission events during
an outbreak of tuberculosis in Canada.
[128]
Table 1.8: Notable studies in bacterial whole-genome epidemiology
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The use of sequencing in genomic epidemiology was pioneered on viruses.
One high-profile example of using phylogenetic recontructions in tracing human-
to-human spread of a pathogen was an investigation of patients who contracted
HIV without obvious risk factors. Epidemiological analysis revealed they had
the same dentist. The dentist, who was infected by HIV was implicated as the
likely source. Sequencing of gp120 and phylogenetic analysis suggested that the
virus from the dentist were closely related to the viruses of infected patients [131].
In bacteria, whole-genome sequencing was used to great effect to show that the
culture of Bacillus anthracis, sent in the US mail to prominent senators and
journalists, belonged to a common laboratory strain, the Ames strain. Whole-
genome sequencing, rather than conventional molecular typing was required in
this case due to the highly genetically monomorphic nature of this pathogen [129].
1.2 Present work
1.2.1 Aim of the studies
I present five studies, which explore the potential of high-throughput sequencing
in clinical microbiology. These studies spring from several vantage points:
• from an infection control standpoint, looking at transmission chains in a
hospital outbreak.
• from the viewpoint of a clinical microbiologist, looking at the impact of
antimicrobial therapy on bacteria in a single patient.
• from a pubic health perspective, looking at a colonisation and infection
within a local human population.
• from an international perspective during a sudden, serious, large outbreak.
• from the perspective of microbiology laboratory staff faced with a choice of
novel technologies and instruments.
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1.2.1.1 High-throughput whole-genome sequencing to dissect the epi-
demiology of Acinetobacter baumannii isolates from a hospi-
tal outbreak
In this study, we investigated a 2008 outbreak of A. baumannii in Selly Oak
Hospital in Birmingham. All outbreak isolates processed by the clinical microbi-
ology laboratory had been determined to be clonal through conventional typing
techniques. The outbreak was significant because there was a suspicion of trans-
mission from military to civilian patients. Military patients had previously been
found to be frequently colonised or infected with A. baumannii [132]. We explored
in general terms whether whole-genome sequencing could aid our understanding
of the outbreak. The series of specific overlapping questions were addressed in
this study:
1. Can whole-genome sequencing be used for bacterial typing?
2. Is there variation between isolates within a small outbreak and can this
variation be detected reliably?
3. Can the high resolution offered by whole-genome sequencing be used for
fine-grained epidemiological typing within short timescales (days, weeks or
months).
4. Can such information be used to resolve alternative infection control hy-
potheses, for example by shedding light on chains of transmission?
5. What are the limitations of this method?
1.2.1.2 Whole-genome comparison of two Acinetobacter baumannii
isolates from a single patient, where resistance developed dur-
ing tigecycline therapy
Following an abdominal procedure, a patient was found to have A. baumannii
in surgical drain fluid, resistant to most antibiotics. Following a course of tige-
cycline chemotherapy A. baumannii was isolated a second time, now resistant
to tigecycline but with increased susceptibility to other antibiotics. The specific
questions asked in this study are:
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1. How do strains evolve during infection of a single patient and during an-
tibiotic treatment?
2. Can whole-genome sequencing provide testable hypotheses as to mecha-
nisms of antibiotic resistance in a case of treatment failure?
1.2.1.3 Open-Source Genomic Analysis of Shiga-Toxin Producing E.
coli O104:H4
During the spring and summer of 2011, a large outbreak of E. coli food poi-
soning occurred in Germany, causing >4000 infections and ≥40 deaths. Work-
ing prospectively, we combined whole-genome sequencing of the strain and dis-
tributed “crowd-sourced” analysis to understand the evolutionary origins and
pathogen biology of this strain.
1. What is the evolutionary origin of the German E. coli O104:H4 outbreak
strain?
2. How does this strain differ from classical enterohaemorrhagic E. coli (EHEC)?
3. What genetic factors might be responsible for the high levels of mortality
in this outbreak?
4. How can whole-genome sequencing be used prospectively during an inter-
national outbreak?
5. What advantages does the open-endedness of genome sequencing offer?
Limtations of this approach?
6. Crowd-sourcing and prospects for future outbreaks
1.2.1.4 Performance comparison of benchtop high-throughput sequenc-
ing platforms
In the previous study, the ability to sequence genomes during an outbreak was
made possible by new technologies; Ion Torrent PGM, 454 GS Junior and Illu-
mina MiSeq, all examples of low-cost benchtop sequencers. These instruments
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are characterised by a much shorter running time and lower cost than the previ-
ous generation of high-throughput sequencers. We wished to determine whether
these instruments were fit-for-purpose for use in future outbreaks and if there
were remaining challenges needed to be addressed before high-throughput se-
quencing could become a routine assay in microbiology. Our specific aims were
to determine:
1. How do the current benchtop sequencing platforms compare for the purpose
of epidemiology and evolution studies in bacteria?
2. What are the limitations in analysing draft genome sequence data?
3. What are the practical limitations of current whole-genome sequencing plat-
forms for genomic epidemiology and evolution?
1.3 Results and discussion
1.3.1 Paper I
1.3.1.1 Can whole-genome sequencing be used for bacterial typing?
Is there variation between isolates within a small outbreak
and can this variation be detected reliably? Can the high
resolution offered by whole-genome sequencing be used for
fine-grained epidemiological typing within short timescales?
(days, weeks or months)
In this study we demonstrate that whole-genome sequencing of isolates, indis-
tinguishable by routine typing methods such as VNTR and PFGE, can both
recapitulate existing typing methods, and detect additional variation as SNPs.
Phylogenetic comparisons with other sequenced strains showed that i) the out-
break strains were very closely related and sometimes there was no detectable
variation between them, ii) belonged to the European Clone I lineage and iii) had
many thousands of SNPs which distinguished them from other, unrelated strains.
The degree of variation we saw was low, with differences between outbreak
strains found at only three loci.
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A notable feature of our approach is the use of de novo assembly of a pooled
outbreak strain, followed by mapping alignments of each isolate against the as-
sembly. This contrasts to the approach used in most other genomic epidemiology
studies which utilise a re-sequencing approach. This was not appropriate in our
case because there was no closely-related reference strain available. It was no-
table that this approach generated a large number of likely false positive SNP
and indel calls, as evidenced by the inspection of the mapping alignment, particu-
larly associated with homopolymeric tracts, contig ends and repetitive regions. A
highly stringent SNP filtering technique, adapted from Holt et al [133], was used
in order to reduce false positives. This stringent filtering resulted in a Sanger se-
quencing validation rate of 100%. This gives confidence that the 454 sequencing
method used, in conjunction with strict SNP filtering, is resilient enough to be
used without additional validation methods in future studies.
1.3.1.2 Can such information be used to resolve alternative infection
control hypotheses, for example by shedding light on chains
of transmission?
The intention was that, should sufficient phylogenetic signal be detected, a tree
could be constructed from the available SNPs. The preference is to use synony-
mous nucleotide substitutions in coding regions, which are more likely to serve
as neutral markers of evolution to do this.
However, in this study we detected only three SNPs and only one was syn-
onymous. In such circumstances, reconstructing an accurate phylogenetic tree,
excluding homoplasy and recombination, is not possible. Therefore, the three
variants were used as a simple genotype (similar to those used in multiplexed
PCR typing systems, for example). In this case we need to make the simplifying
assumption that no homoplasy was present, and that each locus, once mutated
from the ancestral state (inferred by homology to an outlier strain) was unlikely
to revert back to this state.
Making these simplifying assumptions, the genotypes were useful in making
the case for particular chains of transmission being more parsimonious than oth-
ers. However, the evidence shown is circumstantial and can only be interpreted
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in the context of strong epidemiological information.
1.3.1.3 What are the limitations of this method?
Genome sequencing of bacterial isolates usually depends on culture to generate
sufficient DNA template, typically between 500 nanograms and 10 micrograms
depending on the instrument used. This additional culture step is potentially
an issue for genomic epidemiology studies that rely on detecting such a small
amount of variation. There are several potential problems. Firstly, sub-culture
in the laboratory may result in mutations, either neutral or selected for by growth
on a selective medium, which were not present in the original patient’s infection.
Secondly, not all bacterial cells in the pathogen population [in vivo] need be
identical. The patient may have a mixed infection, with two or more quite distinct
strain lineages at one or more sites; and even in a clonal population not all
genotypes need be the same, as shown by the Amerithrax investigation [129]
One answer to this problem is to pick multiple colonies from a plate and se-
quence each one separately. However, this will be expensive and may still miss
genotypes occurring at low frequency, as seen in the Amerithrax cultures. A
better solution may be to employ culture-independent methods such as whole-
genome shotgun metagenomics [134]. These methods permit sequencing in an
unbiased manner of all DNA present in a sample. These approaches currently
suffer from significant complexity in terms of data analysis and in clinical samples,
where human DNA outnumbers microbial DNA significantly, the costs of these
approaches are currently too high. Additionally, many samples will not have suf-
ficient volume of high-quality DNA required for sequencing. These samples could
be subjected to molecular amplification technique such as multiple displacement
amplification (MDA) using random hexamer primers [135, 136]. However, these
may introduce significant artefacts, including very uneven sequence coverage and
the generation of chimeric (hybrid) sequences, which can hamper analysis [137–
139].
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1.3.2 Paper II
1.3.2.1 How do strains evolve during infection of a single patient and
during antibiotic treatment?
In this second study, two isolates were retrieved from the same patient, one be-
fore and one after tigecycline therapy. Intriguingly, despite being conducted over
similar time-scales as the first study, many more sequence variants were discov-
ered, in the form of SNPs and large-scale genomic deletions. In this case, the
numbers of SNPs far exceeded either the predicted nucleotide substitution rate
for this genus, or the rate seen in our epidemiological study [140]. The likely
explanation is the observation that the gene for an important DNA-repair en-
zyme was disrupted in the second isolate. This gene, mutS encodes one half of
the two-component system, mutRS and is commonly associated with a hyper-
mutator phenotype in many species, including Acinetobacter bayli. This report
is the first to suggest that a hypermutator phenotype might be associated with
clinical infection in Acinetobacter baumannii ; this phenotype has subsequently
been confirmed experimentally (Hornsey, personal communication).
Disruption of the mutRS system is associated with an increased mutation fre-
quency, particularly of transitions (A⇔G, C⇔T). In the A. bayli ADP1 strain,
disruption of mutS resulted in an estimated 54-fold increase in mutation rates
[140]. Taken together, these results have important medical implications. A.
baumannii is intrinsically multi-drug resistant and both extremely-drug resistant
and pan-drug resistant strains have been seen. According to Martn´ez, hyper-
mutable bacteria “are significantly more likely to acquire an antibiotic resistance
phenotype when compared to bacteria with lower mutation rates.” [141].
1.3.2.2 Can whole-genome sequencing provide testable hypotheses as
to mechanisms of antibiotic resistance in a case of treatment
failure?
Tigecycline resistance is associated with mutations in adeS, which encodes a his-
tidine kinase sensor involved in the regulation of the drug eﬄux system adeABC
[142] and a mutation in this gene was the likely cause of the drug-resistant pheno-
type. Interestingly, I found several regions of difference between the isolates, with
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the tigecycline-resistant isolate losing several coding regions associated with an-
tibiotic resistance, including several aminoglycoside-resistance determinants and
genes encoding a beta-lactamase gene and a 16S rRNA methylase. An attrac-
tive explanation is that the disruption of mutS accelerated the loss of these
antibiotic-resistance determinants. Whether these mutations have an effect on
fitness [in vivo] or [in vitro] remains a subject for future experiments.
1.3.3 Paper III
1.3.3.1 What is the evolutionary origin of the German E. coli O104:H4
outbreak strain?
E. coli food-poisoning resulting in bloody diarrhoea and haemolytic-uraemic-
syndrome is usually a result of infection by Shiga-toxin-producing strains of
so-called enterohaemorrhagic E. coli (EHEC), most commonly belonging to the
O157:H7 serotype. This outbreak was caused by a serotype only rarely associ-
ated with disease, O104:H4. The outbreak strain was assigned by MLST (real
and virtual, based on the whole-genome sequence) to sequence type ST678. This
sequence type had only one entry in the online MLST database: strain 01-09591,
which had been isolated in 2001, also in Germany. However, it had been seen sev-
eral times before, but none of the previous examples had been subjected to MLST.
Notably, the sequence of E. coli 55989 had been deposited in Genbank, but was
recognised as an ST678 isolate only through phylogenetic and comparative analy-
sis of whole genomes. This strain had been isolated from an HIV-infected patient
with diarrhoea in Africa in 2002.
The German outbreak strain and the two other ST678 strains belong to phy-
logroup B1, a lineage associated with the entero-aggregative pathovar (EAEC)
rather than with EHEC. This was a surprising finding. Its unusual provenance
initially hampered microbiological diagnosis, which relies on detection of sorbitol
non-fermenters (a phenotype associated with the O157:H7 lineage).
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1.3.3.2 How does this strain differ from classical enterohaemorrhagic
E. coli (EHEC)? What genetic factors might be responsible
for the high levels of mortality in this outbreak?
The O104:H4 outbreak strain has a phage-encoded Shiga-like toxin 2 similar
to that found in EHEC strains [143], which accounts for the haemorrhagic di-
arrhoea and haemolytic-uraemic syndrome. However, there are distinct differ-
ences in predicted virulence gene repertoires between the outbreak strain and
O157:H7 strains. The outbreak strain lacks the locus of enterocyte effacement
(LEE), which codes for important virulence determinants including intimin and
a type-III secretion system thought to play a key role in attachment to the lu-
men of the gut and responsible for secreting effector proteins into the cytosol of
enterocytes [144]. However, the outbreak strain, consistent with other entero-
aggregative strains, exploits alternative adhesins, including the plasmid-encoded
AAF/I system. The plasmids also encode for a number of antibiotic resistance
genes including bla(CTX-M-15).
The conflict between traditional medical classification and molecular phy-
logeny was significant when categorising this strain. For example, strains may be
classified as Shiga-toxin producing E. coli (STEC) but this designation is more
commonly reserved for EHEC-like strains. However, certainly this strain was
STEC. However, the molecular data indicate it belongs to an entero-aggregative
lineage and thus should be called an EAEC.
This raises an important issue–if whole-genome data is to be used as the
ultimate typing system–can genomic data alone satisfy both the needs of clin-
ical microbiologists to classify isolates for the purpose of diagnosis, and those
of molecular epidemiologists who wish to understand evolutionary history. Cur-
rently, there is no simple answer to this question.
1.3.3.3 How can whole-genome sequencing be used prospectively dur-
ing an international outbreak?
As with MLST, whole-genome sequencing data is digital and thus easily portable.
The genome sequence of the E. coli outbreak strain was generated during the
outbreak and released into the public domain, kick-starting a process of public
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“crowd-sourced” analysis. This analysis led to an understanding of many impor-
tant characteristics of this strain, with much analysis completed in a manner of
weeks, as documented on the Github repository. A criticism of this approach is
that analysis would suffer from low-quality inputs from enthusiastic amateurs.
However, this was not the case, and most findings online are consistent with the
eventual published literature.
However, genome analysis was confined to a handful of strains during this
outbreak. Therefore there was not the opportunity to perform more extensive ge-
nomic epidemiology during the outbreak which may have mapped to transmission
chains. In a future outbreak, public health laboratories with genome sequencing
capacity may be able to deposit sequences for isolates as they are collected. This
in turn would permit high-resolution phylogenies to be built “on-the-fly”.
1.3.3.4 Crowd-sourcing and prospects for future outbreaks
Crowd-sourcing solutions to scientific problems has been made possible on a vast
scale over the past 15 years enabled by the vast growth in internet-connected per-
sonal computers. A number of crowd-sourcing projects have had success through
appealing to a critical mass of users (Table 1.3.3.4).
During the E. coli outbreak, crowd-sourcing of the genome was encouraged by
timely release of genome data, from BGI and the Health Protection Agency [147]
and the explicit use of licensing to allow free use of the datasets. Subsequent
analysis was enabled by freely-available communications tools including blogs,
Wikis, Twitter, discussion forums and source code repositories such as Github
[148–150]. This was the first example of crowd-sourced analysis for bacterial
genomic epidemiology, although such approaches have been used in virology, most
notably during outbreaks of influenza.
29
RESULTS AND DISCUSSION
Name Type Aim
SETI @ HOME Distributed computing Harness distributed comput-
ing power to search for extra-
terrestrial life through signal
processing of radio transmis-
sions. Two million years to-
tal computing time logged.
Phylo [145] Gaming A “citizen science” project
for improving multiple se-
quence alignments
FOLDIT Gaming Package the process of man-
ual protein structure predic-
tion as an addictive game.
This project resulted in an
improved crystal structure
of the Mason-Pfizer monkey
virus retroviral protease pro-
tein [146]
Table 1.9: Examples of popular crowd-sourcing projects
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1.3.4 Paper IV
1.3.4.1 How do the current benchtop sequencing platforms compare
for the purpose of epidemiology and evolution studies in bac-
teria?
Benchtop sequencers may speed adoption of whole-genome sequencing for clinical
microbiology due to their low-cost and fast running times. The three instruments
currently available on the market were all used to generate valuable data during
the German E. coli outbreak. However, it is far from clear whether they per-
form equally, and whether enthusiastic adoption in public health laboratories is
warranted, or whether issues remain which need to be addressed. In the study,
comparisons were made between price, read length, throughput, quality and ease
of use. Each instruments had strengths and weaknesses, and it was not possible
to call a stand-out winner.
1.3.4.2 What are the technical obstacles in analysing draft genome
sequence data?
1.3.4.3 What are the practical limitations of current whole-genome
sequencing platforms for genomic epidemiology and evolu-
tion?
The final study emphasises that whole-genome data is not created equally be-
tween sequencing platforms. The main differences between platforms result from
variations in read length (from 100 bp to over 500 bp), and in error rates. The
454 GS Junior and Ion Torrent PGM generate systematic errors which hamper
the ability to analyse sequence data. These errors affect assembled sequences
of genes important for virulence, and genes used for MLST through the intro-
duction of frame-shift mutations. Additionally, short read lengths increase the
degree of fragmentation in de novo assemblies, with consequent ambiguity when
performing certain analyses: for example, it may difficult to determine whether
sequences originate from plasmids or the chromosome.
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1.4 Concluding statements
Taken together, these four studies demonstrate the promise of high-throughput
sequencing in clinical microbiology and public health. Whole-genome sequencing
can both recapitulate existing bacterial typing methods as well as laying claim
to being the ultimate bacterial typing method; universal, digital, portable and
potentially able to discriminate strains which differ by as little as one SNP. Whole-
genome sequencing can also give insights into pathogen biology and reveal the
underlying mutational processes responsible for the development of antibiotic
resistance and immune system evasion.
There is still need to make progress in presenting this wealth of information
to the needs of clinicians who currently want to know simply “What is it?” and
“How can I treat it?”. It may be that clinicians do not ask the best questions,
particularly considering the inexorable march of developing antibiotic resistance.
Management decisions in infectious disease may be better when clinicians frame
their questions from an evolutionary perspective–“Where did it come from?” and
“How could it change?”, as well as “What else does it live with?”. The bacterial
species concept, already nebulous, could be discarded and classification could be
based on genome data alone.
I believe that the availability of low-cost benchtop sequencing instruments
will trigger a shift towards adoption of whole-genome sequencing in clinical mi-
crobiology over the next few years. Use by early adopters may be for the pur-
pose of replacing existing bacterial typing techniques such as MLST, PFGE and
VNTR. Sequencing demonstrably offers higher resolution as well as backwards-
compatibility so this should be an “easy sell”. Complete adoption of this tech-
nology by all clinical microbiologists is still by no means certain. In the NHS,
cost will be a major limiting factor until a bacterial genome can be obtained for
a price at least as cheap as existing methods. Other possible constraints to the
adoption of whole-genome sequencing are listed in Table 1.10.
Looking further to the future, there is great promise in using these tech-
niques for diagnosis of infectious disease. This is likely to rely on metagenomic
approaches. Metagenomics are currently limited to research applications due
to technical complexities. However this field is likely on the cusp of becom-
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Microbiological
Reliance on pure culture (particularly important for slow-growing organ-
isms)
Sequencing
High input requirements (>500 nanograms DNA)
Complex laboratory work-flows
Analytical
Difficulties due to short read lengths, errors
Data storage
Internet bandwidth
Availability of robust analysis pipelines
Lack of specialist bioinformatics skills
Professional
Inertia
Resistance to change
Proof of non-inferiority
Social
Regulatory approval (particularly in US)
Data sharing and privacy policies, particularly with metagenomics
Commercial
Competing “closed-source” methods
Table 1.10: Impediments to take up of high-throughput sequencing
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ing genuinely “translatable”. It may be that emerging sequencing technologies,
such as those based on nanopore technologies, may allow for direct detection of
microbial DNA without any sample preparation [151]. This new field, clinical
metagenomics, is the area I wish to explore next, with funding obtained from the
Medical Research Council.
Ultimately we may shift from Koch’s original model of one bacterial species
causing one disease, to a more complete understanding of how the interactions
between microbial communities (the “metagenome”) modulate states of health
and disease. We may be able to model the complex biological interactions of
infection, involving host and microbial community, including but not limited to
the headline “pathogen” [152]. Such an “eco-evo” view of microbial community
dynamics may suggest strategies for treating and preventing infection.
34
Bibliography
1. Robertson, M. Biology in the 1980s, plus or minus a decade. Nature 285,
358–9 (1980).
2. Porter, J. Antony van Leeuwenhoek: tercentenary of his discovery of bac-
teria. Bacteriol Rev 40, 260–9 (1976).
3. Guerrero, R. & Berlanga, M. The hidden side of the prokaryotic cell: re-
discovering the microbial world. Int Microbiol 10, 157–68 (2007).
4. Wainwright, M. An alternative view of the early history of microbiology.
Adv Appl Microbiol 52, 333–55 (2003).
5. Newsom, S. Pioneers in infection control: John Snow, Henry Whitehead,
the Broad Street pump, and the beginnings of geographical epidemiology.
J Hosp Infect 64, 210–6 (2006).
6. Bentivoglio, M. & Pacini, P. Filippo Pacini: a determined observer. Brain
Res Bull 38, 161–5 (1995).
7. Ellis, H. Gerhard Hansen: discoverer of the organism of leprosy. Br J Hosp
Med (Lond) 73, 113 (2012).
8. Maloy, S. & Schaechter, M. The era of microbiology: a golden phoenix. Int
Microbiol 9, 1–7 (2006).
9. Oren, A. & Thane Papke, R. Molecular Phylogeny of Microorganisms (Cais-
ter Academic Press, 2010).
10. Brock, T. D. Milestones in Microbiology 1546-1940 (Milestones in Micro-
biology, 1999).
35
BIBLIOGRAPHY
11. Noguerola, I. & Blanch, A. Identification of Vibrio spp. with a set of di-
chotomous keys. J Appl Microbiol 105, 175–85 (2008).
12. Bergey, D. Bergey’s Manual of Determinative Bacteriology (Wiliams and
Wilkins, 1923).
13. Sneath, P. & Sokal, R. Numerical taxonomy. Nature 193, 855–60 (1962).
14. Sneath, p. The application of computers to taxonomy. J Gen Microbiol 17,
201–26 (1957).
15. O’Malley, M. What did Darwin say about microbes, and how did microbi-
ology respond? Trends Microbiol 17, 341–7 (2009).
16. Dobzhansky, T. Biology, Molecular and Organismic. Am Zool 4, 443–52
(1964).
17. Griffith, F. The Significance of Pneumococcal Types. J Hyg (Lond) 27,
113–59 (1928).
18. Avery, O., Macleod, C. & McCarty, M. Studies on the Chemical Nature of
the Substance Inducing Transformation of Pneumococcal Types : Induction
of Transformation by a Desoxyribonucleic Acid Fraction Isolated From
Pneumococcus Type Iii. J Exp Med 79, 137–58 (1944).
19. Watson, J. & Crick, F. A structure for deoxyribose nucleic acid. 1953.
Nature 421, 397–8; discussion 396 (2003).
20. Smith, H. & Wilcox, K. A restriction enzyme from Hemophilus influenzae.
I. Purification and general properties. J Mol Biol 51, 379–91 (1970).
21. Nathans, D. & Smith, H. Restriction endonucleases in the analysis and
restructuring of DNA molecules. Annu Rev Biochem 44, 273–93 (1975).
22. Cohen, S., Chang, A., Boyer, H. & Helling, R. Construction of biologically
functional bacterial plasmids in vitro. Proc Natl Acad Sci U S A 70, 3240–4
(1973).
23. Jackson, D., Symons, R. & Berg, P. Biochemical method for inserting new
genetic information into DNA of Simian Virus 40: circular SV40 DNA
molecules containing lambda phage genes and the galactose operon of Es-
cherichia coli. Proc Natl Acad Sci U S A 69, 2904–9 (1972).
36
BIBLIOGRAPHY
24. Lobban, P. & Kaiser, A. Enzymatic end-to end joining of DNA molecules.
J Mol Biol 78, 453–71 (1973).
25. Fiers, W. et al. Complete nucleotide sequence of bacteriophage MS2 RNA:
primary and secondary structure of the replicase gene. Nature 260, 500–7
(1976).
26. Maxam, A. & Gilbert, W. A new method for sequencing DNA. Proc Natl
Acad Sci U S A 74, 560–4 (1977).
27. Sanger, F. & Coulson, A. A rapid method for determining sequences in
DNA by primed synthesis with DNA polymerase. J Mol Biol 94, 441–8
(1975).
28. Sanger, F., Nicklen, S. & Coulson, A. DNA sequencing with chain-terminating
inhibitors. Proc Natl Acad Sci U S A 74, 5463–7 (1977).
29. Zuckerkandl, E. & Pauling, L. Molecules as documents of evolutionary
history. J Theor Biol 8, 357–66 (1965).
30. Luria, S. & Delbru¨ck, M. Mutations of Bacteria from Virus Sensitivity to
Virus Resistance. Genetics 28, 491–511 (1943).
31. Saitou, N. & Nei, M. The neighbor-joining method: a new method for
reconstructing phylogenetic trees. Mol Biol Evol 4, 406–25 (1987).
32. Balch, W., Magrum, L., Fox, G., Wolfe, R. & Woese, C. An ancient diver-
gence among the bacteria. J Mol Evol 9, 305–11 (1977).
33. Fox, G., Magrum, L., Balch, W., Wolfe, R. & Woese, C. Classification of
methanogenic bacteria by 16S ribosomal RNA characterization. Proc Natl
Acad Sci U S A 74, 4537–41 (1977).
34. Woese, C. & Fox, G. Phylogenetic structure of the prokaryotic domain: the
primary kingdoms. Proc Natl Acad Sci U S A 74, 5088–90 (1977).
35. Lan, R. & Reeves, P. Escherichia coli in disguise: molecular origins of
Shigella. Microbes Infect 4, 1125–32 (2002).
36. Johnson, J. Shigella and Escherichia coli at the crossroads: machiavellian
masqueraders or taxonomic treachery? J Med Microbiol 49, 583–5 (2000).
37
BIBLIOGRAPHY
37. Fleischmann, R. et al. Whole-genome random sequencing and assembly of
Haemophilus influenzae Rd. Science 269, 496–512 (1995).
38. Murray, K. DNA sequencing by mass spectrometry. J Mass Spectrom 31,
1203–15 (1996).
39. Goffeau, A. et al. Life with 6000 genes. Science 274, 546, 563–7 (1996).
40. Lander, E. et al. Initial sequencing and analysis of the human genome.
Nature 409, 860–921 (2001).
41. Adams, M. et al. The genome sequence of Drosophila melanogaster. Science
287, 2185–95 (2000).
42. NCBI. Genome Project Website (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi,
2012).
43. Alm, R. & Trust, T. Analysis of the genetic diversity of Helicobacter pylori :
the tale of two genomes. J Mol Med (Berl) 77, 834–46 (1999).
44. Fleischmann, R. et al. Whole-genome comparison of Mycobacterium tuber-
culosis clinical and laboratory strains. J Bacteriol 184, 5479–90 (2002).
45. Pizza, M. et al. Identification of vaccine candidates against serogroup B
meningococcus by whole-genome sequencing. Science 287, 1816–20 (2000).
46. Rappuoli, R. Reverse vaccinology. Curr Opin Microbiol 3, 445–50 (2000).
47. Gossger, N. et al. Immunogenicity and tolerability of recombinant serogroup
B meningococcal vaccine administered with or without routine infant vac-
cinations according to different immunization schedules: a randomized con-
trolled trial. JAMA 307, 573–82 (2012).
48. Ochman, H. & Moran, N. Genes lost and genes found: evolution of bacterial
pathogenesis and symbiosis. Science 292, 1096–9 (2001).
49. Van Ham, R. et al. Reductive genome evolution in Buchnera aphidicola.
Proc Natl Acad Sci U S A 100, 581–6 (2003).
50. Djelouadji, Z., Raoult, D. & Drancourt, M. Palaeogenomics of Mycobac-
terium tuberculosis : epidemic bursts with a degrading genome. Lancet In-
fect Dis 11, 641–50 (2011).
38
BIBLIOGRAPHY
51. Singh, P. & Cole, S. Mycobacterium leprae: genes, pseudogenes and genetic
diversity. Future Microbiol 6, 57–71 (2011).
52. Vissa, V. & Brennan, P. The genome of Mycobacterium leprae: a minimal
mycobacterial gene set. Genome Biol 2, 1023 (2001).
53. Cole, S. et al. Massive gene decay in the leprosy bacillus. Nature 409,
1007–11 (2001).
54. Han, X. et al. A new Mycobacterium species causing diffuse lepromatous
leprosy. Am J Clin Pathol 130, 856–64 (2008).
55. Han, X. et al. Comparative sequence analysis of Mycobacterium leprae
and the new leprosy-causing Mycobacterium lepromatosis. J Bacteriol 191,
6067–74 (2009).
56. Smith, J., Smith, N., O’Rourke, M. & Spratt, B. How clonal are bacteria?
Proc Natl Acad Sci U S A 90, 4384–8 (1993).
57. Parkhill, J. et al. Genome sequence of Yersinia pestis, the causative agent
of plague. Nature 413, 523–7 (2001).
58. Van Ert, M. et al. Global genetic population structure of Bacillus anthracis.
PLoS One 2, e461 (2007).
59. Han, C. et al. Pathogenomic sequence analysis of Bacillus cereus and Bacil-
lus thuringiensis isolates closely related to Bacillus anthracis. J Bacteriol
188, 3382–90 (2006).
60. Read, T. et al. The genome sequence of Bacillus anthracis Ames and com-
parison to closely related bacteria. Nature 423, 81–6 (2003).
61. Eppinger, M., Baar, C., Raddatz, G., Huson, D. & Schuster, S. Compar-
ative analysis of four Campylobacterales. Nat Rev Microbiol 2, 872–85
(2004).
62. Furuta, Y. et al. Birth and death of genes linked to chromosomal inversion.
Proc Natl Acad Sci U S A 108, 1501–6 (2011).
63. Armstrong, G., Conn, L. & Pinner, R. Trends in infectious disease mortal-
ity in the United States during the 20th century. JAMA 281, 61–6 (1999).
39
BIBLIOGRAPHY
64. Hinman, A. Global progress in infectious disease control. Vaccine 16, 1116–
21 (1998).
65. Stewart, G., Robertson, B. & Young, D. Tuberculosis: a problem with
persistence. Nat Rev Microbiol 1, 97–105 (2003).
66. Neu, H. The crisis in antibiotic resistance. Science 257, 1064–73 (1992).
67. Bush, K. et al. Tackling antibiotic resistance. Nat Rev Microbiol 9, 894–6
(2011).
68. Dijkshoorn, L., Nemec, A. & Seifert, H. An increasing threat in hospitals:
multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5, 939–51
(2007).
69. Maltezou, H. Metallo-beta-lactamases in Gram-negative bacteria: intro-
ducing the era of pan-resistance? Int J Antimicrob Agents 33, 405.e1–7
(2009).
70. Bonomo, R. New Delhi metallo–lactamase and multidrug resistance: a
global SOS? Clin Infect Dis 52, 485–7 (2011).
71. Loman, N. & Pallen, M. XDR-TB genome sequencing: a glimpse of the
microbiology of the future. Future Microbiol 3, 111–3 (2008).
72. Saleem, A., Ahmed, I., Mir, F., Ali, S. & Zaidi, A. Pan-resistant Acineto-
bacter infection in neonates in Karachi, Pakistan. J Infect Dev Ctries 4,
30–7 (2010).
73. Udwadia, Z., Amale, R., Ajbani, K. & Rodrigues, C. Totally drug-resistant
tuberculosis in India. Clin Infect Dis 54, 579–81 (2012).
74. Wenzel, R. The antibiotic pipeline–challenges, costs, and values. N Engl J
Med 351, 523–6 (2004).
75. Maiden, M. et al. Multilocus sequence typing: a portable approach to the
identification of clones within populations of pathogenic microorganisms.
Proc Natl Acad Sci U S A 95, 3140–5 (1998).
76. Achtman, M. A surfeit of YATMs? J Clin Microbiol 34, 1870 (1996).
40
BIBLIOGRAPHY
77. Selander, R. et al. Methods of multilocus enzyme electrophoresis for bacte-
rial population genetics and systematics. Appl Environ Microbiol 51, 873–
84 (1986).
78. Lindstedt, B. Multiple-locus variable number tandem repeats analysis for
genetic fingerprinting of pathogenic bacteria. Electrophoresis 26, 2567–82
(2005).
79. Anderson, D., Kuhns, J., Vasil, M., Gerding, D. & Janoff, E. DNA finger-
printing by pulsed field gel electrophoresis and ribotyping to distinguish
Pseudomonas cepacia isolates from a nosocomial outbreak. J Clin Micro-
biol 29, 648–9 (1991).
80. Arbeit, R. et al. Resolution of recent evolutionary divergence among Es-
cherichia coli from related lineages: the application of pulsed field elec-
trophoresis to molecular epidemiology. J Infect Dis 161, 230–5 (1990).
81. Tenover, F. et al. Interpreting chromosomal DNA restriction patterns pro-
duced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.
J Clin Microbiol 33, 2233–9 (1995).
82. Saiki, R. et al. Primer-directed enzymatic amplification of DNA with a
thermostable DNA polymerase. Science 239, 487–91 (1988).
83. Woods, C., Versalovic, J., Koeuth, T. & Lupski, J. Whole-cell repetitive
element sequence-based polymerase chain reaction allows rapid assessment
of clonal relationships of bacterial isolates. J Clin Microbiol 31, 1927–31
(1993).
84. Roumagnac, P. et al. Evolutionary history of Salmonella typhi. Science
314, 1301–4 (2006).
85. Wirth, T. et al. Sex and virulence in Escherichia coli : an evolutionary
perspective. Mol Microbiol 60, 1136–51 (2006).
86. Bartual, S. et al. Development of a multilocus sequence typing scheme
for characterization of clinical isolates of Acinetobacter baumannii. J Clin
Microbiol 43, 4382–90 (2005).
41
BIBLIOGRAPHY
87. Diancourt, L., Passet, V., Nemec, A., Dijkshoorn, L. & Brisse, S. The
population structure of Acinetobacter baumannii : expanding multiresistant
clones from an ancestral susceptible genetic pool. PLoS One 5, e10034
(2010).
88. Baker, L., Brown, T., Maiden, M. & Drobniewski, F. Silent nucleotide
polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg
Infect Dis 10, 1568–77 (2004).
89. Comas, I., Homolka, S., Niemann, S. & Gagneux, S. Genotyping of genet-
ically monomorphic bacteria: DNA sequencing in Mycobacterium tuber-
culosis highlights the limitations of current methodologies. PLoS One 4,
e7815 (2009).
90. Margulies, M. et al. Genome sequencing in microfabricated high-density
picolitre reactors. Nature 437, 376–80 (2005).
91. Wheeler, D. et al. The complete genome of an individual by massively
parallel DNA sequencing. Nature 452, 872–6 (2008).
92. Bennett, S. Solexa Ltd. Pharmacogenomics 5, 433–8 (2004).
93. Bentley, D. et al. Accurate whole human genome sequencing using re-
versible terminator chemistry. Nature 456, 53–9 (2008).
94. Metzker, M. Sequencing technologies - the next generation. Nat Rev Genet
11, 31–46 (2010).
95. McKernan, K. et al. Sequence and structural variation in a human genome
uncovered by short-read, massively parallel ligation sequencing using two-
base encoding. Genome Res 19, 1527–41 (2009).
96. Pushkarev, D., Neff, N. & Quake, S. Single-molecule sequencing of an in-
dividual human genome. Nat Biotechnol 27, 847–50 (2009).
97. Eid, J. et al. Real-time DNA sequencing from single polymerase molecules.
Science 323, 133–8 (2009).
98. Rothberg, J. et al. An integrated semiconductor device enabling non-optical
genome sequencing. Nature 475, 348–52 (2011).
42
BIBLIOGRAPHY
99. Smith, T. & Waterman, M. Identification of common molecular subse-
quences. J Mol Biol 147, 195–7 (1981).
100. Needleman, S. & Wunsch, C. A general method applicable to the search
for similarities in the amino acid sequence of two proteins. J Mol Biol 48,
443–53 (1970).
101. Pop, M. & Salzberg, S. Bioinformatics challenges of new sequencing tech-
nology. Trends Genet 24, 142–9 (2008).
102. Li, H., Ruan, J. & Durbin, R. Mapping short DNA sequencing reads and
calling variants using mapping quality scores. Genome Res 18, 1851–8
(2008).
103. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-
Wheeler transform. Bioinformatics 26, 589–95 (2010).
104. Ruffalo, M., LaFramboise, T. & Koyutu¨rk, M. Comparative analysis of
algorithms for next-generation sequencing read alignment. Bioinformatics
27, 2790–6 (2011).
105. Ning, Z., Cox, A. & Mullikin, J. SSAHA: a fast search method for large
DNA databases. Genome Res 11, 1725–9 (2001).
106. Galinsky, V. YOABS: yet other aligner of biological sequences–an efficient
linearly scaling nucleotide aligner. Bioinformatics 28, 1070–7 (2012).
107. Paszkiewicz, K. & Studholme, D. De novo assembly of short sequence reads.
Brief Bioinform 11, 457–72 (2010).
108. Zerbino, D. & Birney, E. Velvet: algorithms for de novo short read assembly
using de Bruijn graphs. Genome Res 18, 821–9 (2008).
109. Li, R. et al. The sequence and de novo assembly of the giant panda genome.
Nature 463, 311–7 (2010).
110. Simpson, J. et al. ABySS: a parallel assembler for short read sequence data.
Genome Res 19, 1117–23 (2009).
111. Delcher, A., Bratke, K., Powers, E. & Salzberg, S. Identifying bacterial
genes and endosymbiont DNA with Glimmer. Bioinformatics 23, 673–9
(2007).
43
BIBLIOGRAPHY
112. Borodovsky, M. & Lomsadze, A. Gene identification in prokaryotic genomes,
phages, metagenomes, and EST sequences with GeneMarkS suite. Curr
Protoc Bioinformatics Chapter 4, Unit 4.5.1–17 (2011).
113. Altschul, S. et al. Gapped BLAST and PSI-BLAST: a new generation of
protein database search programs. Nucleic Acids Res 25, 3389–402 (1997).
114. Lowe, T. & Eddy, S. tRNAscan-SE: a program for improved detection of
transfer RNA genes in genomic sequence. Nucleic Acids Res 25, 955–64
(1997).
115. Lagesen, K. et al. RNAmmer: consistent and rapid annotation of ribosomal
RNA genes. Nucleic Acids Res 35, 3100–8 (2007).
116. Sayers, E. et al. Database resources of the National Center for Biotechnol-
ogy Information. Nucleic Acids Res 40, D13–25 (2012).
117. Chaudhuri, R. et al. xBASE2: a comprehensive resource for comparative
bacterial genomics. Nucleic Acids Res 36, D543–6 (2008).
118. Harris, S. et al. Evolution of MRSA during hospital transmission and in-
tercontinental spread. Science 327, 469–74 (2010).
119. Croucher, N. et al. Rapid pneumococcal evolution in response to clinical
interventions. Science 331, 430–4 (2011).
120. Monot, M. et al. Comparative genomic and phylogeographic analysis of
Mycobacterium leprae. Nat Genet 41, 1282–9 (2009).
121. He, M. et al. Evolutionary dynamics of Clostridium difficile over short and
long time scales. Proc Natl Acad Sci U S A 107, 7527–32 (2010).
122. Stabler, R. et al. Comparative genome and phenotypic analysis of Clostrid-
ium difficile 027 strains provides insight into the evolution of a hyperviru-
lent bacterium. Genome Biol 10, R102 (2009).
123. Chin, C. et al. The origin of the Haitian cholera outbreak strain. N Engl J
Med 364, 33–42 (2011).
124. Mutreja, A. et al. Evidence for several waves of global transmission in the
seventh cholera pandemic. Nature 477, 462–5 (2011).
44
BIBLIOGRAPHY
125. Beres, S. et al. Molecular complexity of successive bacterial epidemics de-
convoluted by comparative pathogenomics. Proc Natl Acad Sci U S A 107,
4371–6 (2010).
126. Fittipaldi, N., Olsen, R., Beres, S., Van Beneden, C. & Musser, J. Genomic
Analysis of emm59 Group A Streptococcus Invasive Strains, United States.
Emerg Infect Dis 18, 650–2 (2012).
127. Gilmour, M. et al. High-throughput genome sequencing of two Listeria
monocytogenes clinical isolates during a large foodborne outbreak. BMC
Genomics 11, 120 (2010).
128. Lienau, E. et al. Identification of a salmonellosis outbreak by means of
molecular sequencing. N Engl J Med 364, 981–2 (2011).
129. Rasko, D. et al. Bacillus anthracis comparative genome analysis in support
of the Amerithrax investigation. Proc Natl Acad Sci U S A 108, 5027–32
(2011).
130. Golubchik, T. et al. Pneumococcal genome sequencing tracks a vaccine
escape variant formed through a multi-fragment recombination event. Nat
Genet 44, 352–5 (2012).
131. Ou, C. et al. Molecular epidemiology of HIV transmission in a dental prac-
tice. Science 256, 1165–71 (1992).
132. Jones, A. et al. Importation of multidrug-resistant Acinetobacter spp in-
fections with casualties from Iraq. Lancet Infect Dis 6, 317–8 (2006).
133. Holt, K. et al. High-throughput sequencing provides insights into genome
variation and evolution in Salmonella Typhi. Nat Genet 40, 987–93 (2008).
134. Handelsman, J. Metagenomics: application of genomics to uncultured mi-
croorganisms. Microbiol Mol Biol Rev 68, 669–85 (2004).
135. Raghunathan, A. et al. Genomic DNA amplification from a single bac-
terium. Appl Environ Microbiol 71, 3342–7 (2005).
136. Marcy, Y. et al. Dissecting biological ”dark matter” with single-cell genetic
analysis of rare and uncultivated TM7 microbes from the human mouth.
Proc Natl Acad Sci U S A 104, 11889–94 (2007).
45
BIBLIOGRAPHY
137. Walker, A. & Parkhill, J. Single-cell genomics. Nat Rev Microbiol 6, 176–7
(2008).
138. Yilmaz, S. & Singh, A. Single cell genome sequencing. Curr Opin Biotech-
nol (2011).
139. Woyke, T. et al. One bacterial cell, one complete genome. PLoS One 5,
e10314 (2010).
140. Hall, L. & Henderson-Begg, S. Hypermutable bacteria isolated from humans–
a critical analysis. Microbiology 152, 2505–14 (2006).
141. Mart´ınez, J., Baquero, F. & Andersson, D. Predicting antibiotic resistance.
Nat Rev Microbiol 5, 958–65 (2007).
142. Ruzin, A., Keeney, D. & Bradford, P. AdeABC multidrug eﬄux pump
is associated with decreased susceptibility to tigecycline in Acinetobacter
calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother
59, 1001–4 (2007).
143. Fraser, M. et al. Structure of Shiga toxin type 2 (Stx2) from Escherichia
coli O157:H7. J Biol Chem 279, 27511–7 (2004).
144. Pallen, M., Beatson, S. & Bailey, C. Bioinformatics analysis of the locus for
enterocyte effacement provides novel insights into type-III secretion. BMC
Microbiol 5, 9 (2005).
145. Kawrykow, A. et al. Phylo: a citizen science approach for improving mul-
tiple sequence alignment. PLoS One 7, e31362 (2012).
146. Khatib, F. et al. Crystal structure of a monomeric retroviral protease solved
by protein folding game players. Nat Struct Mol Biol 18, 1175–7 (2011).
147. Genomic data from Escherichia coli O104:H4 isolate TY-2482. BGI Shen-
zhen. doi:10.5524/100001 (2011).
148. Loman, N. J. 2012. ¡http://pathogenomics.bham.ac.uk/blog¿.
149. Li, J. et al. SEQanswers: an open access community for collaboratively
decoding genomes. Bioinformatics 28, 1272–3 (2012).
150. Li, J. et al. The SEQanswers wiki: a wiki database of tools for high-
throughput sequencing analysis. Nucleic Acids Res 40, D1313–7 (2012).
46
BIBLIOGRAPHY
151. Schneider, G. & Dekker, C. DNA sequencing with nanopores. Nat Biotech-
nol 30, 326–8 (2012).
152. Mokili, J., Rohwer, F. & Dutilh, B. Metagenomics and future perspectives
in virus discovery. Curr Opin Virol 2, 63–77 (2012).
47
Chapter 2
High-throughput whole-genome
sequencing to dissect the
epidemiology of Acinetobacter
baumannii isolates from a
hospital outbreak
48
 1 
Use of high-throughput whole-genome sequencing to dissect the epidemiology of 
Acinetobacter baumannii isolates from a hospital outbreak  
 
*Dr Tom Lewisa, *Dr Nicholas J. Lomanb, Dr Lewis Bingleb, Dr Pauline Jumaaa, Professor 
George M. Weinstockc, Dr Deborah Mortiboya and Professor Mark J. Pallenb,# 
aDepartment of Medical Microbiology,  University Hospitals Birmingham NHS 
Foundation Trust, Birmingham, UK 
 bCentre for Systems Biology, University of Birmingham, Birmingham, UK 
cDepartment of Genetics, Washington University School of Medicine, St. Louis, Missouri, 
USA 
 
*These authors contributed equally to this work 
# Corresponding author. Address: Centre for Systems Biology, University of 
Birmingham, Birmingham, B15 2TT, UK. Tel: +44 121 414 7163. 
E-mail: m.pallen@bham.ac.uk 
Running title High-throughput sequencing of Acinetobacter isolates 
 2 
Summary 
 
Shared care of military and civilian patients has resulted in transmission of multi-drug-
resistant Acinetobacter baumannii  (MDR-Aci) from military casualties to civilians. Current 
typing technologies have proven useful in revealing relationships between A. baumannii 
isolates. However, they are unable to resolve differences between closely related isolates 
from small-scale outbreaks, where chains of transmission are often unclear. In a recent 
hospital outbreak in Birmingham, six patients were colonized with MDR-Aci isolates 
indistinguishable using standard techniques. We have used whole-genome sequencing to 
identify single nucleotide polymorphisms (SNPs) in these isolates, allowing us to 
discriminate between alternative epidemiological hypotheses in this setting. 
 3 
Introduction 
 
In the United Kingdom, military casualties are usually repatriated to Selly Oak Hospital, 
Birmingham, where they are cared for alongside civilian patients. Military patients from 
Iraq and Afghanistan are often colonized with strains of multi-drug-resistant A. 
baumannii (MDR-Aci), which can spread to civilian patients and health-care workers.1-6 
Molecular typing systems, such as pulsed-field gel electrophoresis (PFGE) and variable-
number tandem repeat (VNTR) analyses, have provided evidence of multiple concurrent 
or successive clonal outbreaks in hospitals across the UK.7-8 However, these methods 
have been unable to provide sufficient resolution to determine chains of transmission 
within apparently clonal outbreaks. Nor can they provide detailed information on 
patterns of spread (e.g. the influence of “super-shedders”, environmental persistence, 
staff carriage or infection control practices), even though these questions are important 
when considering where to focus finite infection control resources.  
 
A recent MDR-Aci outbreak in Selly Oak Hospital illustrates some of these problems. Four 
military patients, admitted over a five-week period, were each found to be colonised with 
MDR-Aci a few days after admission. Subsequently, indistinguishable isolates were 
recovered from two civilian patients on the same unit. Molecular typing distinguished 
isolates from this outbreak from those recovered from a similar outbreak in 2007 (same 
PFGE type, different VNTR type). However, such approaches were unable to shed light on 
transmission events within the 2008 outbreak itself. 
 
Whole-genome sequencing represents the ultimate molecular typing method for bacteria, 
because it samples the entire collection of genetic information within each isolate. 
Pioneering work on the “Amerithrax” strain of Bacillus anthracis illustrated the utility of 
this approach9 as long ago as 2002. However, until recently, the cost and technical 
complexity of bacterial whole-genome sequencing placed it beyond the reach of the 
average diagnostic laboratory or academic research group.  This has changed in the last 
couple of years with the advent of “high-throughput sequencing”—an umbrella term for 
several competing technologies that deliver genome sequences around one hundred times 
more quickly and more cheaply than conventional sequencing approaches (see recent 
review by Metzker10). All such technologies do away with the need for cloning of DNA in 
biological systems and instead rely on massively parallel in vitro amplification of template 
molecules attached to a solid surface.  
 
Several recent studies have shown that analysis of single nucleotide polymorphisms 
(SNPs) in bacterial genomes provides a means of determining relatedness between 
epidemiologically linked isolates and tracking bacterial evolution over periods of months 
to years. 11-16 Furthermore, the massive depth of coverage provided by high-throughput 
sequencing means that, when looking for rare genomic changes, it becomes efficient to 
pool samples and identity variable loci by polymorphisms within the consensus sequence. 
SNPs can then be quickly and easily assigned to individual isolates by a small number of 
confirmatory PCRs.  
 
Despite the promise of these new technologies, at the outset of this study, it remained 
unclear whether MDR-Aci lineages associated with individual patients harbour SNPs 
capable of providing useful epidemiological information. We therefore applied one 
particular high-throughput sequencing technology—454 pyrosequencing—to isolates 
from our outbreak in the hope of gaining additional epidemiological information.  
 
Methods 
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Microbiology 
 
A. baumannii isolates were obtained from routine clinical samples. Bacterial identification 
and antibiotic susceptibility testing was performed on the Vitek 2 system according to the 
manufacturer’s instructions (bioMérieux, Basingstoke, UK), supplemented by CLSI-
recommended confirmatory testing. Isolates were frozen on beads and stored at -20°C. 
Isolates M1, M2, M3, M4 were obtained from wound swabs from military patients. Isolates 
C1 and C2 were obtained from sputum cultures from civilian patients. Isolates C1-2a and 
C1-2b were distinct colonies from the same wound specimen, taken two weeks after the 
initial isolate from civilian patient C1. Isolates C1-3a and C1-3b were isolates from a 
different wound specimen, taken at the same time as isolates C1-2a and C1-2b. Multidrug 
resistance was defined as resistance to ≥ 3 classes of antibiotics (quinolones, extended-
spectrum cephalosporins, ß-lactam/ß-lactamase inhibitor combinations, aminoglycosides 
and carbapenems). MDR-Aci isolates were sent to the Laboratory of HealthCare Associated 
Infection for speciation and PFGE and VNTR analysis. Antibiotic sensitivities were 
confirmed by agar dilution methods in two isolates (M1 and C1).  
 
Isolation of genomic DNA and 454 sequencing  
 
Genomic DNA was obtained from colony-purified MDR-Aci, using the DNeasy DNA 
extraction kit (Qiagen, Crawley, UK). DNA was sequenced using 454 Titanium protocols 
(Roche, Welwyn Garden City, Hertfordshire, UK) at the University of Liverpool’s Centre 
for Genomic Research. DNA samples from isolates M1 and C1 were each sequenced on a 
quarter plate; the sample from isolate C2 was sequenced on two quarter-plates. 
Approximately equal quantities of DNA from isolates M2, M3, M4 and C1-2a were pooled 
and sequenced on a full Titanium plate.  
 
Analysis of genome sequence and of sequence variants  
 
454 sequence reads were assembled using Newbler 2.0.01.14 (Roche, Welwyn Garden 
City, Hertfordshire, UK). We combined the sequence data from all MDR-Aci isolates to 
create a consensus outbreak assembly.  The gsMapper component of Newbler was then 
used to map each set of sequence reads against the consensus assembly. False positive 
variants resulting from sequencing errors were excluded, generating a set of high-
confidence variants. This set was subjected to several additional rounds of filtering 
using xBASE-NG17 to generate a set of well-trusted SNPs. During this process, we 
discarded  
1. insertions and deletions  
2. variants present in < 90% of mapped reads from the runs with single genomes, 
or in <25% of reads from the pooled sample. 
3. variants with excess coverage, > 1 standard deviation from the mean (i.e. in 
repetitive regions). 
4. variants occurring within 200 bases of a contig boundary. 
5. variants occurring in clusters (≥3 SNPs in 1000 base pairs)  
6. variants not flanked by good-quality coverage for ≥ 20 basepairs. 
7. variants where the ancestral state could not be determined by reference to 
published genomes using BLASTN 
 
Validation of single nucleotide polymorphisms  
 
All well-trusted SNPs were investigated by polymerase chain reaction (PCR) and Sanger 
sequencing. The sequences of the primers used for this purpose were as follows:  SNP1 
TAAGGCAGAACAAAGCGTGA/AATCGGTTCTGAGGTTTGGA (product size 222bp); SNP2 
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GGTGAACCTTGGTGGTGGTA/AGCTTTAATGGCTGCTCGAA (product size 222bp);  SNP3 
CATTTCCGAAACCCTCTGAT/AGGCGGTATTTGATGATCTTG (product size 218bp). 
 
 
PCR products were purified by ethanol precipitation and sequenced on a 3730 DNA 
analyser (Applied Biosystems, Warrington, UK). The sequences of SNP loci from isolates 
C1-2b, C1-3a and C1-3b were determined only by sequencing of PCR products.  
 
Results 
 
Description of the outbreak 
 
MDR-Aci was isolated from specimens from five male patients, admitted to the Selly Oak 
Hospital critical care unit over a six-week period in late 2008. Three patients were 
military [M1, M2, M3]; two were civilian [C1, C2]. MDR-Aci was also isolated from a 
wound swab from a military patient [M4] in a nearby trauma ward. Figure 1 shows a 
time line of the MDR-Aci cases on the critical care unit. The critical care unit is split into 
a ten-bedded unit and a six bedded-unit, separated by a narrow corridor. Most military 
patients are admitted to the six-bedded unit, which includes a four-bedded bay (beds 1-
4) and a two-bedded bay (beds 5-6), separated by an open thoroughway to the main 
unit. Patient C1 was first found to be colonized while on the main ten-bedded unit, and 
was subsequently transferred to the six-bedded unit.  The other four MDR-Aci-positive 
critical-care patients (M1, M2, M3, C2) were cared for exclusively in the six-bedded unit.  
 
All MDR-Aci isolates had an identical profile by PFGE and VNTR analyses and all fell 
within European clone 1 (Turton, personal communication; data not shown).18 The 
antibiotic resistance profile was also identical for all isolates (resistant to meropenem, 
piptazobactam, amikacin; sensitive to gentamicin and tigecycline).   
 
The first MDR-Aci isolate was from patient M1. The last isolate came from patient C2, 
who yielded a positive sample in week 7. During our initial epidemiological evaluation, 
we assumed that all military patients were colonised prior to admission. However, the 
events leading to colonisation of the civilian patients remained unclear. In particular, 
several epidemiological scenarios could explain the acquisition of MDR-Aci by patient C2 
(Figure 1): 
1. Transmission from M1.  C2 was nursed in a bed next to M1 during week 2.  
2. Transmission from M2. C2 was nursed in a bed next to M2 during week 4.  
3. Transmission from M3, who occupied a nearby bed space in the six-bedded unit 
in the two weeks before MDR-Aci was first isolated from C2.   
4. Transmission from C1, who occupied a nearby bed space in the six-bedded unit 
in the week before MDR-Aci was first isolated from C2 
5. Acquisition from an unknown source, such as an environmental reservoir or an 
unidentified patient or health worker. 
Transmission from M4 was rendered unlikely by the lack of proximity to C2 in time and 
space. 
 
Whole-genome sequencing of outbreak strains 
 
Complete genome sequence data was obtained from the initial MDR-Aci isolates from 
the six patients plus one additional isolate from patient C1 obtained two weeks after 
colonisation was first detected (C1-2a) (Table 1). The consensus outbreak assembly 
output by Newbler comprised 4,110,513 base-pairs, containing 107 contigs ≥500 base-
pairs. Average contig size was 38,416 base-pairs, with an assembly N50 of 79,057 base-
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pairs. The largest contig was 230,667 base pairs. As predicted from multiplex PCR 
(reference 8) and PFGE analysis, the outbreak strains align most closely with sequences 
from other representatives of European clone 1 (data not shown).  
 
Detection and interpretation of SNPs 
 
Several hundred variants were discarded (supplementary data) during the filtering of 
variants to create high-quality informative SNPs associated with three polymorphic loci 
(Table 2). The sequences at each SNP locus in each isolate (including those that had not 
been genome-sequenced) were determined by PCR and Sanger sequencing. For the 
genome-sequenced isolates, there was complete agreement here with the 454 data. The 
SNPs were placed in a biological and phylogenetic context by reference to the complete 
genome sequence of the European clone 1 strain AB0057.19 This comparison identified 
the M1 isolate as bearing the ancestral genotype at all three SNP loci.  
 
The first SNP distinguishes all the other outbreak isolates (M2, M3, M4, C1, C2) from the 
ancestral/M1 state. A second SNP separates the C1 isolate from all the other isolates, 
while a third SNP differentiates the M3 isolate from all the other isolates. No SNPs were 
detected between isolates from patients C2, M2 or M4. Interestingly, patients M2 and M4 
were injured in the same incident and had similar pathways of care until arrival in Selly 
Oak Hospital. However, once in Birmingham, patient M4 did not come into close contact 
with patients M2 and C2.  
 
If we assume that all military patients acquired MDR-Aci before arrival in Birmingham, 
then SNP 1 must have been acquired before admission and so patient M1 cannot be the 
source of any of the civilian cases (Figure 1). Transmission of MDR-Aci from C1 or M3 to 
C2 is ruled out by the very low probability of reversion to the ancestral state for SNPs 2 
and 3. Therefore, we conclude that the most parsimonious interpretation of the data is 
that patient C2 acquired MDR-Aci from patient M2.  
 
Discussion 
 
Current typing systems have provided valuable insights into the epidemiology of MDR-
Aci. However, we postulated that whole-genome sequencing might provide more 
detailed resolution between bacterial isolates from a hospital outbreak. Here, we have 
shown that closely related MDR-Aci lineages contain SNPs that can shed light on 
transmission events within a small-scale outbreak and can discriminate between 
alternative epidemiological hypotheses.  
 
Our analyses support transmission of MDR-Aci from the wound of a military patient M2 
to the respiratory tract of a civilian patient C2. However, as MDR-Aci was not isolated 
from C2 until several weeks after M2 left the adjacent bed, we cannot determine when 
and how transmission occurred. One possibility is that C2 became colonised when the 
two patients were nursed together, but that colonization did not reach detectable levels 
in the sputum until much later. Another possibility is that M2 contaminated the local 
environment and C2 acquired the organism from the environment only after M2 had left 
the ward. This latter option would be consistent with a significant role of the 
environment in transmission of MDR-Aci, as suggested by others. 20-24  
 
Other uncertainties remain in the epidemiology of this outbreak. In particular, we were 
not able to determine the source and mode of MDR-Aci transmission to patient C1. The 
isolate from this patient contained a SNP not present in any of the military isolates and 
prior to detection of MDR-Aci, this patient never came into close proximity with any 
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other patients known to be colonized. Curiously, one of the five MDR-Aci isolates from 
this patient (C1-2a) possessed three additional SNPs not found in any of the other 
isolates (data not shown). The co-existence of two closely related but distinct lineages of 
MDR-Aci in samples from the same patient remains puzzling and perhaps reflects two 
separate acquisition events before arrival in Birmingham.  
 
In conclusion, we have highlighted the potential of whole-genome sequencing in the 
analysis of hospital outbreaks. However, it is worth stressing that in considering only 
well-validated SNPs, we have been conservative in our analysis and in future studies, 
additional phylogenetic analyses (e.g. of short repeats, indels or re-arrangements) 
twinned with genome finishing methods, such as gap closure, might provide further 
discrimination between closely related MDR-Aci isolates.  
 
It is also clear that additional studies are needed to benchmark genomic variability 
within populations of MDR-Aci colonizing individual patients, to determine how 
frequently SNPs arise within a lineage, to dissect the local, national and global 
population genomics of A. baumannii at the highest resolution possible and to optimise 
use of this technology in hospital infection control. In addition, this technology is certain 
to illuminate key biological differences between isolates by revealing the genetic 
determinants associated with virulence or antibiotic resistance. Furthermore, as 
improvements in high-throughput sequencing result in reduced costs and increased 
efficiency, whole-genome sequencing will increasingly come within the reach of clinical 
microbiology laboratories. It is not hard to imagine a time when genome sequencing 
replaces gel-based methods as the typing method of choice for bacterial nosocomial 
pathogens.  
 
Sequence Data 
 
454 sequencing reads have been deposited to the NCBI Short Read Archive under 
reference SRA010038. Supplementary data is available from 
http://pathogenomics.bham.ac.uk/acinetobacter/ 
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Figures and Tables 
 
Figure 1 - Legend 
 
Time line showing bedspaces of individual patients while in the six-bedded bay of the 
critical care unit. Vertical bars indicate a positive MDR-Aci isolate from the patient and 
their corresponding SNP genotype. Patient C2 had sputum samples sent for 
microbiological analysis on day 24 and day 42, from which MDR-Aci was not isolated. 
Patient C1 was initially admitted to the ten bedded main section of the critical care unit, 
on the same day as patient M2 was admitted to the six bedded section. Patient C1 was 
first found to be colonized with MDR-Aci two days after patient M2. The arrow shows 
proposed transmission from M2 to C2. 
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Table 1 
 
Isolate Reads Aligned 
bases 
Mean coverage depth SNPs after 
filtering 
M1 102,493 4115447 9.6 
 
1 
C1 68,448 4094862 6.6 1 
C2 43,540 3991503 4.3 0 
Pool of 4 isolates 
(M2, M3, M4, C1-
2a) 
601,802 4117083 53.3 (~13x per 
isolate) 
5 
 
Result of sequencing and mapping alignment showing number of reads generated in 
each run, the number of nucleotide bases aligned to the reference consensus genome, 
coverage depth and the number of SNPs detected after filtering. 
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Table 2 
 SNP loci 
 1 2 3 
Locus tag AB57_2551 AB57_2001 AB57_1823 
SNP Coordinate 2645863 2093446 1906419 
Predicted Product 
Two-component 
heavy metal 
response regulator 
Hypothetical 
protein 
Transcriptional 
regulator, AraC family 
Predicted SNP 
Effect 
Synonymous 
Non-synonymous 
(E to V) 
Premature 
termination at codon 
203 
 Alleles Alleles Alleles 
AB0057  C A G 
M1 C A G 
M2 T A G 
M3 T A T 
M4 T A G 
C1 T T G 
C2  T A G 
 
SNP loci which vary between outbreak isolates are shown. The corresponding 
annotation for each locus is shown for the ancestral strain AB0057. Alleles in bold 
demonstrate variation from the ancestral state. The predicted effect of the SNP on each 
affected protein product is also shown.  
 
 
Trauma Unit
Bed 3
4
5
6
M1
M2
C2
C1
Weeks
32 4 5 6 71
Main ITU C1
M4
ITU 6 bedded unit
CAG
TAG
TAG
TAG
TAT
TTG
M3
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Objectives: The whole genomes of two Acinetobacter baumannii isolates recovered from a 22 
single patient were sequenced to gain insight into the nature and extent of genomic plasticity in 23 
this important nosocomial pathogen over the course of a short infection. The first, AB210, was 24 
recovered before tigecycline therapy and was susceptible to this agent; the second, AB211, was 25 
recovered after therapy and was resistant.  26 
Methods: DNA from AB210 was sequenced by 454 GS FLX pyrosequencing according to 27 
the standard protocol for whole-genome shotgun sequencing, producing ~250-bp fragment reads. 28 
AB211 was shotgun-sequenced using the Illumina Genetic Analyzer to produce fragment reads 29 
of exactly 36-bp. Single nucleotide polymorphisms (SNPs) and large deletions detected in 30 
AB211 in relation to AB210 were confirmed by PCR and DNA sequencing. 31 
Results: Automated gene-prediction detected 3,850 putative coding sequences (CDS). 32 
Sequence analysis demonstrated the presence of plasmids pAB0057 and pACICU2 in both 33 
isolates. Eighteen putative SNPs were detected between the pre- and post-therapy isolates, 34 
AB210 and AB211. Three contigs in AB210 were not covered by reads in AB211, representing 35 
three deletions of approximately 15, 44 and 17 kb.  36 
Conclusions: This study demonstrates that significant differences were detectable between two 37 
bacterial isolates recovered one week apart from the same patient, and reveals the potential of 38 
whole-genome sequencing as a tool for elucidating the processes responsible for changes in 39 
antibiotic susceptibility profiles. 40 
 41 
 42 
Introduction  43 
Acinetobacter baumannii is an important nosocomial pathogen, with multidrug-resistant (MDR) 44 
and even pan-drug-resistant strains reported world-wide.
1 
In the UK, carbapenem-resistant clonal 45 
lineages limit available treatment options. One successful lineage, designated OXA-23 clone 1, 46 
belonging to European clone II, has been recovered from over 60 hospitals, clustered mainly in 47 
London and South-East England.
2
 Representative isolates of this clone are usually susceptible to 48 
colistin and tigecycline only. We previously reported the emergence of tigecycline resistance 49 
during antibiotic therapy in the OXA-23 clone 1 epidemic lineage, and showed that increased 50 
expression of the resistance-nodulation-division (RND) efflux system, AdeABC was responsible 51 
for the resistance phenotype.
3
 52 
 The recent availability of rapid and inexpensive whole-genome sequencing permits 53 
detailed investigation of genetic differences between pairs of bacterial isolates. In A. baumannii 54 
whole-genome studies have thus far focused either on comparing distinct antibiotic-susceptible 55 
and MDR strains,
4,5
 or related isolates from different patients.
6
 The results of these and other 56 
similar studies
7
 point to a high degree of genome plasticity, the rapid emergence of antibiotic 57 
resistance, and considerable genetic variability even among closely-related isolates.  58 
Tigecycline is used as a treatment of last resort for MDR A. baumannii infection, despite 59 
a lack of formal trial data and the emergence of resistance is a major concern. We sequenced the 60 
genomes of two A. baumannii isolates from a single patient, the first recovered before tigecycline 61 
therapy and susceptible to this agent, the second after one week of therapy for an intra-abdominal 62 
infection and resistant. The study aimed to gain insight into the nature and extent of genomic 63 
plasticity over the course of a short infection. 64 
Materials and Methods  65 
Bacterial isolates  66 
Clinical isolates AB210 and AB211 have been described previously.
3
 As OXA-23 clone 1 67 
representatives, they belong to the globally successful European clone II group, and were 68 
assigned to Group 1 by the multiplex PCR method described by Turton et al.
8
 They were typed 69 
by PFGE of ApaI-digested genomic DNA (Figure 1), as described previously,
2
 and the presence 70 
of blaOXA-23-like was confirmed by multiplex PCR.
9
 71 
Antimicrobial susceptibility testing and DNA manipulations 72 
MICs were determined by BSAC agar dilution or Etest (AB bioMérieux, Solna, Sweden) on 73 
IsoSensitest agar (Oxiod, Basingstoke, UK) with the results interpreted according to BSAC 74 
guidelines.
9
 Genomic DNA was extracted with the Wizard Genomic DNA Purification Kit 75 
(Promega, Southampton, UK) and was used as template for DNA sequencing. Plasmids were 76 
isolated from AB210 and AB211 using the PureYield Plasmid Miniprep System (Promega) and 77 
analysed by agarose gel electrophoresis. 78 
Whole-genome DNA sequencing and data analysis 79 
DNA from AB210 was sequenced by 454 GS FLX pyrosequencing (Roche, Branford, 80 
Connecticut, USA) according to the standard protocol for whole-genome shotgun sequencing, 81 
producing ~250 bp fragment reads. AB211 was shotgun sequenced using the Illumina Genetic 82 
Analyzer (Illumina, Saffron Walden, UK) to produce fragment reads of exactly 36-bp. All 83 
sequencing was performed at GATC Biotech Ltd (Constance, Germany). A draft genome 84 
assembly for AB210 was produced from flowgram data, using Newbler 2.5 (Roche). The 85 
Newbler command-line option ‘-rip’ was used to ensure reads were aligned to single contigs 86 
only. The resulting contigs were annotated by reference to the related strain A. baumannii 87 
ACICU
10
 (also belonging to European clone II) using the automated annotation pipeline on the 88 
xBASE server.
11
  89 
Illumina reads for isolate AB211 were mapped against the draft AB210 assembly using 90 
Bowtie 0.12.0.
12
 For the purposes of single nucleotide polymorphism (SNP) detection, Bowtie 91 
was run with parameter ‘-m 0’ to suppress alignments that map equally to multiple locations in 92 
the genome.  To detect deletions this setting was not used. A consensus pileup was produced 93 
using SAMtools,
13
 and putative SNPs were called using Varscan 2.2
14
 with the following 94 
parameters: minimum coverage (10), min-reads2 (2), min-avg-qual (15), min-var-freq (0.9). To 95 
detect microindels (insertion or deletion events) less than 3-bases long, AB211 reads were 96 
additionally mapped using Novoalign 2.5.
15
 Whole-genome alignments were visualised and 97 
SNPs and deletions manually inspected using the output files from the above steps using 98 
BAMview. 
16
 99 
Confirmation of SNPs and chromosomal deletions 100 
SNPs and deletions detected in AB211 in relation to AB210 were confirmed by PCR and DNA 101 
sequencing using the primers listed in Table S1. Nucleotide sequences of the resulting amplicons 102 
were determined with an ABI 3730xl DNA analyser (Applied Biosystems, Warrington, UK).  103 
 104 
 105 
 106 
 107 
Results & Discussion 108 
Antibiotic susceptibilities  109 
MICs of tigecycline, tobramycin, amikacin, gentamicin and azithromycin for the pre-therapy 110 
isolate AB210 were 0.5, >32, >64, >32 and >256 mg/L, respectively, while MICs for the post-111 
therapy isolate AB211 were 16, 2, 4, 8 and >256 mg/L, respectively.   112 
Sequencing results 113 
Sequencing produced >128 million and >156 million sequence reads for AB210 and AB211, 114 
respectively. The assembly of AB210 resulted in 91 contigs larger than 500-bp, comprising 4.06 115 
megabases of sequence and representing a median 29-fold coverage. Automated gene-prediction 116 
detected 3,850 putative coding sequences (CDS), of which 3,504 were homologous (defined as 117 
BLASTP e-value ≤ 1e-05) to a sequence in the reference genome of A. baumannii ACICU. The 118 
vast majority (96.6 %) of the AB211 reads mapped to a region on the AB210 genome. The 119 
AB210 draft assembly has been deposited in GenBank (accession number: AEOX00000000) and 120 
raw sequence reads for AB210 and AB211 have been submitted to NCBI’s Sequence Read 121 
Archive under Study Accession Number SRP004860. 122 
Plasmid profile 123 
Plasmid profiles of AB210 and AB211 were identical and showed the presence of two plasmids 124 
in each isolate (data not shown). Sequence analysis demonstrated the presence of a 9-kb contig in 125 
AB210 which displayed 99.98 % identity to the previously characterised pAB0057 plasmid.
5  
126 
This was seen at high sequence read coverage in both AB210 and AB211, suggesting it was 127 
present as multiple copies. Three other contigs, totalling 65 kb, were seen at below-average 128 
coverage; taken together these were a full match in length and nucleotide identity to the complete 129 
pACICU2
 
plasmid.
10 
130 
AB210 virulence genes and resistance islands 131 
Resistance islands (RIs) have been detected in all sequenced A. baumannii genomes containing 132 
multiple resistance determinants. They are composite transposons that are complex in nature and 133 
which have been designated AbaR (A. baumannii resistance).
4
 They share a common insertion 134 
site (comM) but vary considerably among isolates in terms of the exact genetic composition, with 135 
that from ACICU, a representative of European clone II being considerably reduced in size 136 
compared to those found in representatives of European clone I.
10,17
 Clinical isolates AB210 and 137 
AB211 were found to contain an AbaR-type RI. In the former isolate (GenBank accession 138 
number HQ700358) this was shown to contain sequence corresponding to nucleotides 587330-139 
599047 of strain AB0057 (GenBank accession number CP001182), with a 2.85 kb section 140 
absent; this is an AbaR4-type island, and contains blaOXA-23.  141 
 142 
SNPs between AB210 and AB211 143 
Eighteen putative SNPs were detected between the pre- and post-therapy isolates. Only one of 144 
these was located outside of coding regions at -35 bp upstream of ureJ which encodes a 145 
hydrogenase/urease accessory protein (AB210 locus tag: AB210-1_2203). The location of this 146 
SNP suggests the possibility of regulatory significance although ureJ appears to be part of a 147 
urease gene cluster which is co-transcribed as an operon in other species.
18
 Of the remaining 17, 148 
eight were synonymous mutations whereas nine were non-synonymous including one missense 149 
mutation (Table 1). Seventeen (94 %) of the SNPs were transitions. Eight of the nine non-150 
synonymous SNPs could be confirmed by PCR and sequencing while one was not validated 151 
(Table 1 and Table S1). Several of these were located within genes predicted to be involved in 152 
core biological functions, including translation (dusB), nucleic acid biosynthesis, α-ketoglutarate 153 
and arabinose transport, environmental sensing (the signal transduction histidine kinase gene, 154 
adeS which had previously been identified through a candidate-gene approach
3
), and signalling. 155 
The mutation in adeS is believed to be responsible for up-regulation of the AdeABC efflux 156 
system and hence tigecycline resistance. Two SNPs were located within a gene coding for a 157 
GGDEF domain-containing protein, one of which was a non-synonymous mutation whilst the 158 
other introduced an internal stop codon, thus giving rise to a truncated product (Table 1). These 159 
proteins are enzymes that catalyze the synthesis of cyclic-di-GMP, which has been recognized 160 
recently as an important second messenger in bacteria and is implicated in adhesin and 161 
extrapolysaccharide biosynthesis.
19
  162 
Large structural changes in the genomes of AB210 and AB211 163 
Three contigs in AB210 were not covered by reads in AB211, these putative deletions were 164 
designated ROD1, 2 and 3. The first, ROD1, was approximately 15 kb in length. This deletion 165 
disrupted the coding sequence of the DNA mismatch repair gene mutS (AB210-1_2445) by 166 
eliminating the N-terminal mutS-I domain. Aside from encoding this mismatch recognition 167 
enzyme, ROD1 also encoded a DMT superfamily permease (AB210-1_2447) and an MFS 168 
permease (AB210-1_2451), transcriptional regulators (AB210-1_2450; AB210-1_2453), an EAL 169 
domain-containing protein (AB210-1_2448), responsible for the degradation of cyclic-di-GMP.
19 
170 
At approximately 44 kb ROD2 was the largest deleted region and comprised of genes encoding 171 
for transcriptional regulators (AB210-1_3253; AB210-1_3262; AB210-1_3269; AB210-172 
1_3273), ion channels and transporters (AB210-1_3254; AB210-1_3259; [AB210-1_3275; 173 
AB210-1_3276; AB210-1_3277]), a class A β-lactamase enzyme (AB210-1_3248) and 174 
components of a type VI secretion system (AB210-1_3280; AB210-1_3281).
20
 Interestingly, part 175 
of the type VI secretion locus was missing even in AB210, suggesting that this was a degenerate 176 
system in both isolates. ROD1 and ROD2 are contiguous in A. baumannii ACICU, suggesting 177 
this may be a single deletion, but this could not be confirmed experimentally for AB210 by PCR 178 
(data not shown). ROD3, approximately 17 kb in length, included a class 1 integron containing 179 
antibiotic resistance genes including macrolide resistance determinants (AB210-1_3691 180 
[phosphotransferase]; AB210-1_3692 [an efflux protein]) and several genes encoding 181 
aminoglycoside resistance determinants, namely aac(6')-Ib (AB210-1_3701), two copies of 182 
aadA (AB210-1_3699; AB210-1_3700) and armA (AB210-1_3695), which encodes a 16S rRNA 183 
methylase.  184 
 185 
Implications for Acinetobacter evolution 186 
The extent of genomic changes detected here are consistent with the marked changes in 187 
phenotype, particularly the loss of aminoglycoside resistance in AB211. However, we were 188 
unable to determine whether these changes were the result of rapid evolution during the course 189 
of infection and treatment, or whether the patient initially had a mixed infection (or re-infection), 190 
involving different variants of the same defined clone, with subsequent selection for tigecycline 191 
resistance.    192 
The disruption of mutS, an important DNA mismatch repair gene, is significant and 193 
suggests the possibility of a hypermutator phenotype, which may have contributed to the 194 
relatively large number of SNPs. Previous work in Acinetobacter sp. ADP1 has shown that mutS 195 
preferentially recognises and repairs transitions,
21
 so its disruption in AB211 is consistent with 196 
our observation that 94 % of the SNPs belonged to this class. 197 
The absence of ROD3 is consistent with the change in aminoglycoside resistance 198 
between AB210 and AB211, with MICs of tobramycin, amikacin and gentamicin reduced at 199 
least 8-fold in AB211. It is notable that the development of tigecycline resistance was 200 
accompanied by increased susceptibility to other antibiotics through a large genomic deletion. 201 
GGDEF and EAL-containing proteins have been implicated in sessile to planktonic 202 
shifts. Taken together, the termination in a GGDEF domain-containing protein as well as the loss 203 
of an EAL-domain containing protein in ROD1 may be advantageous during the process of 204 
infection though this remains to experimentally determined.  205 
In this study, whole-genome sequencing gave insight into the nature of genetic changes 206 
between isolates under selection pressure through antibiotic therapy and a hostile host 207 
environment. This study has demonstrated significant differences between two A. baumannii 208 
isolates belonging to the same epidemic lineage, collected one week apart from the same patient. 209 
Such studies are able to shed light on the relative importance of SNPs and transposon 210 
mutagenesis on the evolution of A. baumannii and can generate hypotheses into the nature of 211 
antibiotic resistance and virulence. Although further studies are needed to assess the extent of 212 
genetic diversity among populations of A. baumannii in a single patient, we clearly demonstrated 213 
the potential of whole-genome sequencing as an important tool for helping elucidate the 214 
evolutionary processes responsible for the rapid development of antibiotic resistance in this 215 
important nosocomial pathogen. 216 
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Table 1. Confirmed SNPs indentified in clinical isolate AB211 resulting in amino acid substitution or termination 
SNP 
Position in 
AB210 
assembly 
Locus tag in 
AB210 assembly 
Protein product 
Amino acid identity 
Orthologue 
AB210 AB211 
1 159509 AB210-1_0138 tRNA-dihydrouridine synthase, DusB A T ABAYE0965 
2 639321 AB210-1_0587 nucleoside-diphosphate-sugar epimerase T A ACICU_01645 
3 755474 AB210-1_0703 major facilitator superfamily permease V A ACICU_01760 
4 1469178 AB210-1_1405 hypothetical protein A V ACICU_02205 
5 2548057 AB210-1_2423 major facilitator superfamily permease A T ACICU_01217 
6 2852737 AB210-1_2721 Signal transduction histidine kinase, AdeS A V ACICU_01827 
7 3362158 AB210-1_3207 GGDEF domain-containing protein Q * ACICU_03492 
8 3362175 AB210-1_3207 GGDEF domain-containing protein G V ACICU_03492 
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Figure Legands 
Figure 1. PFGE profiles of AB210 (lane 2) and AB211 (lane 3).  
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Summ a r y
An outbreak caused by Shiga-toxin–producing Escherichia coli O104:H4 occurred in 
Germany in May and June of 2011, with more than 3000 persons infected. Here, we 
report a cluster of cases associated with a single family and describe an open-source 
genomic analysis of an isolate from one member of the family. This analysis involved 
the use of rapid, bench-top DNA sequencing technology, open-source data release, and 
prompt crowd-sourced analyses. In less than a week, these studies revealed that the 
outbreak strain belonged to an enteroaggregative E. coli lineage that had acquired genes 
for Shiga toxin 2 and for antibiotic resistance.
E scherichia coli is a widespread commensal of the mammalian gut and a versatile pathogen.1,2 Enterovirulent strains of E. coli are classified into a number of overlapping pathotypes, which include Shiga-toxin–producing, entero-
hemorrhagic, and enteroaggregative varieties.2 Enteroaggregative E. coli strains have 
been associated with sporadic and epidemic diarrhea and, in the laboratory, show 
a distinctive pattern of adherence to Hep-2 cells (termed aggregative, or “stacked 
brick”).3 In Shiga-toxin–producing E. coli, the toxin is encoded on a prophage and 
inhibits protein synthesis within susceptible eukaryotic cells. Strains of enterohemor-
rhagic E. coli produce Shiga toxin and a specific protein secretion system (called a type 
III secretion system) that is encoded by the locus of enterocyte effacement (LEE) 
and that is responsible for attachment to the intestine.2 Shiga-toxin–producing and 
enterohemorrhagic E. coli strains are commonly associated with the hemolytic–uremic 
syndrome, a combination of renal impairment, thrombocytopenia, and hemolytic 
anemia that is often accompanied by neurologic and myocardial damage.
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More than 3000 cases of infection with an 
unusual strain of Shiga-toxin–producing E. coli 
O104:H4 were reported to the Robert Koch Insti-
tute in Berlin during a nationwide outbreak in 
Germany in May and June of 2011.4 This out-
break resulted in more than 40 deaths, and as-
sociated cases were reported in more than a 
dozen countries in Europe and North America 
(mostly in travelers returning from Germany). 
Household transmission was described in the 
Netherlands, and life-threatening colonic ischemia 
was reported as a complication in addition to the 
hemolytic–uremic syndrome and bloody diar-
rhea.5,6 Epidemiologic and microbiologic evidence 
indicated that the O104:H4 strain was distributed 
throughout Germany on bean sprouts.7
The outbreak was characterized by several un-
usual features: a high incidence in adults (espe-
cially women), a greatly increased incidence of the 
hemolytic–uremic syndrome (in approximately 
25% of patients, as compared with 1 to 15% in 
previous outbreaks of Shiga-toxin–producing E. 
coli), a predominance of female patients among 
cases of the hemolytic–uremic syndrome, and a 
rare serotype of Shiga-toxin–producing E. coli that 
had been linked to only two sporadic cases of the 
hemolytic–uremic syndrome (one in Germany and 
the other in South Korea).4,8,9 Recognition of 
infection during the outbreak was hampered by a 
laboratory approach that targeted phenotypes as-
sociated with the most common lineage of entero-
hemorrhagic E. coli (the non–sorbitol-fermenting 
O157:H7 serotype) rather than one aimed at find-
ing all strains of Shiga-toxin–producing E. coli.10 
Here, we report a local cluster of cases associated 
with a family from northern Germany and de-
scribe an open-source genomic analysis of an 
isolate from the family cluster.
C a se R eport s
On May 17, 2011, a 16-year-old girl was admitted 
to the pediatric emergency ward at the University 
Medical Center Hamburg–Eppendorf with bloody 
diarrhea and abdominal pain. Her laboratory values 
were normal. Later on the same day, her 12-year-old 
brother was admitted with a 2-day history of mal-
aise and headache and a 1-day history of vomiting 
and nonbloody diarrhea. The boy presented with 
acute renal failure (serum creatinine level, 4.1 mg 
per deciliter [362 μmol per liter]; and potassium 
level, 6 mmol per liter), thrombocytopenia (22,000 
platelets per cubic millimeter), and hemolytic ane-
mia (hemoglobin, 11.6 g per deciliter; bilirubin, 
2.8 mg per deciliter [49 μmol per liter]; and lactate 
dehydrogenase, 2297 U per liter). His hemoglobin 
level fell to 8.4 g per deciliter within 48 hours after 
admission, thereby fulfilling the case definition 
of the hemolytic–uremic syndrome.
The children, their parents, and a teenage friend 
had eaten a meal together a week earlier. The meal 
included a freshly prepared salad containing bean 
sprouts. The children’s mother had no symptoms, 
and no Shiga-toxin–producing E. coli was isolated 
from her stool. However, the hemolytic–uremic 
syndrome developed in the father, and his stool 
sample was culture-positive for Shiga-toxin–pro-
ducing E. coli. The teenage friend had diarrhea but 
was not admitted to the medical center.
Stool samples from the siblings were plated 
on Sorbitol–MacConkey agar and incubated in a 
liquid enrichment culture. The next day, super-
natants from the liquid cultures tested positive for 
Shiga toxin on enzyme-linked immunosorbent 
assay. Uniformly sorbitol-positive colonies were 
identified as E. coli on MALDI-TOF (matrix-assisted 
laser desorption ionization –time of flight) mass 
spectrometry. Several single colonies were positive 
for the stx2 gene and negative for the stx1 and eae 
genes on polymerase-chain-reaction (PCR) assay. 
None of the isolates agglutinated with polyvalent 
serum samples directed against the serotypes that 
are most frequently associated with Shiga-toxin–
producing E. coli. Subsequent analyses showed that 
the strain belonged to the rare serotype O104:H4 
harboring an extended-spectrum beta-lactamase 
(ESBL) gene of the CTX-M-15 class.
Although our 16-year-old patient had a mild 
course of disease without the hemolytic–uremic 
syndrome and was discharged from the hospital 
on the same day, the clinical picture for her broth-
er was much less benign. The boy’s renal function, 
hemoglobin level, and thromobocytopenia im-
proved after 9 days of peritoneal dialysis, but severe 
neurologic symptoms, including somnolence, vi-
sual impairment, speech disturbances, hemiplegia, 
and incontinence, developed. He underwent four 
cycles of plasmapheresis and therapy with the 
anti–C5-antibody eculizumab. After this treat-
ment, his clinical condition improved, and he was 
discharged after 24 days with serum creatinine 
levels just above the normal range. However, he 
was left with neurologic sequelae and required 
rehabilitation.
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Me thods a nd R esult s
Open-Source Genomics
To investigate the evolutionary origins and patho-
genic potential of the outbreak strain, we set in 
motion an open-source genomics program of re-
search that incorporated new high-throughput se-
quencing approaches, public data release, and rapid 
outsourcing of analyses to bioinformaticians 
worldwide (crowd-sourcing) (Fig. 1). Initially, we 
sequenced the genome of the isolate from the 
16-year-old girl (TY2482), using the Ion Torrent Per-
sonal Genome Machine (PGM), and obtained an 
initial draft of the genome 3 days after receipt of 
the DNA sample. Three DNA libraries were pre-
pared and seven sequencing runs performed, fol-
lowing the protocols of the manufacturer (Life 
Technologies), to generate 79 Mb of sequence data, 
with an average read length of 101 bp. (For details 
regarding the sequencing procedures, see the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org.)
We released these data into the public domain 
under a Creative Commons 0 license, which elic-
ited a burst of crowd-sourced, curiosity-driven 
analyses carried out by bioinformaticians on four 
continents.11 Twenty-four hours after the release of 
the genome, it had been assembled; 2 days after 
its dissemination, it had been assigned to an ex-
isting sequence type. Five days after the release of 
the sequence data, we had designed and released 
strain-specific diagnostic primer sequences, and 
within a week, two dozen reports had been filed 
on an open-source wiki (a Web site that facilitates 
collaborative effort) dedicated to analysis of the 
strain. These analyses provided timely information 
on the strain’s virulence and resistance genes, in 
addition to its phylogenetic lineage.
We also performed sequencing on the Illumina 
HiSeq platform in accordance with the manufac-
turer’s instructions. An initial single-end run was 
used to correct errors in the Ion Torrent sequence, 
principally in homopolymeric tracts. We later per-
formed paired-end and mate-pair sequencing on 
this platform, exploiting libraries with insert sizes 
of 470 bp, 2 kb, and 6 kb, and generated enough 
data (1 Gb, 576 Mb, and 576 Mb from each library, 
respectively) to create a high-quality draft genome 
sequence within 2 weeks after receipt of the DNA 
samples. (Additional details are provided in the 
Supplementary Appendix.) The reads were depos-
ited in GenBank’s Short Read Archive with acces-
sion numbers SRA037315 for Ion Torrent reads and 
SRA039136 for Illumina platform reads.
Phylogenetic Analysis
The assembled Ion Torrent data provided gene se-
quences that could be analyzed with an existing 
multilocus-sequence-typing scheme for E. coli that 
relied on sequence comparisons for seven con-
served housekeeping genes (adk, fumC, gyrB, mdh, 
purA, recA, and icd).12 This analysis revealed a close 
relationship to a strain, 01-09591, which was iso-
lated in Germany in 2001 and which fell into se-
quence type ST678. The TY2482 sequences differed 
from the profile of the 2001 strain by a single base 
pair in the adk gene and a single-base difference in 
a homopolymeric sequence in the recA gene. (We 
subsequently discovered that the latter difference 
was a sequencing error generated by the PGM.) The 
2001 strain, which produced Shiga toxin and was 
associated with the hemolytic–uremic syndrome, 
fell into the O104:H4 serotype but did not have the 
genes associated with type III secretion in typical 
enterohemorrhagic E. coli.13,14 Additional scrutiny 
of the multilocus-sequence-typing database re-
vealed that strains with the broad O104 serotype 
were scattered across several sequence types, 
whereas strains with the narrower O104:H4 sero-
type appeared to be limited to ST678.10
Comparisons of the TY2482 genome with all 
previously sequenced complete genomes of E. coli 
isolates revealed a very close relationship to E. coli 
strain 55989, with an average nucleotide identity 
of 99.8% (see the Supplementary Appendix). This 
strain was isolated in the Central African Repub-
lic from a stool sample obtained from an adult 
with human immunodeficiency virus infection 
who had persistent watery diarrhea.15 It has been 
classified as an enteroaggregative E. coli, but unlike 
TY2482, it does not have Shiga toxin genes.15 How-
ever, it is worth noting that Mossoro et al.,15 who 
first described E. coli strain 55989, also described 
strains of enteroaggregative E. coli with Shiga 
toxin genes in the same human population.15
Comparison of the Chromosomes of TY2482 
and 55989
Isolates from the German outbreak were initially 
described as enterohemorrhagic E. coli. However, 
the close relationship between TY2482 and 55989 
led us to consider the likelihood that TY2482 is an 
enteroaggregative E. coli. Our analysis of the gene 
content of TY2482 showed that it, like 01-09591, 
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lacked the LEE and genes encoding effectors as-
sociated with type III secretion.16 Instead, we found 
that the TY2482 genome encodes virulence factors 
that are typical of enteroaggregative E. coli. Other 
investigators working on the outbreak strain have 
also observed genes typically found in enteroag-
gregative strains on PCR assay and have noted a 
behavioral phenotype that is characteristic of this 
pathotype on cell-adherence assay.17
To identify strain-specific genes, we performed 
a detailed comparison of the chromosomes of 
TY2482 and enteroaggregative E. coli strain 55989. 
First, we aligned the TY2482 assembly against the 
55989 chromosome (for details, see the Supple-
mentary Appendix). We then adopted the gene 
predictions and annotation from the 55989 ge-
nome for these conserved sequences. Next, we 
identified several isolate-specific regions of differ-
ence (i.e., regions present in the TY2482 chromo-
some and absent from the 55989 genome or vice 
versa) that were more than 5 kb (Table 1 and Fig. 
2, and the Supplementary Appendix). TY2482-
specific regions of difference included prophage 
remnants or apparently intact prophages, such as 
the stx2 prophage, which, like its close relatives 
in the genomes of O157:H7 strains EDL933 and 
Sakai, is inserted into the wrbA locus. The stx2
genes differ by only one single-nucleotide polymor-
phism from the stx2 allele seen in O157 enterohe-
morrhagic E. coli strain EDL933.
TY2482 Plasmids
From our de novo assembly (i.e., assembly without 
the use of a reference genome), we concluded that 
the TY2482 genome contains two large conjuga-
tive plasmids, pESBL TY2482 and pAA TY2482, 
and a small plasmid, pG2011 TY2482 (Fig. 2). From 
scrutiny of copy numbers of sequence reads, it was 
clear that the two large plasmids were replicating 
at an approximate ratio of 1:1 with the chromo-
some, whereas the small plasmid was maintained 
at a copy number at least nine times that of the 
other replicons. No phenotype could be ascribed 
to the small plasmid.
The largest plasmid, pESBL TY2482, was an IncI 
plasmid similar to pEC_Bactec, which was found 
in an E. coli strain isolated from the joint of a 
horse with arthritis.18 The pESBL TY2482 plas-
mid encodes a CTX-M-15 ESBL, as well as a beta-
lactamase from the TEM class. The second large 
plasmid, pAA TY2482, resembled a plasmid from 
strain 55989 but carried a gene cluster encoding a 
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Figure 1. Timeline of the Open-Source Genomics Program.
After receiving the first batch of DNA samples on May 28, 2011, sequencing runs with the use of the Ion Torrent 
Personal Genome Machine (PGM) and Illumina (small-insert library) were initiated simultaneously. On May 31, the 
second batch of DNA was received and used for Illumina large-insert sequencing. An assembly of the Ion Torrent 
reads was released on June 2, which enabled subsequent analyses (multilocus sequence typing, phylogenetic analysis, 
and genome comparisons). Errors in the Ion Torrent data were corrected with the use of later Illumina data, and a 
high-quality draft genome sequence was created. GS denotes generation of sequencing technology. The symbols at 
May 28 and May 31 in the timeline indicate the arrival of DNA samples.
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rare type of aggregative adherence fimbria (AAF/I) 
instead of the more common type (AAF/III) en-
coded by genes in the 55989 plasmid. We ex-
ploited this AAF/I cluster as a target for strain-
specific PCR primers as part of a suite of primers 
to identify the outbreak isolate.
Discussion
Our genomic analyses suggest that the German 
outbreak strain evolved from a progenitor that 
belonged to the enteroaggregative pathotype and 
resembled strain 55989. The emergence of the 
outbreak strain depended on the acquisition of a 
stx2 prophage and of a plasmid encoding a CTX-
M-15 ESBL. Sometime during this process, the 
strain also appears to have lost one gene cluster, 
encoding AAF/III fimbriae, and gained another, 
encoding the rarer AAF/I fimbriae.
Although this outbreak strain has surprised 
the general public and public health officials, re-
lated potential progenitor strains have been re-
ported from three continents. The appearance of 
an O104:H4 strain associated with the hemolytic–
uremic syndrome in Korea in 2005 is unexplained, 
and its link to the German outbreak is unclear.9 
Also, the O104:H4 strain 01-09591 that was iso-
lated in Germany in 2001 urgently requires further 
investigation. Both strains should undergo ge-
nome sequencing and comparison with TY2482. 
The link to strain 55989, which was isolated in 
the Central African Republic in the late 1990s, is 
also intriguing. Genome sequencing of additional 
Central African isolates from the study that yielded 
55989 is likely to illuminate the evolution of this 
lineage and of enterovirulent E. coli in general (see 
the article by Rasko et al. elsewhere in this issue 
of the Journal19).
Although the genome sequence alone cannot 
provide a full explanation for the high degree of 
virulence of this strain, it prompts a reassessment 
of our assumptions and provides a framework for 
future hypothesis-driven research. Both commen-
sal and pathogenic varieties of E. coli have to survive 
in the gut. However, mere survival, even if twinned 
with the production of Shiga toxin, is probably 
Table 1. Genetic Elements in Strain TY2482 of Shiga-Toxin–Producing Escherichia coli O104:H4.
Genetic Element Notable Features or Functions Size or 55989 Coordinates*
Plasmid
pESBL TY2482 IncI1 plasmid, homologous to pEC_Bactec carrying 
bla CTX-M-15
88 kb
pAA TY2482 Plasmid encoding aggregative adherence fimbriae I 76 kb
pG2011 TY2482 Plasmid with no obvious phenotype 1.5 kb
Region of difference
I-ROD1 Degenerate prophage 296227 (tRNA-Thr)
I-ROD2 Stx2-encoding prophage 1176265 (wrbA)
I-ROD3 Microcin gene cluster; tellurite resistance gene cluster 1207704 (tRNA-Ser)
I-ROD4 Prophage 1811905 (ynfG)
I-ROD5 Prophage 2102453 (yecE)
I-ROD6 Molybdate metabolism regulator; yehL 2426442 (IS1)
I-ROD7 Multidrug-resistant gene cluster (dfA7, suII, suIII, 
strA, strB, tetA); mercury resistance
4211244 (tRNA-Sec)
D-ROD1 Prophage 1094587–1140306
D-ROD2 Prophage 1413924–1446834
D-ROD3 Prophage 1754689–1800354
D-ROD4 Prophage 2688656–2701228
D-ROD5 Type VI secretion genes 3401720–3427357
D-ROD6 Prophage 4944269–5004333
* Coordinates from the genome of E. coli strain 55989 are given for predicted boundaries of regions of difference, with 
the gene carrying the insertion site shown in parentheses for a region of difference involving an insertion into 55989 
(I-ROD). D-ROD denotes a region of difference involving a deletion.
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not enough to cause the hemolytic–uremic syn-
drome or bloody diarrhea. For that, the bacteria 
would probably need to adhere to the gut mucosa. 
In the past, much research has been concentrated 
on the adhesion systems of typical enterohemor-
rhagic E. coli, particularly the LEE-encoded type III 
secretion system.16,20 This German outbreak strain 
shows us that Shiga-toxin–producing E. coli can 
exploit alternative adhesion mechanisms, very like-
ly including aggregative adherence fimbriae, to the 
same end. This strain also shows that pathotypes 
of E. coli can overlap and that they evolve rather 
than stand as fixed archetypes.
It remains unclear why this strain has proved to 
be so virulent. As noted, a novel suite of adhesins 
might provide an explanation. Alternatively, per-
haps this strain exploits more efficient mecha-
nisms for toxin release. It is worth remembering 
that strains of enteroaggregative E. coli have caused 
large sprout-associated outbreaks before, including 
one outbreak21 that affected more than 2000 per-
sons in Japan in 1993. Thus, there is clearly an 
urgent need to understand how the German out-
break strain and other strains of enteroaggregative 
E. coli adhere to and colonize seeds and seedlings.
Our rapid open-source analysis of an outbreak-
associated bacterial pathogen was characterized 
by a propitious confluence of high-throughput 
genomics, crowd-sourced analyses, and a liberal 
approach to data release. Although phenotypic or 
molecular analyses that exploit known virulence, 
resistance, or epidemiologic targets are useful in 
diagnostic and public health microbiology, ge-
nome sequencing offers the advantages of open-
endedness (revealing the “unknown unknowns”), 
universal applicability, and the ultimate in reso-
lution. Our study shows how benchtop sequenc-
ing platforms can generate data with sufficient 
speed to have an important effect on clinical and 
epidemiologic problems.
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Figure 2. Comparison of the TY2482 and 55989 Genomes.
The outer circle depicts the Escherichia coli 55989 chromosome. The inner circle represents the TY2482 assembly 
mapped against the 55989 chromosome. Regions of difference (ROD) that are present in 55989 but not TY2482 
(D-RODs) are shown as gaps in the inner circle. The positions of RODs that were found in TY2482 but not 55989 
(I-RODs) are shown as wedges on the outer circle at positions corresponding to the predicted insertion sites. Tell-R 
denotes tellurite resistance.
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Supplementary Appendix: Open-source genomics of a Shiga-toxin-producing 
Escherichia coli O104:H4  
Crowd-sourcing consortium 
The following members of  the E. coli O104:H4 Genome Analysis Crowd-sourcing 
consortium made contributions that influenced the analyses reported here: Kathryn E. Holt, 
David J. Studholme, Michael Feldgarden and Marina Manrique.  
A full account of crowd-sourcing efforts can be accessed here:  https://github.com/ehec-
outbreak-crowdsourced/BGI-data-analysis/wiki/   
Methods and Results 
Ion Torrent library construction and sequencing 
Genomic DNA was extracted and purified using a conventional SDS lysis and phenol-
chloroform method. 5µg of DNA (OD260/OD280 = 1.85) was dissolved in TE buffer to a 
total volume of 100 µl and fragmented by sonication (Covaris S2, Massachusetts, USA) to a 
size distribution of 50-300 bp. Library preparation and template preparation of live Ion 
Sphere™ Particles was performed according to the manufacturer’s protocol (Ion Torrent, 
USA). During the library preparation, nick-translation was followed by 5 cycles of PCR 
amplification. Finally the sequencing was performed on the PGM Sequencer. Seven 314 
chips were run to generate 79.1 Mb of sequence, with average length of 101 bp. 
Illumina library construction and sequencing 
Whole-genome sequencing was performed using Illumina HiSeq 2000 (Illumina Inc. U.S.A) 
by generating paired-end libraries with an average insert size of 470 bp, 2 kbp and 6 kbp 
2 
 
following the manufacturer’s instruction. The read lengths were 90bp, 50bp, 50bp and 1Gb, 
576Mb and 576Mb high quality data were generated from each library respectively. 
Creation of a draft genome assembly using Ion Torrent PGM data (2nd June 2011) 
An assembly was performed using MIRA 3.2.1.17_dev using command-line parameters --
job=denovo,genome,accurate,iontor -GE:not=1. The Ion Torrent PGM assembly from 5 
chips of Ion Torrent 314 data produced an assembly of 3,057 contigs, total bases: 5,491,032 
with an N50 value of 3,675. 
Creation of a hybrid assembly using Ion Torrent PGM data and Illumina single-end data (6th 
June 2011) 
Ion Torrent and Illumina read data were quality filtered before assembly including removal of 
adapter contamination. The Ion Torrent PGM assembly from 7 chips of Ion Torrent 314 data 
were assembled with Newbler 2.0.00.22. Illumina single-end data (taken from the in-progress 
paired-end run) were assembled using SOAPdenovo 1.06
1
 (with k-mer of 51 and parameters 
"-d 1, -R". Assemblies were combined using AMOS minimus2 1.59 with parameters 
REFCOUNT=0, OVERLAP=50, MINID=94, MAXTRIM=10
2
. The resulting assembly 
consisted of 451 contigs  greater than 200bp with an N50 of 53266bp. The largest contig was 
204342bp. 
Creation of a draft genome scaffold assembly using Illumina paired-end and mate-pair reads 
A draft de novo assembly was produced using SOAPdenovo version 1.05. Contigs were first 
assembled using the 470bp paired-end library initially using a k-mer value of 45 for de Bruijn 
graph construction. These were subsequently scaffolded in a hierarchical fashion using 2kb 
followed by 6kb mate-pair libraries by way of the rank parameter in the SOAPdenovo 
configuration file. Other parameters supplied to SOAPdenovo included -F to attempt to fill 
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gaps in scaffolds. Where possible, in order to fill remaining scaffold gaps, local information 
available from the abundant mate-pair data was utilised by the GapCloser utility which was 
run over the assembly output with a k-mer size of 23. Both scaffolds and un-scaffolded 
contigs were used in further analysis, with the exception of contigs smaller than 200bp which 
were excluded. 
De novo assembly produced 24 scaffolds plus 75 un-scaffolded contigs. The largest scaffold 
was 757969bp, the smallest was 552bp. Scaffold N50 was 403980bp. After gap filling the 
scaffolds contained 143 distinct stretches of gaps (represented as ambiguous 'N' bases) 
comprising 94491bp of sequence. 
Insert sizes 
The estimated insert size with standard deviations predicted by SOAPdenovo are 
demonstrated in Table S1. 
Table S1. The estimated insert size determined by the de novo assembly process. 
Library Estimated insert size Standard deviation 
470bp 468 31 
2kb 2548 246 
6kb 6193 566 
 
Determination of closest reference by average nucleotide identity (ANI) 
Average nucleotide identity with all complete E. coli genomes available in GenBank was 
calculated using the ANIb algorithm which uses BLAST as the underlying alignment 
method
3-4
. Scrutiny of results (Table S2) revealed that E. coli 55989 showed the highest 
nucleotide identity with an ANI of 99.8% between the TY2482 draft chromosome and E. coli 
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55989. The ANIb algorithm shreds sequences into 1kb segments. BLAST alignments needed 
to be longer than 700bp and have >70% nucleotide identity to count towards ANIb 
calculation. ANIb parameters to BLAST were "-F F -e 0.001 -v 1 -b 1 -X 150 -q -1". 
Table S2. Average nucleotide identities for TY2482 compared against all complete E. 
coli genomes 
TY2482 vs ANIb 
Escherichia coli 55989 99.84 
Escherichia coli IAI1 99.2 
Escherichia coli W 99.14 
Escherichia coli E24377A 99.09 
Escherichia coli SE11 99.09 
Escherichia coli O103:H2 str. 12009 98.95 
Escherichia coli O26:H11 str. 11368 98.98 
Escherichia coli O111:H- str. 11128 98.85 
Escherichia coli HS 98.67 
Escherichia coli ATCC 8739 98.55 
Escherichia coli str. K-12 substr. W3110 98.54 
Escherichia coli str. K-12 substr. MG1655 98.54 
Escherichia coli DH1 98.54 
Escherichia coli BL21-Gold(DE3)plyss AG 98.53 
Escherichia coli BL21(DE3) 98.53 
Escherichia coli BL21(DE3) 98.53 
Escherichia coli B str. REL606 98.53 
Escherichia coli BW2952 98.49 
Escherichia coli str. K-12 substr. DH10B 98.5 
Escherichia coli H10407 98.5 
Escherichia coli ETEC H10407 98.5 
Escherichia coli O55:H7 str. CB9615 97.92 
Escherichia coli O157:H7 str. TW14359 97.86 
Escherichia coli O157:H7 str. Sakai 97.87 
Escherichia coli O157:H7 str. EC4115 97.86 
Escherichia coli O157:H7 str. EDL933 97.82 
Escherichia coli 042 97.45 
Escherichia coli UMN026 97.39 
Escherichia coli IAI39 97.3 
Escherichia coli SMS-3-5 97.21 
Escherichia coli SE15 97.06 
Escherichia coli CFT073 97.02 
Escherichia coli S88 96.97 
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Escherichia coli O83:H1 str. NRG 857C 96.99 
Escherichia coli O127:H6 str. E2348/69 96.95 
Escherichia coli UM146 96.94 
Escherichia coli 536 96.95 
Escherichia coli UTI89 96.93 
Escherichia coli APEC O1 96.98 
Escherichia coli ED1a 96.82 
 
Annotation of putative regions of difference between TY2482 and 59989 
The TY2482 scaffold assembly was aligned against E. coli 55989 using progressiveMauve
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(part of Mauve 2.3.1) using default settings. For ease of viewing, scaffolds were moved and 
where necessary reverse complemented to fit the order of the E. coli 55989 chromosome 
using the Mauve contig mover, again run with default parameters. Unaligned regions of the 
TY2482 >= 5kb were examined as putative regions of difference. Gene prediction within 
these regions was performed using Glimmer 3.02
6
 using the g3-iterated.sh workflow with 
default options. Genes with a raw score of >= 1.0 were extracted for further analysis. Due to 
Glimmer mis-predictions when run on the plasmid sequences, plasmids pESBL and pAA 
instead used Heuristic GeneMark.hmm
7
 PROKARYOTIC (version 2.8a) for gene calling. 
This was run with default settings and model file "heuristic_no_rbs.mat" 
(http://opal.biology.gatech.edu/GeneMark/heuristic_hmm2.cgi). Putative protein products >= 
50 aa in length were searched against the Genbank non-redundant protein database using 
PHMMER using HMMER (http://hmmer.janelia.org/). Genome visualisation plots were 
generated using CGview
8
. 
Manual inspection of scaffolds revealed each plasmid was contained within a single scaffold. 
Manual curation of pG2011 demonstrated an ~1.5kb plasmid with >99% nucleotide identity 
to E. coli strain H30 plasmid pO26-S1. This plasmid sequence was present as a 2-copy 
tandem repeat in the assembly, likely an artefact of the mate-pair assembly process (as insert 
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sizes longer than the plasmid were used) and has been manually edited to form a single copy. 
The location of the plasmids in the assembly are as follows: pESBL-TY2482 = scaffold19, 
pAA-TY2482 = scaffold16, pG2011 = scaffold21. 
Accession numbers 
The sequencing reads have been deposited into NCBI's Short Read Archive with accession 
numbers SRR227300, SRR227337, SRR227338, SRR227339, SRR227340, SRR231653, 
SRR231654 (Ion Torrent) and SRX079806 (Illumina mate-pair), SRX079805 (Illumina mate-
pair) , SRX079804 (Illumina paired-end). 
 
The scaffolded assembly and annotation has been deposited to Genbank, accession number 
AFVR00000000 (draft Illumina scaffold assembly), AFVS00000000  (Ion Torrent assembly) 
and AFOG01000000 (hybrid Ion Torrent and Illumina single-end assembly). 
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Table S3. Annotated genes on the RODs and plasmids of TY2482 
ROD_ID CDS_ID Best hit (NR) Curated 
annotation 
Best hit (species) 
I-ROD1 irod1_orf00001 conserved domain protein  Escherichia coli MS 84-1 
I-ROD1 irod1_orf00002 hypothetical protein ERKG_00886  Escherichia coli H252 
I-ROD1 irod1_orf00003 transposon Tn21 resolvase  Escherichia coli B7A 
I-ROD1 irod1_orf00005 hypothetical protein ECoL_00180  Escherichia coli EC4100B 
I-ROD1 irod1_orf00007 conserved domain protein  Escherichia coli MS 187-1 
I-ROD1 irod1_orf00008 conserved domain protein  Escherichia coli MS 187-1 
I-ROD1 irod1_orf00009 hypothetical protein HMPREF9550_01817  Escherichia coli MS 187-1 
I-ROD1 irod1_orf00011 putative acyl-carrier-protein S-malonyltransferase  Escherichia coli B7A 
I-ROD1 irod1_orf00012 hypothetical protein EcB7A_3346  Escherichia coli B7A 
I-ROD1 irod1_orf00013 hypothetical protein HMPREF9550_01813  Escherichia coli MS 187-1 
I-ROD1 irod1_orf00015 hypothetical protein ECoL_00172  Escherichia coli EC4100B 
I-ROD1 irod1_orf00016 hypothetical protein HMPREF9542_01440  Escherichia coli MS 117-3 
I-ROD1 irod1_orf00017 phage integrase  Escherichia coli H252 
I-ROD2 irod2_orf00001 integrase  Escherichia coli O26:H11 str. 11368 
I-ROD2 irod2_orf00002 hypothetical bacteriophage protein  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00004 conserved hypothetical protein  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00006 putative antirepressor  Escherichia coli O103:H2 str. 12009 
I-ROD2 irod2_orf00007 hypothetical protein ECO26_1566  Escherichia coli O26:H11 str. 11368 
I-ROD2 irod2_orf00008 hypothetical protein ECO26_1570  Escherichia coli O26:H11 str. 11368 
I-ROD2 irod2_orf00009 gp43  Escherichia coli B171 
I-ROD2 irod2_orf00010 conserved hypothetical protein  Escherichia coli O157:H7 str. EC508 
I-ROD2 irod2_orf00011 conserved hypothetical protein  Escherichia coli O157:H7 str. EC508 
I-ROD2 irod2_orf00012 hypothetical protein ECO103_2866  Escherichia coli O103:H2 str. 12009 
I-ROD2 irod2_orf00013 hypothetical protein ECO103_2865  Escherichia coli O103:H2 str. 12009 
I-ROD2 irod2_orf00014 putative exonuclease  Escherichia coli O103:H2 str. 12009 
I-ROD2 irod2_orf00015 RecT protein  Escherichia coli O157:H7 str. EC508 
I-ROD2 irod2_orf00016 conserved hypothetical protein  Escherichia coli O157:H7 str. EC4501 
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I-ROD2 irod2_orf00017 hypothetical protein ECH7EC4501_4934  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00019 conserved domain protein  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00020 conserved hypothetical protein  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00021 phage regulatory protein, Rha family  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00022 type II restriction enzyme BsuBI  Escherichia coli O157:H7 str. TW14588 
I-ROD2 irod2_orf00023 modification methylase BsuBI  Escherichia coli O157:H7 str. TW14588 
I-ROD2 irod2_orf00025 repressor protein CI  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00026 hypothetical protein SDY_1924  Shigella dysenteriae Sd197 
I-ROD2 irod2_orf00027 helicase domain protein  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00028 hypothetical protein ECOK1180_4044  Escherichia coli 1180 
I-ROD2 irod2_orf00029 hypothetical protein ECO103_2848  Escherichia coli O103:H2 str. 12009 
I-ROD2 irod2_orf00030 protein ninG  Escherichia coli 1180 
I-ROD2 irod2_orf00033 DNA modification methylase  Stx2-converting phage 86 
I-ROD2 irod2_orf00034 Shiga toxin 2 subunit A  Enterobacteria phage 933W 
I-ROD2 irod2_orf00036 Shiga toxin 2 subunit B  Enterobacteria phage 933W 
I-ROD2 irod2_orf00037 hypothetical protein  Shigella phage 7888 
I-ROD2 irod2_orf00038 hypothetical protein ECs2970  Escherichia coli O157:H7 str. Sakai 
I-ROD2 irod2_orf00039 conserved domain protein  Escherichia coli O157:H7 str. EC4113 
I-ROD2 irod2_orf00040 lysozyme  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00041 anti-repressor protein Ant  Enterobacteria phage VT2phi_272 
I-ROD2 irod2_orf00044 endopeptidase (Protein gp15)  Escherichia coli S88 
I-ROD2 irod2_orf00045 Rha protein  Escherichia coli O157:H7 str. TW14588 
I-ROD2 irod2_orf00048 putative terminase small subunit  Stx2-converting phage 86 
I-ROD2 irod2_orf00049 hypothetical protein ECOK1180_4067  Escherichia coli 1180 
I-ROD2 irod2_orf00050 large subunit terminase  Escherichia coli O157:H7 str. EC4113 
I-ROD2 irod2_orf00051 putative phage portal protein  Stx2-converting phage 86 
I-ROD2 irod2_orf00052 hypothetical protein 933Wp53  Enterobacteria phage 933W 
I-ROD2 irod2_orf00053 hypothetical protein 933Wp54  Enterobacteria phage 933W 
I-ROD2 irod2_orf00054 hypothetical protein 933Wp55  Enterobacteria phage 933W 
I-ROD2 irod2_orf00055 hypothetical protein 933Wp56  Enterobacteria phage 933W 
I-ROD2 irod2_orf00056 hypothetical protein ECs1226  Escherichia coli O157:H7 str. Sakai 
I-ROD2 irod2_orf00057 hypothetical protein ECO103_2826  Escherichia coli O103:H2 str. 12009 
10 
 
I-ROD2 irod2_orf00059 tail fiber protein  Escherichia coli O157:H7 str. EC4113 
I-ROD2 irod2_orf00061 hypothetical protein Stx2-86_gp25  Stx2-converting phage 86 
I-ROD2 irod2_orf00063 conserved hypothetical protein  Escherichia coli O157:H7 str. EC4196 
I-ROD2 irod2_orf00065 outer membrane protein Lom precursor  Enterobacteria phage 933W 
I-ROD2 irod2_orf00066 conserved hypothetical protein  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00067 hypothetical protein 933Wp68  Enterobacteria phage 933W 
I-ROD2 irod2_orf00068 conserved hypothetical protein  Escherichia coli O157:H7 str. EC4501 
I-ROD2 irod2_orf00069 hypothetical protein 933Wp70  Enterobacteria phage 933W 
I-ROD2 irod2_orf00071 hypothetical protein 933Wp71  Enterobacteria phage 933W 
I-ROD2 irod2_orf00072 hypothetical protein Stx2-86_gp35  Stx2-converting phage 86 
I-ROD2 irod2_orf00073 hypothetical protein  Enterobacteria phage Min27 
I-ROD3 irod3_orf00001 predicted integrase  Escherichia sp. 4_1_40B 
I-ROD3 irod3_orf00002 unknown  Shigella flexneri 2a 
I-ROD3 irod3_orf00003 prophage CP4-57 regulatory protein alpA  Escherichia coli 3431 
I-ROD3 irod3_orf00004 unknown  Shigella flexneri 2a 
I-ROD3 irod3_orf00005 type III restriction enzyme, res subunit  Pelobacter propionicus DSM 2379 
I-ROD3 irod3_orf00006 hypothetical protein E4_08923  Escherichia sp. 4_1_40B 
I-ROD3 irod3_orf00007 Transposase  Shigella dysenteriae CDC 74-1112 
I-ROD3 irod3_orf00008 IS66 family element, orf2  Shigella boydii CDC 3083-94 
I-ROD3 irod3_orf00011 hypothetical protein  Escherichia coli 
I-ROD3 irod3_orf00012 hypothetical protein HMPREF9552_03072  Escherichia coli MS 198-1 
I-ROD3 irod3_orf00013 hypothetical protein E4_08823  Escherichia sp. 4_1_40B 
I-ROD3 irod3_orf00014 hypothetical protein Z1185  Escherichia coli O157:H7 EDL933 
I-ROD3 irod3_orf00015 conserved hypothetical protein  Escherichia coli O157:H7 str. TW14588 
I-ROD3 irod3_orf00016 hypothetical protein Z1188  Escherichia coli O157:H7 EDL933 
I-ROD3 irod3_orf00017 putative glucosyltransferase  Escherichia coli O157:H7 EDL933 
I-ROD3 irod3_orf00018 putative ferric enterochelin esterase McmK  Escherichia coli 
I-ROD3 irod3_orf00019 MchS2 protein  Escherichia coli 
I-ROD3 irod3_orf00020 hypothetical protein p1ECUMN_0112  Escherichia coli UMN026 
I-ROD3 irod3_orf00022 MchC protein  Escherichia coli CFT073 
I-ROD3 irod3_orf00023 microcin H47 secretion protein  Escherichia coli 042 
I-ROD3 irod3_orf00024 MtfB  Escherichia coli 
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I-ROD3 irod3_orf00025 conserved hypothetical protein  Escherichia coli O157:H7 str. EC4196 
I-ROD3 irod3_orf00026 hypothetical protein ECDG_03856  Escherichia coli B185 
I-ROD3 irod3_orf00027 hypothetical protein ROD_49891  Citrobacter rodentium ICC168 
I-ROD3 irod3_orf00028 hypothetical protein ROD_49911  Citrobacter rodentium ICC168 
I-ROD3 irod3_orf00029 ImpA-related N- superfamily  Escherichia coli M605 
I-ROD3 irod3_orf00030 hypothetical protein AHA_1063  Aeromonas hydrophila subsp. hydrophila 
ATCC 7966 
I-ROD3 irod3_orf00031 immunoglobulin-binding regulator A  Escherichia coli M605 
I-ROD3 irod3_orf00032 insertion element IS1 7 protein insA  Shigella dysenteriae 1617 
I-ROD3 irod3_orf00034 hypothetical protein ECNA114_2538  Escherichia coli NA114 
I-ROD3 irod3_orf00035 putative transposase  Shigella flexneri K-671 
I-ROD3 irod3_orf00036 putative ATP synthase F0, A subunit  Escherichia coli MS 116-1 
I-ROD3 irod3_orf00037 aspartate racemase  Shigella flexneri K-272 
I-ROD3 irod3_orf00038 hypothetical protein HMPREF9541_00362  Escherichia coli MS 116-1 
I-ROD3 irod3_orf00039 putative transcriptional regulator  Shigella flexneri 2a 
I-ROD3 irod3_orf00042 conserved domain protein  Escherichia coli MS 116-1 
I-ROD3 irod3_orf00043 predicted protein  Nematostella vectensis 
I-ROD3 irod3_orf00044 protein kinase  Yersinia pseudotuberculosis IP 31758 
I-ROD3 irod3_orf00045 hypothetical protein ESA_01782  Cronobacter sakazakii ATCC BAA-894 
I-ROD3 irod3_orf00046 putative tellurium resistance protein TerY3 Serratia marcescens 
I-ROD3 irod3_orf00047 putative tellurium resistance protein TerY2 Serratia marcescens 
I-ROD3 irod3_orf00049 tellurium resistance protein TerX Serratia marcescens 
I-ROD3 irod3_orf00050 putative tellurium resistance protein TerY TerY1 Enterobacter cloacae subsp. cloacae ATCC 
13047 
I-ROD3 irod3_orf00051 terW TerW Citrobacter sp. 30_2 
I-ROD3 irod3_orf00052 hypothetical protein SMR0069  Serratia marcescens 
I-ROD3 irod3_orf00053 hypothetical protein Z1166  Escherichia coli O157:H7 EDL933 
I-ROD3 irod3_orf00054 putative ATP-binding protein  Escherichia coli APEC O1 
I-ROD3 irod3_orf00055 hypothetical protein APECO1_O1R65  Escherichia coli APEC O1 
I-ROD3 irod3_orf00056 hypothetical protein APECO1_O1R66  Escherichia coli APEC O1 
I-ROD3 irod3_orf00057 hypothetical protein APECO1_O1R67  Escherichia coli APEC O1 
I-ROD3 irod3_orf00058 putative phage inhibition, colicin resistance and tellurite resistance protein TerZ Escherichia coli O157:H7 EDL933 
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I-ROD3 irod3_orf00059 putative phage inhibition, colicin resistance and tellurite resistance protein TerA Escherichia coli O157:H7 EDL933 
I-ROD3 irod3_orf00060 putative phage inhibition, colicin resistance and tellurite resistance protein TerB Escherichia coli O157:H7 EDL933 
I-ROD3 irod3_orf00061 putative phage inhibition, colicin resistance and tellurite resistance protein TerC Escherichia coli O157:H7 EDL933 
I-ROD3 irod3_orf00063 putative phage inhibition, colicin resistance and tellurite resistance protein TerD Escherichia coli O157:H7 EDL933 
I-ROD3 irod3_orf00064 putative phage inhibition, colicin resistance and tellurite resistance protein TerE Escherichia coli O157:H7 EDL933 
I-ROD3 irod3_orf00065 putative tellurium resistance protein TerF TerF Escherichia coli O103:H2 str. 12009 
I-ROD3 irod3_orf00067 putative GTP-binding protein  Escherichia coli 042 
I-ROD3 irod3_orf00068 antigen 43 precursor  Escherichia coli 
I-ROD3 irod3_orf00071 putative autotransporter  Shigella sp. D9 
I-ROD3 irod3_orf00072 hypothetical protein EscherichiacoliO157_22726  Escherichia coli O157:H7 str. FRIK2000 
I-ROD3 irod3_orf00073 hypothetical protein ECS88_2092  Escherichia coli S88 
I-ROD3 irod3_orf00074 hypothetical protein ECS88_2092  Escherichia coli S88 
I-ROD3 irod3_orf00075 conserved hypothetical protein  Escherichia coli H591 
I-ROD3 irod3_orf00077 hypothetical protein SD1617_3951  Shigella dysenteriae 1617 
I-ROD3 irod3_orf00078 hypothetical protein ECS88_2094  Escherichia coli S88 
I-ROD3 irod3_orf00079 hypothetical protein APECO1_1098  Escherichia coli APEC O1 
I-ROD3 irod3_orf00080 hypothetical protein ECO103_3758  Escherichia coli O103:H2 str. 12009 
I-ROD3 irod3_orf00081 hypothetical protein ECNA114_2131  Escherichia coli NA114 
I-ROD3 irod3_orf00083 toxin of the YeeV-YeeU toxin-antitoxin system  Escherichia sp. 4_1_40B 
I-ROD3 irod3_orf00084 conserved hypothetical protein  Escherichia coli ETEC H10407 
I-ROD3 irod3_orf00086 hypothetical protein UTI89_C4999  Escherichia coli UTI89 
I-ROD3 irod3_orf00087 hypothetical protein Z1226  Escherichia coli O157:H7 EDL933 
I-ROD4 irod4_orf00001 AntB  Escherichia coli 
I-ROD4 irod4_orf00003 conserved hypothetical protein  Escherichia coli FVEC1302 
I-ROD4 irod4_orf00004 valyl-tRNA synthetase  Escherichia coli E110019 
I-ROD4 irod4_orf00006 hypothetical protein Stx2-86_gp35  Stx2-converting phage 86 
I-ROD4 irod4_orf00008 hypothetical protein SDY_1670  Shigella dysenteriae Sd197 
I-ROD4 irod4_orf00010 hypothetical protein ECED1_1152  Escherichia coli ED1a 
I-ROD4 irod4_orf00011 hypothetical protein ECED1_1151  Escherichia coli ED1a 
I-ROD4 irod4_orf00012 hypothetical protein 933Wp68  Enterobacteria phage 933W 
I-ROD4 irod4_orf00013 hypothetical protein Stx2-86_gp30  Stx2-converting phage 86 
I-ROD4 irod4_orf00014 putative outer membrane precursor Lom  Escherichia coli O103:H2 str. 12009 
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I-ROD4 irod4_orf00016 hypothetical protein Stx2Ip034  Stx2 converting phage I 
I-ROD4 irod4_orf00018 hypothetical protein Stx2-86_gp25  Stx2-converting phage 86 
I-ROD4 irod4_orf00020 putative long tail fiber protein  Stx2-converting phage 86 
I-ROD4 irod4_orf00021 hypothetical protein ECED1_1137  Escherichia coli ED1a 
I-ROD4 irod4_orf00022 hypothetical protein ECED1_1136  Escherichia coli ED1a 
I-ROD4 irod4_orf00023 hypothetical protein ECED1_1135  Escherichia coli ED1a 
I-ROD4 irod4_orf00024 hypothetical protein Stx2-86_gp17  Stx2-converting phage 86 
I-ROD4 irod4_orf00025 hypothetical protein ECED1_1133  Escherichia coli ED1a 
I-ROD4 irod4_orf00026 hypothetical protein ECED1_1132  Escherichia coli ED1a 
I-ROD4 irod4_orf00027 putative phage portal protein  Stx2-converting phage 86 
I-ROD4 irod4_orf00028 hypothetical protein ECOK1180_4067  Escherichia coli 1180 
I-ROD4 irod4_orf00029 large subunit terminase  Escherichia coli O157:H7 str. EC4113 
I-ROD4 irod4_orf00030 putative terminase small subunit  Stx2-converting phage 86 
I-ROD4 irod4_orf00033 bacteriophage lysis protein  Shigella dysenteriae 1012 
I-ROD4 irod4_orf00036 putative endolysin  Shigella dysenteriae Sd197 
I-ROD4 irod4_orf00037 protein S  Enterobacteria phage 933W 
I-ROD4 irod4_orf00038 conserved hypothetical protein  Shigella dysenteriae 1617 
I-ROD4 irod4_orf00039 hypothetical protein SGF_04061  Shigella flexneri CDC 796-83 
I-ROD4 irod4_orf00040 YjhS  Shigella boydii CDC 3083-94 
I-ROD4 irod4_orf00041 putative NinH protein  Phage BP-4795 
I-ROD4 irod4_orf00042 crossover junction endodeoxyribonuclease  Escherichia coli ED1a 
I-ROD4 irod4_orf00044 hypothetical protein E2348C_2522  Escherichia coli O127:H6 str. E2348/69 
I-ROD4 irod4_orf00045 putative ninB protein  Escherichia coli ED1a 
I-ROD4 irod4_orf00046 putative antirepressor protein Ant from prophage  Escherichia coli ED1a 
I-ROD4 irod4_orf00047 hypothetical protein ECO26_2262  Escherichia coli O26:H11 str. 11368 
I-ROD4 irod4_orf00048 death-on-curing family protein  Escherichia coli STEC_7v 
I-ROD4 irod4_orf00049 hypothetical protein ECSTEC7V_1837  Escherichia coli STEC_7v 
I-ROD4 irod4_orf00050 hypothetical protein ECO111_1061  Escherichia coli O111:H- str. 11128 
I-ROD4 irod4_orf00051 hypothetical protein G2583_1712  Escherichia coli O55:H7 str. CB9615 
I-ROD4 irod4_orf00052 hypothetical protein EcE24377A_1426  Escherichia coli E24377A 
I-ROD4 irod4_orf00053 hypothetical protein ECO103_1369  Escherichia coli O103:H2 str. 12009 
I-ROD4 irod4_orf00055 putative replication protein  Escherichia coli ED1a 
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I-ROD4 irod4_orf00056 hypothetical protein ECED1_1103  Escherichia coli ED1a 
I-ROD4 irod4_orf00057 hypothetical protein ECED1_1102  Escherichia coli ED1a 
I-ROD4 irod4_orf00058 regulatory protein CII from prophage  Escherichia coli ED1a 
I-ROD4 irod4_orf00059 prophage repressor CI  Enterobacteria phage HK97 
I-ROD4 irod4_orf00060 hypothetical protein ECED1_1098  Escherichia coli ED1a 
I-ROD4 irod4_orf00061 hypothetical protein ECED1_1097  Escherichia coli ED1a 
I-ROD4 irod4_orf00063 monocarboxylate transporter  Culex quinquefasciatus 
I-ROD4 irod4_orf00064 hypothetical protein ECED1_1095  Escherichia coli ED1a 
I-ROD4 irod4_orf00065 hypothetical protein ECED1_1094  Escherichia coli ED1a 
I-ROD4 irod4_orf00067 FtsZ inhibitor protein  Escherichia coli ED1a 
I-ROD4 irod4_orf00068 hypothetical protein ECED1_1091  Escherichia coli ED1a 
I-ROD4 irod4_orf00069 Exodeoxyribonuclease VIII (putative partial) from phage origin  Escherichia coli ED1a 
I-ROD4 irod4_orf00070 putative host-nuclease inhibitor protein Gam  Shigella dysenteriae Sd197 
I-ROD4 irod4_orf00071 Recombination protein bet from phage origin  Escherichia coli ED1a 
I-ROD4 irod4_orf00072 putative exonuclease encoded by prophage CP-933K  Escherichia coli O157:H7 EDL933 
I-ROD4 irod4_orf00074 prophage DLP12 integrase  Escherichia coli 101-1 
I-ROD5 irod5_orf00001 hypothetical protein SSON_1273  Shigella sonnei Ss046 
I-ROD5 irod5_orf00002 hypothetical protein EC55989_1079  Escherichia coli 55989 
I-ROD5 irod5_orf00005 triple helix repeat-containing collagen  Clostridium beijerinckii NCIMB 8052 
I-ROD5 irod5_orf00006 hypothetical protein SD15574_2985  Shigella dysenteriae 155-74 
I-ROD5 irod5_orf00008 hypothetical protein ECE128010_5420  Escherichia coli E128010 
I-ROD5 irod5_orf00011 Putative tail component of prophage  Escherichia coli NA114 
I-ROD5 irod5_orf00012 hypothetical protein ECLG_05105  Escherichia coli TA271 
I-ROD5 irod5_orf00015 Superoxide dismutase (Cu-Zn)  Escherichia coli O55:H7 str. CB9615 
I-ROD5 irod5_orf00019 minor tail protein  Escherichia coli UTI89 
I-ROD5 irod5_orf00021 minor tail protein  Escherichia coli UTI89 
I-ROD5 irod5_orf00022 putative tail fiber component H of prophage CP-933U  Escherichia coli O157:H7 EDL933 
I-ROD5 irod5_orf00024 Phage minor tail protein  Escherichia coli EC4100B 
I-ROD5 irod5_orf00025 Phage minor tail protein  Escherichia coli EC4100B 
I-ROD5 irod5_orf00026 phage major tail protein  Escherichia coli 042 
I-ROD5 irod5_orf00027 hypothetical protein DAPPUDRAFT_279812  Daphnia pulex 
I-ROD5 irod5_orf00029 polysaccharide Transporter, PST family  Enterococcus faecium E1679 
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I-ROD5 irod5_orf00032 hypothetical protein  Arthrospira platensis NIES-39 
I-ROD5 irod5_orf00034 terminase large subunit domain protein  Escherichia coli RN587/1 
I-ROD5 irod5_orf00035 conserved hypothetical protein  Escherichia albertii TW07627 
I-ROD5 irod5_orf00036 phage major capsid protein E  Escherichia coli H489 
I-ROD5 irod5_orf00039 Hypothetical protein CBG02325  Caenorhabditis briggsae 
I-ROD5 irod5_orf00041 conserved domain protein  Escherichia coli MS 153-1 
I-ROD5 irod5_orf00042 hypothetical protein c1457  Escherichia coli CFT073 
I-ROD5 irod5_orf00043 Phage minor tail protein  Escherichia coli EC4100B 
I-ROD5 irod5_orf00045 hypothetical protein MK0973  Methanopyrus kandleri AV19 
I-ROD5 irod5_orf00047 hypothetical protein SCA50_1305  Salmonella enterica subsp. enterica serovar 
Choleraesuis str. SCSA50 
I-ROD5 irod5_orf00049 hypothetical protein ECOK1_1278  Escherichia coli IHE3034 
I-ROD5 irod5_orf00052 phage DNA packaging protein Nu1  Escherichia coli MS 21-1 
I-ROD5 irod5_orf00053 putative phage protein  Escherichia coli 042 
I-ROD5 irod5_orf00055 hypothetical protein ECS88_0566  Escherichia coli S88 
I-ROD5 irod5_orf00056 endopeptidase  Escherichia coli 2362-75 
I-ROD5 irod5_orf00058 hypothetical protein SBO_1923  Shigella boydii Sb227 
I-ROD5 irod5_orf00059 putative membrane-associated lysozyme; Qin prophage  Escherichia coli 55989 
I-ROD5 irod5_orf00061 hypothetical protein Stx2-86_gp06  Stx2-converting phage 86 
I-ROD5 irod5_orf00062 hypothetical protein Stx2-86_gp05  Stx2-converting phage 86 
I-ROD5 irod5_orf00063 lysis protein S  Stx2-converting phage 86 
I-ROD5 irod5_orf00066 hypothetical protein DAPPUDRAFT_52038  Daphnia pulex 
I-ROD5 irod5_orf00068 heterokaryon incompatibility protein  Glomerella graminicola M1.001 
I-ROD5 irod5_orf00070 DNA methylase family protein  Shigella flexneri J1713 
I-ROD5 irod5_orf00071 hypothetical protein HMPREF9542_00842  Escherichia coli MS 117-3 
I-ROD5 irod5_orf00072 hypothetical protein EcF11_4284  Escherichia coli F11 
I-ROD5 irod5_orf00075 hypothetical protein ECRN5871_4170  Escherichia coli RN587/1 
I-ROD5 irod5_orf00076 hypothetical protein E4_10746  Escherichia sp. 4_1_40B 
I-ROD5 irod5_orf00077 endodeoxyribonuclease RusA family protein  Escherichia coli STEC_7v 
I-ROD5 irod5_orf00078 LexA repressor  Escherichia coli S88 
I-ROD5 irod5_orf00079 DNA adenine methylase  Escherichia coli UTI89 
I-ROD5 irod5_orf00080 hypothetical protein ECS88_0547  Escherichia coli S88 
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I-ROD5 irod5_orf00081 hypothetical protein PcdtI_gp46  Phage cdtI 
I-ROD5 irod5_orf00082 putative antirepressor  Escherichia coli EC4100B 
I-ROD5 irod5_orf00083 nucleic acid-binding protein; e14 prophage  Escherichia coli S88 
I-ROD5 irod5_orf00084 hypothetical protein ECD227_2469  Escherichia fergusonii ECD227 
I-ROD5 irod5_orf00085 regulatory protein cI  Escherichia coli EC4100B 
I-ROD5 irod5_orf00086 hypothetical protein ECoL_03975  Escherichia coli EC4100B 
I-ROD5 irod5_orf00087 hypothetical protein ECoL_03976  Escherichia coli EC4100B 
I-ROD5 irod5_orf00089 Hypothetical protein yfdR  Escherichia coli EC4100B 
I-ROD5 irod5_orf00090 hypothetical protein ShiD9_12075  Shigella sp. D9 
I-ROD5 irod5_orf00091 conserved hypothetical protein  Escherichia coli E22 
I-ROD5 irod5_orf00093 conserved hypothetical protein  Escherichia coli E22 
I-ROD5 irod5_orf00095 Phage EaA protein  Escherichia coli EC4100B 
I-ROD5 irod5_orf00096 Phage EaA protein  Escherichia coli EC4100B 
I-ROD5 irod5_orf00097 Integrase  Escherichia coli EC4100B 
I-ROD6 irod6_orf00001 molybdate metabolism regulator  Escherichia coli 536 
I-ROD6 irod6_orf00003 hypothetical protein ECP_2154  Escherichia coli 536 
I-ROD6 irod6_orf00005 yehL protein  Escherichia coli B088 
I-ROD6 irod6_orf00006 hypothetical protein ECP_2157  Escherichia coli 536 
I-ROD6 irod6_orf00007 hypothetical protein ECIAI1_2197  Escherichia coli IAI1 
I-ROD6 irod6_orf00008 hypothetical protein ECP_2159  Escherichia coli 536 
I-ROD7 irod7_orf00001 integrase  Escherichia coli 
I-ROD7 irod7_orf00002 Evolved beta-D-galactosidase, beta subunit  Shigella dysenteriae CDC 74-1112 
I-ROD7 irod7_orf00003 transposase TnpA  Corynebacterium glutamicum 
I-ROD7 irod7_orf00004 resolvase for Tn21  Plasmid R100 
I-ROD7 irod7_orf00006 Urf2 protein  Escherichia fergusonii ECD227 
I-ROD7 irod7_orf00007 integrase  Plasmid R100 
I-ROD7 irod7_orf00008 dihydrofolate reductase type A7  Salmonella enterica subsp. enterica serovar 
Weltevreden 
I-ROD7 irod7_orf00010 putative transposase  Klebsiella pneumoniae subsp. pneumoniae 
MGH 78578 
I-ROD7 irod7_orf00014 3-hydroxyisobutyrate dehydrogenase  Mycobacterium tuberculosis 210 
I-ROD7 irod7_orf00016 protein RepC  Salmonella enterica subsp. enterica serovar 
Enteritidis 
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I-ROD7 irod7_orf00017 dihydropteroate synthase  Salmonella enterica subsp. enterica serovar 
Typhi str. CT18 
I-ROD7 irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase  Escherichia coli MS 200-1 
I-ROD7 irod7_orf00019 beta-lactamase  Escherichia coli 3431 
I-ROD7 irod7_orf00021 hypothetical protein R100p008  Plasmid R100 
I-ROD7 irod7_orf00022 putative mercury resistance protein  Plasmid R100 
I-ROD7 irod7_orf00023 transcriptional regulator MerD  Plasmid R100 
I-ROD7 irod7_orf00026 RecName: Full=Mercuric reductase; AltName: Full=Hg(II) reductase  
I-ROD7 irod7_orf00027 putative mercury transport protein MerC  Aeromonas salmonicida subsp. salmonicida 
A449 
I-ROD7 irod7_orf00029 Tn501 orf, hypotheical  Shigella flexneri 5a 
I-ROD7 irod7_orf00033 InsL  Escherichia coli 53638 
I-ROD7 irod7_orf00034 hypothetical protein pFL129_4  Escherichia coli 
I-ROD7 irod7_orf00036 TetA  Salmonella enterica subsp. enterica serovar 
Choleraesuis 
I-ROD7 irod7_orf00037 integral membrane protein DUF6  Escherichia coli MS 78-1 
I-ROD7 irod7_orf00038 hypothetical protein HMPREF9544_05491  Escherichia coli MS 153-1 
I-ROD7 irod7_orf00039 conserved hypothetical protein  Escherichia coli ETEC H10407 
I-ROD7 irod7_orf00040 conserved hypothetical protein  Escherichia coli SE15 
I-ROD7 irod7_orf00042 hypothetical protein HMPREF9553_03865  Escherichia coli MS 200-1 
I-ROD7 irod7_orf00044 putative regulatory protein  Escherichia coli 536 
I-ROD7 irod7_orf00045 conserved hypothetical protein  Escherichia coli SE15 
I-ROD7 irod7_orf00046 transposase  Escherichia coli SE15 
I-ROD7 irod7_orf00048 hypothetical protein  Escherichia coli SE15 
I-ROD7 irod7_orf00049 hypothetical protein ECUMN_4880  Escherichia coli UMN026 
I-ROD7 irod7_orf00051 putative autotransporter  Escherichia coli 536 
I-ROD7 irod7_orf00052 antigen 43 domain protein  Escherichia coli LT-68 
I-ROD7 irod7_orf00053 hypothetical protein EcE24377A_4893  Escherichia coli E24377A 
I-ROD7 irod7_orf00054 hypothetical protein ECNA114_2131  Escherichia coli NA114 
I-ROD7 irod7_orf00056 conserved domain protein  Escherichia coli MS 187-1 
I-ROD7 irod7_orf00058 conserved hypothetical protein  Escherichia coli SE15 
I-ROD7 irod7_orf00059 putative radC-like protein yeeS  Escherichia coli CFT073 
I-ROD7 irod7_orf00060 hypothetical protein c0272  Escherichia coli CFT073 
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I-ROD7 irod7_orf00061 unknown  Escherichia coli 
I-ROD7 irod7_orf00063 DNA repair protein  Escherichia coli MS 78-1 
I-ROD7 irod7_orf00064 hypothetical protein c4574  Escherichia coli CFT073 
I-ROD7 irod7_orf00065 conserved hypothetical protein  Shigella dysenteriae 1617 
I-ROD7 irod7_orf00067 hypothetical protein APECO1_3486  Escherichia coli APEC O1 
I-ROD7 irod7_orf00068 hypothetical protein SF3000  Shigella flexneri 2a str. 301 
I-ROD7 irod7_orf00069 hypothetical protein ECO103_3594  Escherichia coli O103:H2 str. 12009 
I-ROD7 irod7_orf00070 hypothetical protein ECED1_4984  Escherichia coli ED1a 
pESBL scaffold19_orf0002 YciB  Escherichia coli 
pESBL scaffold19_orf0003 hypothetical protein pECBactecp21  Escherichia coli 
pESBL scaffold19_orf0004 hypothetical protein SC121  Salmonella enterica subsp. enterica serovar 
Choleraesuis str. SC-B67 
pESBL scaffold19_orf0005 single-stranded DNA-binding protein  Salmonella enterica subsp. enterica serovar 
Choleraesuis str. SC-B67 
pESBL scaffold19_orf0006 hypothetical protein pO157p50  Escherichia coli O157:H7 str. Sakai 
pESBL scaffold19_orf0007 plasmid SOS inhibition protein B  Escherichia coli 
pESBL scaffold19_orf0008 plasmid SOS inhibition protein A  Salmonella enterica subsp. enterica serovar 
Choleraesuis str. SC-B67 
pESBL scaffold19_orf0009 hypothetical protein SC115  Salmonella enterica subsp. enterica serovar 
Choleraesuis str. SC-B67 
pESBL scaffold19_orf0010 antirestriction protein  Escherichia coli MS 107-1 
pESBL scaffold19_orf0011 hypothetical protein ECSE_P1-0063  Escherichia coli SE11 
pESBL scaffold19_orf0012 hypothetical protein HMPREF9542_03988  Escherichia coli MS 117-3 
pESBL scaffold19_orf0013 hypothetical protein SeHA_A0062  Salmonella enterica subsp. enterica serovar 
Heidelberg str. SL476 
pESBL scaffold19_orf0014 hypothetical protein EcE22_3665  Escherichia coli E22 
pESBL scaffold19_orf0015 CcgAII protein  Salmonella enterica subsp. enterica serovar 
Choleraesuis str. SC-B67 
pESBL scaffold19_orf0016 putative transposase  Escherichia coli E22 
pESBL scaffold19_orf0018 hypothetical protein SC107  Salmonella enterica subsp. enterica serovar 
Choleraesuis str. SC-B67 
pESBL scaffold19_orf0019 hypothetical protein R64_p076  Salmonella enterica subsp. enterica serovar 
Typhimurium 
pESBL scaffold19_orf0020 hypothetical protein SC105  Salmonella enterica subsp. enterica serovar 
Choleraesuis str. SC-B67 
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pESBL scaffold19_orf0021 hypothetical protein pECBactecp14  Escherichia coli 
pESBL scaffold19_orf0022 hypothetical protein LH0067  Escherichia coli 
pESBL scaffold19_orf0023 relaxosome component  Plasmid ColIb-P9 
pESBL scaffold19_orf0024 NikB  Escherichia coli O157:H7 str. Sakai 
pESBL scaffold19_orf0025 hypothetical protein EcE24377A_D0057  Escherichia coli E24377A 
pESBL scaffold19_orf0026 hypothetical protein pECBactecp09  Escherichia coli 
pESBL scaffold19_orf0027 hypothetical protein pECBactecp08  Escherichia coli 
pESBL scaffold19_orf0028 putative protein FinQ  Escherichia coli MS 84-1 
pESBL scaffold19_orf0029 counter protein for PndA  Escherichia coli 
pESBL scaffold19_orf0030 hypothetical protein SC084  Salmonella enterica subsp. enterica serovar 
Choleraesuis str. SC-B67 
pESBL scaffold19_orf0031 conserved hypothetical protein  Escherichia coli MS 107-1 
pESBL scaffold19_orf0032 hypothetical protein ECSE_P1-0081  Escherichia coli SE11 
pESBL scaffold19_orf0033 putative regulator protein  Escherichia coli SE11 
pESBL scaffold19_orf0034 exclusion-determining family protein  Escherichia coli MS 84-1 
pESBL scaffold19_orf0035 TraY  Escherichia coli O157:H7 str. EC4486 
pESBL scaffold19_orf0036 F pilin acetylation protein  Escherichia coli 
pESBL scaffold19_orf0037 F pilus assembly  Escherichia coli 
pESBL scaffold19_orf0038 F pilus assembly  Escherichia coli 
pESBL scaffold19_orf0039 TraU  Escherichia coli O157:H7 str. EC4401 
pESBL scaffold19_orf0040 hypothetical protein HMPREF9542_01329  Escherichia coli MS 117-3 
pESBL scaffold19_orf0041 TraR protein  Escherichia coli 
pESBL scaffold19_orf0042 hypothetical protein ColIb-P9_p070  Plasmid ColIb-P9 
pESBL scaffold19_orf0043 hypothetical protein ColIb-P9_p071  Plasmid ColIb-P9 
pESBL scaffold19_orf0044 hypothetical protein ColIb-P9_p072  Plasmid ColIb-P9 
pESBL scaffold19_orf0045 hypothetical protein ColIb-P9_p073  Plasmid ColIb-P9 
pESBL scaffold19_orf0046 hypothetical protein ColIb-P9_p074  Plasmid ColIb-P9 
pESBL scaffold19_orf0047 thick pilus signal peptide  Escherichia coli W 
pESBL scaffold19_orf0048 DNA primase  Escherichia coli O157:H7 str. EC4401 
pESBL scaffold19_orf0049 EDTA-resistant nuclease  Escherichia coli 
pESBL scaffold19_orf0051 ATP-binding protein  Plasmid ColIb-P9 
pESBL scaffold19_orf0052 lipoprotein  Salmonella enterica subsp. enterica serovar 
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Typhimurium 
pESBL scaffold19_orf0053 hypothetical protein ColIb-P9_p082  Plasmid ColIb-P9 
pESBL scaffold19_orf0054 hypothetical protein ColIb-P9_p083  Plasmid ColIb-P9 
pESBL scaffold19_orf0055 F pilus assembly  Escherichia coli 
pESBL scaffold19_orf0056 TraE protein  Escherichia coli 
pESBL scaffold19_orf0057 shufflon-specific DNA recombinase  Escherichia coli AA86 
pESBL scaffold19_orf0058 hypothetical protein HMPREF9536_01879  Escherichia coli MS 84-1 
pESBL scaffold19_orf0059 conserved hypothetical protein  Escherichia coli MS 107-1 
pESBL scaffold19_orf0060 hypothetical protein R64_p118  Salmonella enterica subsp. enterica serovar 
Typhimurium 
pESBL scaffold19_orf0061 shufflon protein C'  Escherichia coli O157:H7 str. EC4486 
pESBL scaffold19_orf0062 conserved hypothetical protein  Escherichia coli MS 107-1 
pESBL scaffold19_orf0063 shufflon protein A  Salmonella enterica subsp. enterica serovar 
Kentucky str. CVM29188 
pESBL scaffold19_orf0064 peptidase A24A prepilin type IV  Escherichia coli W 
pESBL scaffold19_orf0065 type IV prepilin cluster  Escherichia coli 
pESBL scaffold19_orf0066 type IV prepilin cluster; prepilin  Escherichia coli 
pESBL scaffold19_orf0067 integral membrane protein  Escherichia coli E22 
pESBL scaffold19_orf0068 ATP-binding protein PilQ  Escherichia coli SE11 
pESBL scaffold19_orf0069 IncI1 conjugal transfer protein PilP  Escherichia coli 
pESBL scaffold19_orf0070 IncI1 conjugal transfer protein PilO  Escherichia coli 
pESBL scaffold19_orf0071 lipoprotein PilN  Escherichia coli SE11 
pESBL scaffold19_orf0072 hypothetical protein ColIb-P9_p101  Plasmid ColIb-P9 
pESBL scaffold19_orf0073 IncI1 conjugal transfer protein PilL  Escherichia coli 
pESBL scaffold19_orf0074 predicted protein  Nematostella vectensis 
pESBL scaffold19_orf0075 IncI1 conjugal transfer protein TraC  Escherichia coli 
pESBL scaffold19_orf0076 transcription termination factor NusG  Escherichia coli MS 84-1 
pESBL scaffold19_orf0077 TraA protein  Escherichia coli SE11 
pESBL scaffold19_orf0078 replication initiation protein  Salmonella enterica subsp. enterica serovar 
Kentucky str. CVM29188 
pESBL scaffold19_orf0079 hypothetical protein ND12IncI1_3  Escherichia coli 
pESBL scaffold19_orf0080 hypothetical protein pECBactecp34  Escherichia coli 
pESBL scaffold19_orf0081 YagA  Escherichia coli O157:H7 str. EC4486 
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pESBL scaffold19_orf0082 transposase  Salmonella enterica subsp. enterica serovar 
Infantis 
pESBL scaffold19_orf0083 conserved hypothetical protein  Escherichia coli MS 21-1 
pESBL scaffold19_orf0084 hypothetical protein  Escherichia coli 
pESBL scaffold19_orf0085 hypothetical protein pC15-1a_016 blaCTX-
M-15 
Escherichia coli 
pESBL scaffold19_orf0086 ISEcp1 transposase  Escherichia coli 
pESBL scaffold19_orf0087 transposase for transposon Tn3  Escherichia coli 
pESBL scaffold19_orf0088 hypothetical protein pC15-1a_019  Escherichia coli 
pESBL scaffold19_orf0089 TEM-1 beta-lactamase blaTEM-1 Salmonella enterica subsp. enterica serovar 
Montevideo 
pESBL scaffold19_orf0090 conserved domain protein  Escherichia coli MS 21-1 
pESBL scaffold19_orf0091 cobyrinic acid a,c-diamide synthase  Escherichia coli 
pESBL scaffold19_orf0093 protein impB domain protein  Escherichia coli 1357 
pESBL scaffold19_orf0094 hypothetical protein ColIb-P9_p029  Plasmid ColIb-P9 
pESBL scaffold19_orf0095 DinI-like family protein  Escherichia coli MS 21-1 
pESBL scaffold19_orf0096 hypothetical protein p026VIR_p092  Escherichia coli 
pESBL scaffold19_orf0097 hypothetical protein ECO103_p71  Escherichia coli O103:H2 str. 12009 
pESBL scaffold19_orf0098 conserved hypothetical protein  Escherichia coli H299 
pESBL scaffold19_orf0099 hypothetical protein ND12IncI1_24  Escherichia coli 
pESBL scaffold19_orf0100 conserved hypothetical protein  Escherichia coli W 
pAA scaffold16_orf0001 putative secreted protein  Streptomyces hygroscopicus ATCC 53653 
pAA scaffold16_orf0002 hypothetical protein c3579  Escherichia coli CFT073 
pAA scaffold16_orf0003 unknown protein encoded in ISEc8  Escherichia coli O157:H7 EDL933 
pAA scaffold16_orf0004 hypothetical protein SbBS512_A0019  Shigella boydii CDC 3083-94 
pAA scaffold16_orf0005 AggA457 protein AggA Escherichia coli 
pAA scaffold16_orf0006 RecName: Full=Protein AggB; Flags: Precursor AggB  
pAA scaffold16_orf0007 HdaC, HUS-associated diffuse adherence AggC Escherichia coli 
pAA scaffold16_orf0008 RecName: Full=Chaperone protein AggD; Flags: Precursor AggD  
pAA scaffold16_orf0010 putative resolvase  Escherichia coli 
pAA scaffold16_orf0011 3-hydroxyisobutyrate dehydrogenase  Mycobacterium tuberculosis 210 
pAA scaffold16_orf0012 hypothetical protein ColIb-P9_p027  Plasmid ColIb-P9 
pAA scaffold16_orf0013 StbA protein  Escherichia coli MS 84-1 
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pAA scaffold16_orf0015 putative 60 kDa chaperonin  Escherichia coli E24377A 
pAA scaffold16_orf0016 hypothetical protein ColIb-P9_p024  Plasmid ColIb-P9 
pAA scaffold16_orf0017 resolvase  Salmonella enterica subsp. enterica serovar 
Kentucky str. CVM29188 
pAA scaffold16_orf0018 plasmid maintenance protein CcdB  Escherichia coli 
pAA scaffold16_orf0019 plasmid maintenance protein CcdA  Escherichia coli 
pAA scaffold16_orf0021 hypothetical protein E4_23171  Escherichia sp. 4_1_40B 
pAA scaffold16_orf0022 hypothetical protein p1ECUMN_0160  Escherichia coli UMN026 
pAA scaffold16_orf0024 orf906  Escherichia coli 
pAA scaffold16_orf0026 phage integrase  Escherichia coli M863 
pAA scaffold16_orf0027 COG1506: Dipeptidyl aminopeptidases/acylaminoacyl-peptidases  Magnetospirillum magnetotacticum MS-1 
pAA scaffold16_orf0028 hypothetical protein pECL46p020  Escherichia coli 
pAA scaffold16_orf0029 hypothetical protein pEC55989_0007  Escherichia coli 55989 
pAA scaffold16_orf0030 hypothetical protein IPF_103  Escherichia coli 1520 
pAA scaffold16_orf0031 incFII family plasmid replication initiator RepA  Escherichia coli MS 78-1 
pAA scaffold16_orf0032 replication initiation protein  Escherichia coli E128010 
pAA scaffold16_orf0033 replication protein  Escherichia sp. 4_1_40B 
pAA scaffold16_orf0034 conjugal transfer pilus acetylation protein TraX  Shigella flexneri 2a str. 301 
pAA scaffold16_orf0035 hypothetical protein pYT1_p113  Salmonella enterica subsp. enterica serovar 
Typhimurium 
pAA scaffold16_orf0036 DNA helicase TraI  Escherichia coli MS 57-2 
pAA scaffold16_orf0037 conserved hypothetical protein  Salmonella enterica subsp. enterica serovar 
Kentucky 
pAA scaffold16_orf0038 hypothetical protein c3659  Escherichia coli CFT073 
pAA scaffold16_orf0039 hypothetical protein c3661  Escherichia coli CFT073 
pAA scaffold16_orf0040 hypothetical protein pB171_031  Escherichia coli 
pAA scaffold16_orf0041 conserved hypothetical protein  Escherichia coli H299 
pAA scaffold16_orf0042 conjugal transfer fertility inhibition protein FinO  Escherichia coli 
pAA scaffold16_orf0043 conjugal transfer pilus acetylation protein TraX  Salmonella enterica subsp. enterica serovar 
Kentucky str. CVM29188 
pAA scaffold16_orf0044 hypothetical protein pYT1_p113  Salmonella enterica subsp. enterica serovar 
Typhimurium 
pAA scaffold16_orf0045 conjugal transfer nickase/helicase TraI  Escherichia coli 
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pAA scaffold16_orf0046 conjugal transfer nickase/helicase TraI  Salmonella enterica subsp. enterica serovar 
Kentucky str. CVM29188 
pAA scaffold16_orf0047 hypothetical protein R100p115.2br  Plasmid R100 
pAA scaffold16_orf0048 Protein traJ  Escherichia coli 55989 
pAA scaffold16_orf0049 TraM  Escherichia coli 
pAA scaffold16_orf0050 putative lytic transglycosylase  Escherichia coli ETEC H10407 
pAA scaffold16_orf0051 conserved hypothetical protein  Escherichia coli MS 185-1 
pAA scaffold16_orf0052 putative recombinase  Escherichia coli 
pAA scaffold16_orf0053 SepA  Escherichia coli 536 
pAA scaffold16_orf0054 putative transposase  Escherichia coli 
pAA scaffold16_orf0057 conserved hypothetical protein  Escherichia coli MS 153-1 
pAA scaffold16_orf0058 AatD  Escherichia sp. 4_1_40B 
pAA scaffold16_orf0059 AatC ATB binding protein of ABC transporter  Escherichia coli 55989 
pAA scaffold16_orf0060 AatB  Escherichia coli 55989 
pAA scaffold16_orf0061 AatA outermembrane protein  Escherichia coli 55989 
pAA scaffold16_orf0062 AatP permease  Escherichia sp. 4_1_40B 
pAA scaffold16_orf0063 serine protease eatA  Shigella dysenteriae 1617 
pAA scaffold16_orf0064 protease IgA1  Escherichia coli 
pAA scaffold16_orf0065 hypothetical protein E4_23001  Escherichia sp. 4_1_40B 
pAA scaffold16_orf0066 Serine protease sat precursor (Secreted autotransporter toxin sat) 
(fragment) 
 Escherichia coli 55989 
pAA scaffold16_orf0067 ISPsy2, transposase  Escherichia coli MS 185-1 
pAA scaffold16_orf0069 14 kDa aggregative adherence fimbriae I protein (Fragment) (modular 
protein) 
 Escherichia coli 55989 
pAA scaffold16_orf0070 putative transposase domain protein  Escherichia coli 3431 
pAA scaffold16_orf0071 Serine protease sepA precursor (fragment)  Escherichia sp. 4_1_40B 
pAA scaffold16_orf0072 IS186 transposase  Escherichia coli UMNK88 
pAA scaffold16_orf0073 CvaB, IS186 transposase  Escherichia coli BW2952 
pAA scaffold16_orf0074 hypothetical protein  Escherichia coli 
pAA scaffold16_orf0075 hypothetical protein Mtub2_09757  Mycobacterium tuberculosis 210 
pAA scaffold16_orf0076 putative IS639 ORF1  Escherichia coli ETEC 1392/75 
pAA scaffold16_orf0077 putative transcriptional activator aggR (AAF-III) regulatory protein)  Escherichia coli 55989 
pAA scaffold16_orf0078 transposase ORF A, IS1  Escherichia coli 55989 
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pAA scaffold16_orf0079 transposase  Escherichia coli M863 
pAA scaffold16_orf0080 hypothetical protein Mtub2_09757  Mycobacterium tuberculosis 210 
pAA scaffold16_orf0081 hypothetical protein E4_23056  Escherichia sp. 4_1_40B 
pAA scaffold16_orf0083 putative transposase (fragment)  Escherichia coli 55989 
pAA scaffold16_orf0084 putative Isopentenyl-diphosphate delta-isomerase (IPP isomerase) 
(Isopentenyl pyrophosphate isomerase) (IPP:DMAPP isomerase) 
 Escherichia coli 55989 
pAA scaffold16_orf0085 hypothetical protein pEC55989_0080  Escherichia coli 55989 
pAA scaffold16_orf0086 conserved hypothetical protein  Escherichia coli MS 119-7 
pAA scaffold16_orf0087 transposase  Escherichia coli M863 
pAA scaffold16_orf0088 putative transposase insK for insertion sequence element IS150  Shigella sonnei 53G 
pAA scaffold16_orf0089 putative protein encoded within IS  Shigella sonnei Ss046 
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Abstract
Three bench-top high-throughput sequencing instruments are now available. The 454 GS Junior
(Roche), MiSeq (Illumina) and Ion Torrent PGM (Life Technologies) are laser-printer sized and
offer modest set-up and running costs. Each instrument can generate a draft bacterial genome
sequence in days, making them attractive for use in the identification and characterization of
pathogens in the clinical setting. We compared the performance of these instruments by sequencing
isolates of Escherichia coli O104:H4 from the German outbreak of 2011. We compared performance
of the platforms, analysing throughput, read length, read error profile and rate, de novo assembly
quality and completeness. MiSeq had the highest throughput and lowest error rate. The 454 Junior
generated the longest reads and best assemblies. The Ion Torrent PGM produced intermediate
throughput with the shortest reads. The Ion Torrent PGM and 454 GS Junior both suffer from
errors in homopolymers.
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Over the past decade and a half, genome sequencing has transformed almost every corner of the
biomedical sciences, including the study of bacterial pathogens [1]. In the last five years, high-
throughput (or "next-generation") sequencing technologies have delivered a step change in our
ability to sequence genomes, whether human or bacterial [2, 3]. Since arriving in the market
place, these technologies have experienced sustained technical improvement, which, twinned with
lively competition between alternative platforms, has placed genome sequencing in a state of
permanent revolution.
Although high-throughput sequencing has seen extensive use in bacteriology, e.g. in the ge-
nomic epidemiology of bacterial pathogens [4], until recently sequencing platforms were tailored
chiefly towards large-scale applications, focused on the race to the "$1,000 human genome", with
footprints, workflows, reagent costs and run times poorly matched to the needs of small labo-
ratories studying small genomes. However three different bench-top high-throughput sequencing
instruments are currently available, all roughly the size of a laser printer, with modest set-up and
running costs and all capable of sequencing bacterial genomes in a matter of days (Table 1).
The 454 GS Junior from Roche was released in early 2010 and is a smaller, lower-throughput
version of the 454 GS FLX machine, exploiting similar emulsion PCR and pyrosequencing ap-
proaches, but with lower set-up and running costs. The Ion Torrent Personal Genome Machine
(PGM) was launched in early 2011 [5]. Like the 454 GS Junior, this technology exploits emulsion
PCR. This platform also incorporates a sequencing-by-synthesis approach, but uses native dNTP
chemisty and relies on a modified silicon chip to detect hydrogen ions released during base incor-
poration by DNA polymerase (making it the first "post-light" sequencing instrument). The MiSeq
(Illumina) was announced in January 2011 and began to ship to customers in the fourth quarter
of 2011. The MiSeq is based on the existing Solexa sequencing-by-synthesis chemistry [6] but has
dramatically reduced run times compared to the Illumina HiSeq (fastest run 4 hours versus 1.5
for 36-cycle sequencing or 16 hours versus 8.5 days for 200-cycle sequencing) made possible by a
reduced size flow cell, reduced imaging time and faster microfluidics.
We wished to compare the performance of these three sequencing platforms by analysing data
with commonly used assembly and analysis pipelines. We therefore benchmarked these platforms
by using them to genome-sequence isolates from the recent outbreak of Shiga-toxin-producing E.
coli (STEC) O104:H4 that struck Germany between May and July 2011. This outbreak was re-
sponsible for over 4000 infections and more than 40 deaths [7]. Previous whole-genome sequencing
efforts applied to isolates from the outbreak yielded novel diagnostic reagents and provided im-
portant clues as to the nature, origins and evolution of the outbreak strain [8–12]. These efforts
also demonstrated the utility of an "open-source" approach to outbreak genomics that included
rapid sequencing, a liberal approach to data release and use of crowdsourcing [10]. Although all
infections during the outbreak were acquired in Germany, travellers took their infections back to
other countries in Europe and North America, including the United Kingdom [7]. Here, we have
focused on a single E. coli isolate of serotype O104 from the United Kingdom epidemiologically
linked to the German outbreak.
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Results
Creation of reference assembly
To permit comparisons of bench-top sequencing data we generated a reference assembly for E. coli
O104:H4 280 (HPA materials identifier H112160280) using established high-throughput sequencing
platforms. This strain was recovered from a female traveller returning from Germany who had
developed hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. The strain was
confirmed as typical of an outbreak strain (ST678, stx-2 ositive and intimin negative) [13].
We used the Roche 454 GS FLX+ system to generate very long fragment reads (modal read
length 812bp bases, maximum read length 1170 bases) to an estimated 32-fold mean coverage.
Additionally, Roche 454 GS FLX was used to sequence an 8kb insert paired-end library using
Titanium chemistry. The reads were assembled into contigs, which were scaffolded to produce a
draft reference assembly. The use of abundant long reads and long-insert paired-end information
plus error correction from a complementary sequencing technology resulted in a very high quality
draft genome assembly consisting of three scaffolds. 99.42% of the bases in the assembly are Q64
bases (the highest quality assigned by Newbler, representing accuracy of one miscall around every
2.5m bases), 99.6% are Q30 or higher. Lower quality bases were masked with a lower-case letter.
The largest scaffold corresponded to the chromosome (5,340,022 bp), the two smaller scaffolds
corresponded to two large plasmids (pESBL and pAA). The 1.5kb plasmid sequence was present
in a single contig. Although each scaffold represented a single circular replicon, 153 gaps remained
within the scaffolds. These gaps represent repetitive regions longer than the mean read length
and shorter than the paired-end insert library and which cannot be resolved by this sequencing
strategy.
Characteristics of reads from bench-top sequencers
Genome depth, evenness of coverage, read length and read quality are the four major factors
which determine the ability to reconstruct genome sequences from sequence data. There were large
differences in the number, predicted quality and length of reads obtained from the three platforms
(Table 2, Figure 1). 454 Junior produced the longest reads, with a mean length of 522 bases, but
had the lowest throughput of the three instruments. Ion Torrent PGM runs generated over four
times the throughput of 454 Junior but generated the shortest reads (mean 121 bases). MiSeq
produced the greatest throughput with reads slightly longer than Ion Torrent PGM, permitting
the multiplexing of seven E. coli strains on a single run. MiSeq reads were paired-end: that
is, fragments were sequenced in both directions. Across the reference chromosome, coverage was
generally even although in the MiSeq data we saw a peak associated with the Shiga-toxin producing
phage, a smaller peak was detectable in the Ion Torrent PGM data (Supplementary Figure 3).
Differences in relative coverage levels were also seen in the pESBL and pAA plasmids between
instruments.
Because each manufacturer uses a unique software implementation to generate base quality
score predictions, direct comparison of these scores between platforms is difficult. We recalibrated
quality scores for each instrument by first aligning reads to the reference genome. By observing the
counts of matched and mismatched bases in each aligned read a new quality score can be calculated
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(alignment quality, AQ). We used the scoring system of Ewing and Green which scores both
substitutions, insertions and deletions. Mismatches resulting in deletions are assigned randomly
to the position of one of the adjacent bases in the read. Alignment quality scores predicted in
this way generally had good agreement with predicted scores, with the Ion Torrent PGM generally
underestimating accuracy and the other instruments slightly overestimating (Figure 2). The MiSeq
produced the highest quality reads, due to a low substitution error rate and the near absence of
indel errors compared to the other platforms. The Ion Torrent PGM showed a steadily decreasing
accuracy across the read to 100 bases. The accuracy seems to improve after this point due to the
aligner soft-clipping trailing bases. Comparison of the frequency of indels through alignment to
the reference demonstrated Ion Torrent PGM reads had 1.5 indels per 100 bases (1.72 indels per
read). The 454 Junior had 0.38 indels per 100 bases (1.74 indels per read). In contrast, indels
were detected very infrequently in MiSeq data with <0.001 indels per 100 bases. These results
were confirmed by alignment to two other reference genomes sequenced with other sequencing
technologies (see Supplementary Materials). As with 454 sequencing, the major source of indels in
Ion Torrent PGM data are runs of identical bases (homopolymers). Comparison of homopolymer
accuracy between Ion Torrent PGM and 454 Junior demonstrated that Ion Torrent PGM was less
accurate when calling homopolymers of any length (Figure 3). The dominant source of error were
deletions, with accuracy rates as low as 60% for homopolymers of length six or grater.
Comparison of de novo assemblies
The use of high-throughput sequencing for the discovery of differences in gene content and ar-
rangement relies on the generation of accurate de novo assemblies. We compared draft, de novo
assemblies from bench-top instruments using a variety of metrics. Assembly metrics such as to-
tal assembly size and N50 [14] give a guide to assembly completeness or fragmentation but not
accuracy. An ideal assembly produces a single accurate contig for each replicon but this is rarely
possible due to the presence of long repeat sequences. When comparing bench-top de novo as-
semblies we saw two major groupings of assembly quality. Heavily fragmented assemblies were
obtained from with Ion Torrent data (single runs or combined), 454 Junior (single runs) and MiSeq
contigs. Less heavily fragmented assemblies were obtained when reads from two 454 Junior runs
were combined to increase depth of coverage and when paired-end information was used to scaf-
fold contigs generated from the MiSeq data. However, runs of ambiguous bases were seen in the
scaffolded MiSeq assemblies, unlike the assemblies obtained from the 454 Junior data.
The number of contigs that can be mapped unambiguously to the reference gives a measure
of genome coverage. Differences in genome coverage were seen when comparing assemblies from
each platform (Table 3). No platform delivered data that aligned unambiguously to 100% of the
reference. Contigs obtained from the 454 Junior data aligned to the largest proportion of the
reference, with 5.4% of the reference unmapped. This compared to 6.5% for Ion Torrent PGM
and 5.9% for MiSeq.
The Ion Torrent PGM assemblies had large numbers of gaps (Figure 5), compared to as-
semblies obtained from 454 Junior and MiSeq data. Increasing sequence coverage by combining
assemblies from the two Ion Torrent PGM runs reduced the numbers of gaps in the assembly.
However this had little effect on the miscalls in long homopolymeric tracts, so that even in this
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combined Ion Torrent PGM assembly, around 10% of the coding sequences (as predicted from the
reference assembly) were disrupted either by contig breaks or apparent frameshifts. Of the 1,864
gaps seen in the combined Ion Torrent PGM assembly around a quarter were due to gaps asso-
ciated with ends of contig or unmapped sequence, the rest being associated with homopolymeric
tracts. Manual inspection of assembly alignments revealed that many of the indels associated
with short homopolymeric tracts demonstrated strand bias, with the correct call predominantly
associated with either forward or reverse reads and the erroneous sequences associated with the
opposite strand (Supplementary Figure 2). While problems with homopolymers are known to
result from flow-based chemistries, it is unclear why this strand bias should occur with Ion Tor-
rent technology. However, scrutiny of other public data sets from this instrument (http://mira-
assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html) suggests it is a pervasive problem.
How useful are bench-top assemblies for public health microbiology?
A key test for a genome-sequencing technology is whether it can deliver trustworthy new insights
into the biology of the organism under scrutiny. We therefore evaluated how de novo assemblies
from each platform performed in reporting features of biological interest in the outbreak strain.
For some features, all platforms did well–for example all documented the presence and accurate
full-length sequence of the genes encoding the Shiga toxin type-2 subunits. However, at the
other extreme, all instruments did badly–for instance, in all assemblies the two larger plasmids
were broken into multiple contigs, which could not be readily assigned to chromosome or plasmid
without alignment to the reference genome.
We used 31 protein sequences linked to pathogen biology as queries in translated BLAST
searches of the assemblies obtained from the bench-top sequencing platforms (Supplementary
Table 1 and Supplementary Files ??. No assembly contained a full set of full-length sequences.
The best MiSeq assembly captured 28/31 full-length sequences; the best 454 Junior assembly found
26 and the best Ion Torrent PGM assembly found 22. Perhaps the most challenging targets in the
survey were the four serine protease autotransporters encoded in the genome of the outbreak strain.
These genes code for multiple-domain proteins. None of the platforms managed to recover all four
genes as full-length fragments: the Ion Torrent PGM assembly recovered only one of them. This
is because the SPATEs are multiple-domain proteins and some domains exist as multiple copies
in the genome which are assembled into repeat consensus contigs which cannot be unambiguously
placed in the genome.
Integration of whole-genome sequencing into existing practice in a public health laboratory re-
quires backwards compatibility with existing typing methods. We therefore attempted to generate
multi-locus sequence typing (MLST) profiles from each assembly. An accurate MLST profile was
generated for the outbreak strain by the 454 Junior and MiSeq. However, all Ion Torrent PGM
assemblies generated indel errors in at least one housekeeping gene.
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Discussion
Sequencing and Public Health 2.0
In our evaluation, all three benchtop sequencing platforms generated useful draft genome sequences
of the German E. coli outbreak strain. All could be judged "fit for purpose" in producing assem-
blies that mapped to 93% or more of the reference genome and recovered the vast majority of
coding sequences. However, no instrument could on its own generate completely accurate one-
contig-per-replicon assemblies that might equate to a finished genome. Thus, for each technology
there is a trade-off between advantages and disadvantages. In our survey, the MiSeq generated
the highest throughput per run and lowest error rate of the instruments, without significant indel
or substitution errors (although accuracy does drop off toward the ends of reads). However, the
MiSeq delivered shorter read lengths, and thus worse assemblies, than the 454 Junior. Even with
paired-end sequencing, the single scaffold assemblies from the MiSeq are interrupted by unfillable
gaps, representing difficult-to-resolve repeats. Furthermore, paired-end 150 base sequencing on
a pre-release instrument took over 27 hours (60 megabases per hour). The 454 Junior delivered
the longest read length but the lowest throughput (eight megabases per hour during a nine-hour
run) and suffered from errors in homopolymeric tracts, even at high coverage. The Ion Torrent
PGM produced intermediate throughput with the shortest reads and the worst performance with
homopolymers. However, it delivered the fastest throughput (80-100 megabases per hour) and
shortest run time (around 3 hours). This platform has also shown the greatest improvement in
performance in recent months-an assembly for the outbreak strain generated in May 2011 from
data from the original Ion Torrent 314 chip contained >3000 contigs [10], whereas, in this study,
data from the recently available 316 chip assembled into <600 contigs.
Speed, set-up and running costs and ease of workflow are also important factors when com-
paring these platforms. However, as these may vary from one time or place to another and may
be subject to rapid changes, it is harder to make objective durable evaluations on these criteria.
Nonetheless, whatever the setting, the cost per base of generating sequence data appears to be an
order of magnitude higher for the 454 Junior than the other two platforms. The MiSeq workflow
has the fewest manual steps due to the bridge amplification occurring on the instrument as the
initial step of sequencing, whereas Ion Torrent PGM and 454 GS Junior require a sequence-ready
library which has been amplified through emulsion PCR and subsequently enriched. All three
platforms have protocols for generating and sequencing long mate-pair libraries (templates with
ends a fixed distance apart in the genome). Since this study was performed, a paired-end proto-
col for the Ion Torrent PGM has been announced similar to that on the MiSeq which requires a
second sequencing reaction to be carried out immediately after the first which also has the effect
of doubling the run-time (http://www.iontorrent.com/lib/images/PDFs/pe_appnote_v12b.pdf).
One important conclusion from this evaluation is that saying that one has "sequenced a bac-
terial genome" means different things on different benchtop sequencing platforms. Potential users
of these technologies need to be sensitive to these differences, particularly when comparing or
combining data generated on different platforms. Other important questions include how far can
errors be corrected by comparison to reference data, when is it safe to use a mapping approach
that makes assumptions that a novel sequence is like an existing reference sequence and how
much should one have to rely on human insight rather than automated analyses and pipelines?
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In this study, we set a tough test by evaluating algorithmically generated de novo assemblies.
However, during the real-world test case of the German E. coli outbreak, even the first-generation
Ion Torrent platform, with its low throughput and high error-rate, delivered useful insights into
the biology and evolution of the outbreak strain [9, 10]. For example, a homopolymer error in
an MLST profile was easily corrected by expert opinion. We are thus confident that benchtop
high-throughput sequencing platforms are poised to make a decisive impact on diagnostic and
public health microbiology in the near future.
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Figure 1: Evaluation of read length and quality from bench-top sequencers. Row A) Boxplots
showing the predicted per-base quality score for combined sequencing runs for each bench-top
instrument at each read position created by the qrqc package. Grey lines indicate the 10% and 90%
quantiles, orange lines indicate the lower and upper quartiles, the blue dot is the median, and the
green dash the mean. A purple smooth curve is fit through the distributions [15]. Quality scores are
given as Phred-scaled quality values where Q = −10 log10 P (P being the probability of the base
call being correct). Row B) Histograms showing read lengths produced by each instrument. Row
B) Comparison of the predicted and measured accuracy for each benchtop sequencer. Predicted
accuracy is determined by multiplying the number of alignments of bases of each quality score by
the probability of an incorrect base call (10
−Q
10 ). Row C) The percentage of reads aligned at any
given position.
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Methods
Collection of isolates
Five UK isolates, all with epidemiological links to the German outbreak were included in the
study, with strain 280 being sequenced by each of the bench-top instruments (Supplementary
Table ??). Two E. coli O104 isolates were not linked to the German outbreak and were included
as comparators. Isolates were grown according to the protocol described in Chattaaway et al [13].
To generate enough DNA for sequencing, isolates were grown on multiple occasions.
Sequencing workflow
A general, simplified workflow for library preparation, amplification and sequencing is shown
(Supplementary Figure 1) with approximate timings for each stage. These stages comprise library
preparation from genomic DNA, amplification and sequencing. Library preparation steps are
similar for each instrument, involving extraction and purification of genomic DNA, fragmentation
through either enzymatic or physical means, fragment size selection and ligation of sequencing
adapters.
Ion Torrent Sequencing
Ion Torrent sequencing was performed at the University of Birmingham according to the Ion
Torrent protocol (Life Technologies, Gaithersburg, MD). Total DNA from E. coli O104:H4 280
was isolated. 10 µg of this DNA was fragmented with a Bioruptor instrument (Diagenode, Liège,
Belgium) using the protocol recommended by Life Technologies. A broad profile of fragment sizes
(75-500 bp, peak at 255 bp) were obtained which were end-repaired, ligated with Ion Torrent A
and P1 adapters and size selected using E-Gel EX 2% Gel (Invitrogen, Carlsbad, CA) for 150-250
bp fragments. The size-selected fragments were amplified and DNA was purified with Agencourt
AMPure XP beads (Beckman Coulter Genomics, High Wycombe, UK). The median fragment size
of the final library was 200 bp (assessed by a BioAnalyzer High Sensitivity LabChip, Agilent).
Library was diluted to 40pM and two emulsion PCR reactions were set up at two templates per
sphere. Sequencing primer and polymerase were added to the final enriched spheres prior to
loading onto the 316 chip. Two 316 chips were run in total. Base calls were generated using
version 1.5 of the Ion Torrent software suite and for further analysis the resulting flowgram files
(assembly) or FASTQ files (alignment) were used.
454 Junior Sequencing
454 Junior sequencing was performed on an instrument at the Health Protection Agency, Colindale,
UK. E. coli O104:H4 280 DNA was prepared following the Roche Rapid Library protocol (Roche,
Welwyn Garden City, UK), whereby 5 ng/µl was taken from each sample and libraries prepared.
Briefly, samples were subjected to the following key steps: DNA fragmentation by nebulization,
fragment end-repair, AMPure XP bead preparation (Amersham International, Buckinghamshire,
UK), adaptor ligation, small fragment removal, quality assessment using the Agilent 2100 Bio-
analyzer, library quantitation and finally preparation of working aliquots at a final concentration
18
of 1× 107molecules/µl (500 ng total). Emulsions PCR, enrichment and 454 GS Junior sequenc-
ing were carried out as per manufacturer’s protocols. The resulting flowgram files were used for
downstream analysis.
454 GS FLX+ and 454 GS FLX 8kb Titanium sequencing
454 GS FLX 8kb Titanium paired-end and 454 FLX+ (long read) library construction and se-
quencing was performed at Roche Diagnostics (Burgess Hill, UK) according to their standard
protocols.
Illumina MiSeq Sequencing
Illumina MiSeq sequencing was performed at Illumina UK, Little Chesterford, UK, on a pre-
release, prototype MiSeq instrument. The seven E. coli samples were quantified with a Qubit
High Sensitivity kit and the total amount of DNA for each sample varied between 523ng and
954ng. Samples were sheared with Covaris followed by end repair, A-tailing and the ligation of
Truseq adapters containing indexes. Samples were run on a 2% agarose gel (2 samples per gel)
and DNA was size selected at 600-700 bp. 10 cycles of PCR were carried out and samples run
out on a second 2% agarose gel (2 samples per gel). Samples were excised from the gel and
quantified with a Qubit high sensitivity kit. Libraries were diluted to 2nM in EB+0.1% tween
and a pool containing an equimolar concentration of each library was prepared. MiSeq instrument
was prepared following routine procedures. Briefly, a standard MiSeq flowcell was inserted into
the flowcell chamber. Next, the DNA sample containing the pool of seven E. coli libraries was
diluted to 6.2pmol and pipetted into the sample well on the MiSeq Consumable Cartridge before
loading in the chiller section of the MiSeq instrument. A sample sheet was prepared on the MiSeq
instrument to provide run details. The run was initiated for 2x151 bases of SBS sequencing,
including on-board clustering and paired-end preparation, the sequencing of the seven barcode
indices, and analysis. On the completion of the run, data was basecalled and demultiplexed on
the instrument (provided as Illumina FASTQ files, phred+64 encoding). FASTQ format files in
Illumina 1.5 format were considered for downstream analaysis. Although MiSeq produces reads of
fixed lengths, tails of these reads may be designated as uncallable as indicated by the read segment
quality control indicator, noted a quality score of two (’B’). In these cases these low quality tails
were trimmed and not used for further analysis.
Bioinformatics
Construction of reference assembly
A high-quality reference sequence for E. coli strain 280 was constructed by assembling 454 FLX+
long read data and 454 Titanium paired-end data (8kb insert) using Newbler 2.6. Newbler was run
with parameters -scaffold -tr -cpu 8 -siom 28 -rip. The resulting scaffolds were used for
further analysis. Newbler masks certain bases in the assembly regarded as uncertain by assigning
it a lower-case nucleotide. These masked bases correspond with bases with a low quality score.
In bacterial genomes these bases are seen predominantly in consensus contigs resulting from long
repeat regions, long homopolymeric tracts and contig ends. The resulting assembly was annotated
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using the automated xBASE annotation pipeline [16] which utilises Glimmer for coding sequence
prediction [17] and tRNAScan-SE and RNAmmer for stable RNA prediction [18, 19].
De novo assembly of individual strains
Assemblies were generated from data generated by each of the bench-top sequencing platforms sep-
arately. All data were assembled by MIRA 3.4.0 using default parameters in genome,denovo,accurate
mode and the appropriate setting for each instrument type (454,iontor,solexa). Ion Torrent
and 454 Junior data were additionally assembled with Newbler 2.6 with default parameters. Il-
lumina MiSeq data were additionally assembled using Velvet and CLC Assembly Cell (both de
Bruijn graph assemblers). Velvet was run using a k -mer value of 55 and exp_cov and cov_cutoff
set to auto. The program was run again with -scaffolding off to generate a separate assem-
bly without scaffolds. CLC Assembly Cell version 4.0.6 beta was run with default parameters.
De novo assemblies were compared for chromosomal coverage, broken genes, etc. using Mauve
(mauve_snapshot_2011-08-19) and the Mauve Assembly Metrics package [20]. Assemblies were
manually examined using the Tablet viewer [21].
Read mapping
For substitution and indel detection, reads from each platform were aligned to the reference assem-
bly using the bwasw module of BWA (version 0.5.9rc1) [22]. The reference genome was indexed
with bwa index -a is. Bwasw was run with default parameters (gap open penalty 5, gap ex-
tension penalty 2) using FASTQ files as input. Output BAM files were post-processed using
the calmd module of samtools which adds MD tags to each alignment. The MD tag describes
the positions of base substitutions. Reads which align to masked bases in the reference genome
were excluded from analysis. Read group information was added to the output BAM files using
Picard (http://picard.sourceforge.net/). Read accuracy was determined a custom Python script
(calculate_accuracy.py, available in the Github repository) which utilises the pysam module
(http://code.google.com/p/pysam/) to read the BAM alignment. The calculate_accuracy script
counts mismatches using the method of Ewing and Green [23] which counts mismatches resulting
from substitutions, insertions and deletions. In the case of deletions, mismatches are assigned to
one of the adjacent reads in the alignment at random. Depth of coverage reports were gener-
ated using DepthOfCoverage module of GATK [24]. Reads were additionally mapped against E.
coli strain c236-11 (PacBio and Illumina sequenced) and E. coli strain 55989 (Sanger sequenced)
[12][25].
For generation of homopolymer accuracy plots reads for each of the bench-top sequencing
platforms were mapped to the reference assembly using Novoalign (version V2.07.13, Novocraft,
Malaysia, registered version). Gap penalties were adjusted with parameters as recommended by
the documentation -g 20 -x 5. Novoalign was set to align its maximum supported read length
of 300 using -n 300. Homopolymeric tract statistics were enabled using the –hpstats option.
Quality score recalibration was enabled using the -K option. Only reads that aligned without
indels and with a mapping quality of greater than 60 were included in quality score recalibration.
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Table 2: Indel summary for benchtop reads against E. coli 280 - 454 + Illumina reference
insertions deletions indels_per_100 indels_per_read total_reads
454 GS Junior (1) 176502 62427 0.38 1.75 136876
454 GS Junior (1+2) 354946 121344 0.38 1.74 275437
454 GS Junior (2) 178444 58917 0.38 1.72 138561
Illumina MiSeq (280) 657 1828 0.00 0.00 1769608
Ion Torrent (1) 1905499 1886049 1.45 1.68 2484481
Ion Torrent (1+2) 3535011 3687275 1.50 1.72 4639731
Ion Torrent (2) 1629512 1801226 1.56 1.77 2155250
Table 3: Indel summary for benchtop reads against E. coli 55989 (Sanger sequenced) reference
insertions deletions indels_per_100 indels_per_read total_reads
454 GS Junior (1) 162292 56866 0.37 1.71 137457
454 GS Junior (1+2) 327199 110863 0.37 1.70 276545
454 GS Junior (2) 164907 53997 0.37 1.69 139088
Illumina MiSeq (280) 2598 5128 0.01 0.01 1772571
Ion Torrent (1) 1720816 1699829 1.44 1.66 2485113
Ion Torrent (1+2) 3195610 3326520 1.49 1.71 4640859
Ion Torrent (2) 1474794 1626691 1.55 1.76 2155746
Table 4: Indel summary for benchtop reads against E. coli c236-11 - Illumina + PacBio reference
insertions deletions indels_per_100 indels_per_read total_reads
454 GS Junior (1) 175391 62434 0.38 1.75 137059
454 GS Junior (1+2) 352620 121470 0.38 1.73 275821
454 GS Junior (2) 177229 59036 0.38 1.72 138762
Illumina MiSeq (280) 909 5338 0.00 0.00 1771145
Ion Torrent (1) 1898486 1879639 1.45 1.68 2484567
Ion Torrent (1+2) 3522207 3674905 1.50 1.72 4639926
Ion Torrent (2) 1623721 1795266 1.56 1.77 2155359
Supplementary Excel File 1. Assembly_comparison_supplemental.xlsx
Supplementary Excel File 2. Assembly_summary_supplemental.xlsx
Supplementary Excel File 3. BLAST_searches.xlsx
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Supplementary Figures
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Figure 1: Simplified workflow for bench-top sequencing
26
Figure 2: Homopolymeric tract error demonstrating strand bias (light blue is forward strand, dark
blue is reverse strand)
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Figure 3: Depth of coverage plot for reads from each benchtop instrument against the E. coli
strain 280 reference chromosome. In the MiSeq plot the large peak at 1.5 megabases corresponds
to the Shiga-toxin producing phage, indicating the phage was likely undergoing lysis when DNA
was being prepared. A smaller peak can be seen at the same position in the Ion Torrent PGM
data.)
27
Platform Reference Assembler
Number 
of contigs
Assembly 
size
Largest 
contig
Assembly 
N50
Locally 
colinear 
blocks
Total gaps 
reference
Total gaps 
assembly Total gaps
% genome 
not 
covered Assembly gap
Homopolyme
r gap
454 GS Junior (1) 280 MIRA 188 5122871 195066 42287 38 1177 480 1657 7.5437 926 728
454 GS Junior (1) 280 Newbler 362 5274907 214937 50603 8 364 477 841 5.8339 538 297
454 GS Junior (1+2) 280 MIRA 98 5364151 340118 123481 30 345 292 637 3.7242 375 252
454 GS Junior (1+2) 280 Newbler 216 5326447 385415 119080 3 170 273 443 4.374 271 169
454 GS Junior (2) 280 MIRA 150 5124508 193239 51086 28 811 405 1216 7.2748 604 600
454 GS Junior (2) 280 Newbler 415 5276110 230383 39823 8 457 595 1052 5.4645 628 421
Ion Torrent PGM (1) 280 MIRA 366 5352778 144998 48188 95 459 1785 2244 4.519 725 1513
Ion Torrent PGM (1) 280 Newbler 553 5256982 234450 58782 10 511 1915 2426 5.8175 742 1681
Ion Torrent PGM (1+2) 280 MIRA 385 5379335 225465 60073 69 345 1472 1817 4.5922 593 1218
Ion Torrent PGM (1+2) 280 Newbler 577 5254254 155086 55431 10 451 1568 2019 5.865 707 1310
Ion Torrent PGM (2) 280 MIRA 376 5342081 196317 41831 77 436 2501 2937 4.7057 752 2178
Ion Torrent PGM (2) 280 Newbler 589 5254958 224797 51211 16 498 1927 2425 5.871 777 1642
MiSeq (contigs) 280 CLC 311 5292732 227129 82564 15 272 259 531 5.101 497 30
MiSeq (contigs) 280 MIRA 214 5353451 341174 81730 53 203 201 404 3.947 371 25
MiSeq (contigs) 280 Velvet 612 5333187 170725 46119 19 358 355 713 4.9435 664 46
MiSeq (scaffolds) 280 CLC 200 5298061 288834 100763 13 267 214 481 4.7433 437 39
MiSeq (scaffolds) 280 Velvet 505 5339506 289526 111638 20 411 398 809 5.0727 765 39
454 Junior (1) 55989 MIRA 188 5122871 195066 42287 63 1208 580 1788 8.7287 not calc not calc
454 Junior (1) 55989 Newbler 362 5274907 214937 50603 38 425 529 954 7.5219 not calc not calc
454 Junior (1+2) 55989 MIRA 98 5364151 340118 123481 45 420 369 789 6.5567 not calc not calc
454 Junior (1+2) 55989 Newbler 216 5326447 385415 119080 38 296 383 679 7.1745 not calc not calc
454 Junior (2) 55989 MIRA 150 5124508 193239 51086 58 895 523 1418 8.1431 not calc not calc
454 Junior (2) 55989 Newbler 415 5276110 230383 39823 37 484 611 1095 7.5227 not calc not calc
Ion Torrent (1) 55989 MIRA 366 5352778 144998 48188 59 511 1661 2172 7.2288 not calc not calc
Ion Torrent (1) 55989 Newbler 553 5256982 234450 58782 37 489 1758 2247 7.9091 not calc not calc
Ion Torrent (1+2) 55989 MIRA 385 5379335 225465 60073 52 390 1337 1727 7.2274 not calc not calc
Ion Torrent (1+2) 55989 Newbler 577 5254254 155086 55431 33 474 1489 1963 7.8686 not calc not calc
Ion Torrent (2) 55989 MIRA 376 5342081 196317 41831 46 471 2268 2739 7.3526 not calc not calc
Ion Torrent (2) 55989 Newbler 589 5254958 224797 51211 34 499 1795 2294 7.8792 not calc not calc
MiSeq (contigs) 55989 CLC 311 5292732 227129 82564 43 356 340 696 7.558 not calc not calc
MiSeq (contigs) 55989 MIRA 214 5353451 341174 81730 52 324 331 655 7.0667 not calc not calc
MiSeq (contigs) 55989 Velvet 612 5333187 170725 46119 47 372 379 751 7.5342 not calc not calc
MiSeq (scaffolds) 55989 CLC 200 5298061 288834 100763 44 396 349 745 7.2292 not calc not calc
MiSeq (scaffolds) 55989 Velvet 505 5339506 289526 111638 50 398 397 795 7.6076 not calc not calc
454 Junior (1) c236-11 MIRA 188 5122871 195066 42287 46 1179 553 1732 6.9523 not calc not calc
454 Junior (1) c236-11 Newbler 362 5274907 214937 50603 4 370 517 887 4.4932 not calc not calc
454 Junior (1+2) c236-11 MIRA 98 5364151 340118 123481 22 347 389 736 2.8244 not calc not calc
454 Junior (1+2) c236-11 Newbler 216 5326447 385415 119080 1 196 363 559 2.969 not calc not calc
454 Junior (2) c236-11 MIRA 150 5124508 193239 51086 26 820 465 1285 7.1697 not calc not calc
454 Junior (2) c236-11 Newbler 415 5276110 230383 39823 5 462 652 1114 4.328 not calc not calc
Ion Torrent (1) c236-11 MIRA 366 5352778 144998 48188 54 394 1771 2165 4.1383 not calc not calc
Ion Torrent (1) c236-11 Newbler 553 5256982 234450 58782 3 419 1850 2269 4.8337 not calc not calc
Ion Torrent (1+2) c236-11 MIRA 385 5379335 225465 60073 57 336 1508 1844 3.985 not calc not calc
Ion Torrent (1+2) c236-11 Newbler 577 5254254 155086 55431 1 363 1508 1871 5.0554 not calc not calc
Ion Torrent (2) c236-11 MIRA 376 5342081 196317 41831 69 416 2519 2935 3.926 not calc not calc
Ion Torrent (2) c236-11 Newbler 589 5254958 224797 51211 1 429 1866 2295 4.8281 not calc not calc
MiSeq (contigs) c236-11 CLC 311 5292732 227129 82564 9 270 303 573 3.9489 not calc not calc
MiSeq (contigs) c236-11 MIRA 214 5353451 341174 81730 32 203 287 490 3.4491 not calc not calc
MiSeq (contigs) c236-11 Velvet 612 5333187 170725 46119 7 302 337 639 3.9768 not calc not calc
MiSeq (scaffolds) c236-11 CLC 200 5298061 288834 100763 9 273 267 540 3.5143 not calc not calc
MiSeq (scaffolds) c236-11 Velvet 505 5339506 289526 111638 15 355 390 745 3.9977 not calc not calc
Supplementary Table 5
Category Platform Reference Gene Length
Mis-
match
es Indels identity
agree with 
280?
st678.fa 280 Reference Reference ADK6 536 0 0 100.00% agreement
st678.fa 454 Junior (1) Newbler ADK6 536 0 0 100.00% agreement
st678.fa 454 Junior (1) MIRA ADK6 376 0 0 70.15% disagreement
st678.fa 454 Junior (1+2) Newbler ADK6 536 0 0 100.00% agreement
st678.fa 454 Junior (1+2) MIRA ADK6 536 0 0 100.00% agreement
st678.fa 454 Junior (2) Newbler ADK6 377 0 0 70.34% disagreement
st678.fa 454 Junior (2) MIRA ADK6 536 0 0 100.00% agreement
st678.fa C236-11 Reference ADK6 536 0 0 100.00% agreement
st678.fa Ion Torrent (1) Newbler ADK6 536 0 0 100.00% agreement
st678.fa Ion Torrent (1) MIRA ADK6 536 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) Newbler ADK6 536 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) MIRA ADK6 536 0 0 100.00% agreement
st678.fa Ion Torrent (2) Newbler ADK6 536 0 0 100.00% agreement
st678.fa Ion Torrent (2) MIRA ADK6 536 0 0 100.00% agreement
st678.fa MiSeq (contigs) MIRA ADK6 536 0 0 100.00% agreement
st678.fa MiSeq (contigs) Velvet ADK6 536 0 0 100.00% agreement
st678.fa MiSeq (contigs) CLC ADK6 536 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) Velvet ADK6 536 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) CLC ADK6 536 0 0 100.00% agreement
st678.fa 280 Reference Reference FUMC6 469 0 0 100.00% agreement
st678.fa 454 Junior (1) Newbler FUMC6 469 0 0 100.00% agreement
st678.fa 454 Junior (1) MIRA FUMC6 469 0 0 100.00% agreement
st678.fa 454 Junior (1+2) Newbler FUMC6 469 0 0 100.00% agreement
st678.fa 454 Junior (1+2) MIRA FUMC6 469 0 0 100.00% agreement
st678.fa 454 Junior (2) Newbler FUMC6 469 0 0 100.00% agreement
st678.fa 454 Junior (2) MIRA FUMC6 469 0 0 100.00% agreement
st678.fa C236-11 Reference FUMC6 469 0 0 100.00% agreement
st678.fa Ion Torrent (1) Newbler FUMC6 469 0 0 100.00% agreement
st678.fa Ion Torrent (1) MIRA FUMC6 469 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) Newbler FUMC6 469 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) MIRA FUMC6 469 0 0 100.00% agreement
st678.fa Ion Torrent (2) Newbler FUMC6 469 0 0 100.00% agreement
st678.fa Ion Torrent (2) MIRA FUMC6 469 0 0 100.00% agreement
st678.fa MiSeq (contigs) MIRA FUMC6 469 0 0 100.00% agreement
st678.fa MiSeq (contigs) Velvet FUMC6 469 0 0 100.00% agreement
st678.fa MiSeq (contigs) CLC FUMC6 469 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) Velvet FUMC6 469 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) CLC FUMC6 469 0 0 100.00% agreement
st678.fa 280 Reference Reference GYRB5 460 0 0 100.00% agreement
st678.fa 454 Junior (1) Newbler GYRB5 460 0 0 100.00% agreement
st678.fa 454 Junior (1) MIRA GYRB5 460 0 0 100.00% agreement
st678.fa 454 Junior (1+2) Newbler GYRB5 460 0 0 100.00% agreement
st678.fa 454 Junior (1+2) MIRA GYRB5 461 1 1 100.00% disagreement
st678.fa 454 Junior (2) Newbler GYRB5 460 0 0 100.00% agreement
st678.fa 454 Junior (2) MIRA GYRB5 460 0 0 100.00% agreement
st678.fa C236-11 Reference GYRB5 460 0 0 100.00% agreement
st678.fa Ion Torrent (1) Newbler GYRB5 460 0 0 100.00% agreement
st678.fa Ion Torrent (1) MIRA GYRB5 460 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) Newbler GYRB5 460 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) MIRA GYRB5 460 0 0 100.00% agreement
st678.fa Ion Torrent (2) Newbler GYRB5 460 0 0 100.00% agreement
st678.fa Ion Torrent (2) MIRA GYRB5 460 0 0 100.00% agreement
st678.fa MiSeq (contigs) MIRA GYRB5 460 0 0 100.00% agreement
st678.fa MiSeq (contigs) Velvet GYRB5 460 0 0 100.00% agreement
st678.fa MiSeq (contigs) CLC GYRB5 460 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) Velvet GYRB5 460 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) CLC GYRB5 460 0 0 100.00% agreement
st678.fa 280 Reference Reference ICD136 518 0 0 100.00% agreement
st678.fa 454 Junior (1) Newbler ICD136 518 0 0 100.00% agreement
st678.fa 454 Junior (1) MIRA ICD136 518 0 0 100.00% agreement
st678.fa 454 Junior (1+2) Newbler ICD136 518 0 0 100.00% agreement
st678.fa 454 Junior (1+2) MIRA ICD136 518 0 0 100.00% agreement
st678.fa 454 Junior (2) Newbler ICD136 518 0 0 100.00% agreement
st678.fa 454 Junior (2) MIRA ICD136 31 3 0 5.41% disagreement
st678.fa C236-11 Reference ICD136 518 0 0 100.00% agreement
st678.fa Ion Torrent (1) Newbler ICD136 518 1 1 99.81% disagreement
st678.fa Ion Torrent (1) MIRA ICD136 518 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) Newbler ICD136 518 1 1 99.81% disagreement
st678.fa Ion Torrent (1+2) MIRA ICD136 518 0 0 100.00% agreement
st678.fa Ion Torrent (2) Newbler ICD136 518 1 1 99.81% disagreement
st678.fa Ion Torrent (2) MIRA ICD136 518 0 0 100.00% agreement
st678.fa MiSeq (contigs) MIRA ICD136 518 0 0 100.00% agreement
st678.fa MiSeq (contigs) Velvet ICD136 518 0 0 100.00% agreement
st678.fa MiSeq (contigs) CLC ICD136 518 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) Velvet ICD136 518 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) CLC ICD136 518 0 0 100.00% agreement
st678.fa 280 Reference Reference MDH9 452 0 0 100.00% agreement
st678.fa 454 Junior (1) Newbler MDH9 452 0 0 100.00% agreement
st678.fa 454 Junior (1) MIRA MDH9 452 0 0 100.00% agreement
st678.fa 454 Junior (1+2) Newbler MDH9 452 0 0 100.00% agreement
st678.fa 454 Junior (1+2) MIRA MDH9 452 0 0 100.00% agreement
st678.fa 454 Junior (2) Newbler MDH9 452 0 0 100.00% agreement
st678.fa 454 Junior (2) MIRA MDH9 452 0 0 100.00% agreement
st678.fa C236-11 Reference MDH9 452 0 0 100.00% agreement
st678.fa Ion Torrent (1) Newbler MDH9 452 0 0 100.00% agreement
st678.fa Ion Torrent (1) MIRA MDH9 452 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) Newbler MDH9 452 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) MIRA MDH9 452 0 0 100.00% agreement
st678.fa Ion Torrent (2) Newbler MDH9 452 0 0 100.00% agreement
st678.fa Ion Torrent (2) MIRA MDH9 452 0 0 100.00% agreement
st678.fa MiSeq (contigs) MIRA MDH9 452 0 0 100.00% agreement
st678.fa MiSeq (contigs) Velvet MDH9 452 0 0 100.00% agreement
st678.fa MiSeq (contigs) CLC MDH9 452 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) Velvet MDH9 452 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) CLC MDH9 452 0 0 100.00% agreement
st678.fa 280 Reference Reference PURA7 478 0 0 100.00% agreement
st678.fa 454 Junior (1) Newbler PURA7 478 0 0 100.00% agreement
st678.fa 454 Junior (1) MIRA PURA7 478 0 0 100.00% agreement
st678.fa 454 Junior (1+2) Newbler PURA7 478 0 0 100.00% agreement
st678.fa 454 Junior (1+2) MIRA PURA7 478 0 0 100.00% agreement
st678.fa 454 Junior (2) Newbler PURA7 478 0 0 100.00% agreement
st678.fa 454 Junior (2) MIRA PURA7 478 0 0 100.00% agreement
st678.fa C236-11 Reference PURA7 478 0 0 100.00% agreement
st678.fa Ion Torrent (1) Newbler PURA7 478 0 0 100.00% agreement
st678.fa Ion Torrent (1) MIRA PURA7 478 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) Newbler PURA7 478 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) MIRA PURA7 478 0 0 100.00% agreement
st678.fa Ion Torrent (2) Newbler PURA7 478 0 0 100.00% agreement
st678.fa Ion Torrent (2) MIRA PURA7 478 0 0 100.00% agreement
st678.fa MiSeq (contigs) MIRA PURA7 478 0 0 100.00% agreement
st678.fa MiSeq (contigs) Velvet PURA7 478 0 0 100.00% agreement
st678.fa MiSeq (contigs) CLC PURA7 478 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) Velvet PURA7 478 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) CLC PURA7 478 0 0 100.00% agreement
st678.fa 280 Reference Reference RECA7 510 0 0 100.00% agreement
st678.fa 454 Junior (1) Newbler RECA7 510 0 0 100.00% agreement
st678.fa 454 Junior (1) MIRA RECA7 510 0 0 100.00% agreement
st678.fa 454 Junior (1+2) Newbler RECA7 510 0 0 100.00% agreement
st678.fa 454 Junior (1+2) MIRA RECA7 510 0 0 100.00% agreement
st678.fa 454 Junior (2) Newbler RECA7 510 0 0 100.00% agreement
st678.fa 454 Junior (2) MIRA RECA7 510 0 0 100.00% agreement
st678.fa C236-11 Reference RECA7 510 0 0 100.00% agreement
st678.fa Ion Torrent (1) Newbler RECA7 510 0 0 100.00% agreement
st678.fa Ion Torrent (1) MIRA RECA7 510 0 0 100.00% agreement
st678.fa Ion Torrent (1+2) Newbler RECA7 510 1 1 99.80% disagreement
st678.fa Ion Torrent (1+2) MIRA RECA7 510 0 0 100.00% agreement
st678.fa Ion Torrent (2) Newbler RECA7 510 0 0 100.00% agreement
st678.fa Ion Torrent (2) MIRA RECA7 510 1 1 99.80% disagreement
st678.fa MiSeq (contigs) MIRA RECA7 510 0 0 100.00% agreement
st678.fa MiSeq (contigs) Velvet RECA7 510 0 0 100.00% agreement
st678.fa MiSeq (contigs) CLC RECA7 510 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) Velvet RECA7 510 0 0 100.00% agreement
st678.fa MiSeq (scaffolds) CLC RECA7 510 0 0 100.00% agreement
spates.fa 280 Reference Reference gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa 454 Junior (1) Newbler gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa 454 Junior (1) MIRA gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa 454 Junior (1+2) Newbler gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa 454 Junior (1+2) MIRA gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]9 3 2 0 69.31% disag eement
spates.fa 454 Junior (2) Newbler gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa 454 Junior (2) MIRA gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]987 3 0 71.72% disag eement
spates.fa C236-11 Reference gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa Ion Torrent (1) Newbler gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]128 2 0 93.51% disag eement
spates.fa Ion Torrent (1) MIRA gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1363 5 0 98.98% disag eement
spates.fa Ion Torrent (1+2) Newbler gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa Ion Torrent (1+2) MIRA gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]572 0 0 41.69% disag eement
spates.fa Ion Torrent (2) Newbler gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa Ion Torrent (2) MIRA gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]827 370 18 33.31% disag eement
spates.fa MiSeq (contigs) MIRA gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1387 618 37 56.05% disag eement
spates.fa MiSeq (contigs) Velvet gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa MiSeq (contigs) CLC gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa MiSeq (scaffolds) Velvet gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa MiSeq (scaffolds) CLC gi|218697865|ref|YP_002405532.1| Serine protease pic precursor (ShMu) [Escherichia coli 55989]1372 2 0 99.85% ag eement
spates.fa 280 Reference Reference gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa 454 Junior (1) Newbler gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]679 0 0 52.84% disagreement
spates.fa 454 Junior (1) MIRA gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]846 0 0 65.84% disagreement
spates.fa 454 Junior (1+2) Newbler gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa 454 Junior (1+2) MIRA gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]846 0 0 65.84% disagreement
spates.fa 454 Junior (2) Newbler gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa 454 Junior (2) MIRA gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]679 0 0 52.84% disagreement
spates.fa C236-11 Reference gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa Ion Torrent (1) Newbler gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa Ion Torrent (1) MIRA gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa Ion Torrent (1+2) Newbler gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa Ion Torrent (1+2) MIRA gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa Ion Torrent (2) Newbler gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa Ion Torrent (2) MIRA gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa MiSeq (contigs) MIRA gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa MiSeq (contigs) Velvet gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa MiSeq (contigs) CLC gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 29 0 0 95.64% disagreement
spates.fa MiSeq (scaffolds) Velvet gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 85 0 0 100.00% agreement
spates.fa MiSeq (scaffolds) CLC gi|30064291|ref|NP_838462.1| serine protease [Shigella flexneri 2a str. 2457T]1 87 2 2 100.00% disagreement
spates.fa 280 Reference Reference gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa 454 Junior (1) Newbler gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa 454 Junior (1) MIRA gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa 454 Junior (1+2) Newbler gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa 454 Junior (1+2) MIRA gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]953 41 1 66.52% disagreement
spates.fa 454 Junior (2) Newbler gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa 454 Junior (2) MIRA gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]987 42 1 68.93% disagreement
spates.fa C236-11 Reference gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa Ion Torrent (1) Newbler gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1 85 50 1 90.08% disagreement
spates.fa Ion Torrent (1) MIRA gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1363 53 1 95.55% disagreement
spates.fa Ion Torrent (1+2) Newbler gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa Ion Torrent (1+2) MIRA gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]572 13 0 40.77% disagreement
spates.fa Ion Torrent (2) Newbler gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa Ion Torrent (2) MIRA gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]8 7 366 18 33.63% disagreement
spates.fa MiSeq (contigs) MIRA gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1384 612 32 56.31% disagreement
spates.fa MiSeq (contigs) Velvet gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa MiSeq (contigs) CLC gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa MiSeq (scaffolds) Velvet gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa MiSeq (scaffolds) CLC gi|331681632|ref|ZP_08382265.1| serine protease pic [Escherichia coli H299]1372 50 1 96.43% agreement
spates.fa 280 Reference Reference gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]1262 7 0 99.45% agreement
spates.fa 454 Junior (1) Newbler gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]798 5 0 62.84% disagreement
spates.fa 454 Junior (1) MIRA gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]863 13 4 67.35% disagreement
spates.fa 454 Junior (1+2) Newbler gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]12 3 6 0 95.64% disagreement
spates.fa 454 Junior (1+2) MIRA gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]1100 17 0 85.82% disagreement
spates.fa 454 Junior (2) Newbler gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]923 5 0 72.74% disagreement
spates.fa 454 Junior (2) MIRA gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]897 445 33 35.82% disagreement
spates.fa C236-11 Reference gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]1163 6 0 91.68% disagreement
spates.fa Ion Torrent (1) Newbler gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]1196 551 35 51.11% disagreement
spates.fa Ion Torrent (1) MIRA gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]932 5 0 73.45% disagreement
spates.fa Ion Torrent (1+2) Newbler gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]8 1 6 0 63.79% disagreement
spates.fa Ion Torrent (1+2) MIRA gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]646 6 1 50.71% disagreement
spates.fa Ion Torrent (2) Newbler gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]791 6 0 62.20% disagreement
spates.fa Ion Torrent (2) MIRA gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]8 1 5 0 63.87% disagreement
spates.fa MiSeq (contigs) MIRA gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]1263 10 1 99.29% disagreement
spates.fa MiSeq (contigs) Velvet gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]860 5 0 67.75% disagreement
spates.fa MiSeq (contigs) CLC gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]929 5 0 73.22% disagreement
spates.fa MiSeq (scaffolds) Velvet gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]860 5 0 67.75% disagreement
spates.fa MiSeq (scaffolds) CLC gi|58045130|gb|AAW64900.1| SepA [Shigella flexneri]929 5 0 73.22% disagreement
antigens.fa 280 Reference Reference gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]370 1 0 99.73% agreement
antigens.fa 454 Junior (1) Newbler gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]76 56 11 5.41% disagreement
antigens.fa 454 Junior (1) MIRA gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]76 56 11 5.41% disagreement
antigens.fa 454 Junior (1+2) Newbler gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]76 56 11 5.41% disagreement
antigens.fa 454 Junior (1+2) MIRA gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]76 56 11 5.41% disagreement
antigens.fa 454 Junior (2) Newbler gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]76 56 11 5.41% disagreement
antigens.fa 454 Junior (2) MIRA gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]76 56 11 5.41% disagreement
antigens.fa C236-11 Reference gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]370 1 0 99.73% agreement
antigens.fa Ion Torrent (1) Newbler gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]370 1 0 99.73% agreement
antigens.fa Ion Torrent (1) MIRA gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]323 2 0 86.76% disagreement
antigens.fa Ion Torrent (1+2) Newbler gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]370 1 0 99.73% agreement
antigens.fa Ion Torrent (1+2) MIRA gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]323 1 0 87.03% disagreement
antigens.fa Ion Torrent (2) Newbler gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]323 1 0 87.03% disagreement
antigens.fa Ion Torrent (2) MIRA gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]315 1 0 84.86% disagreement
antigens.fa MiSeq (contigs) MIRA gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]370 1 0 99.73% agreement
antigens.fa MiSeq (contigs) Velvet gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]370 1 0 99.73% agreement
antigens.fa MiSeq (contigs) CLC gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]370 1 0 99.73% agreement
antigens.fa MiSeq (scaffolds) Velvet gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]370 1 0 99.73% agreement
antigens.fa MiSeq (scaffolds) CLC gi|14517807|gb|AAK64372.1|AF361371_7 Wzy [Escherichia coli]370 1 0 99.73% agreement
antigens.fa 280 Reference Reference gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]431 1 0 99.77% agreement
antigens.fa 454 Junior (1) Newbler gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]342 4 0 78.42% disagreement
antigens.fa 454 Junior (1) MIRA gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]57 41 1 3.71% disagreement
antigens.fa 454 Junior (1+2) Newbler gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]327 1 0 75.64% disagreement
antigens.fa 454 Junior (1+2) MIRA gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]279 0 63.11% disagreement
antigens.fa 454 Junior (2) Newbler gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]269 71 2 45.94% disagreement
antigens.fa 454 Junior (2) MIRA gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]21 2 0 4.41% disagreement
antigens.fa C236-11 Reference gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]431 1 0 99.77% agreement
antigens.fa Ion Torrent (1) Newbler gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]431 1 0 99.77% agreement
antigens.fa Ion Torrent (1) MIRA gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]309 0 0 71.69% disagreement
antigens.fa Ion Torrent (1+2) Newbler gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]431 1 0 99.77% agreement
antigens.fa Ion Torrent (1+2) MIRA gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]431 1 0 99.77% agreement
antigens.fa Ion Torrent (2) Newbler gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]310 0 0 71.93% disagreement
antigens.fa Ion Torrent (2) MIRA gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]306 0 0 71.00% disagreement
antigens.fa MiSeq (contigs) MIRA gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]431 1 0 99.77% agreement
antigens.fa MiSeq (contigs) Velvet gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]431 1 0 99.77% agreement
antigens.fa MiSeq (contigs) CLC gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]431 1 0 99.77% agreement
antigens.fa MiSeq (scaffolds) Velvet gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]431 1 0 99.77% agreement
antigens.fa MiSeq (scaffolds) CLC gi|14517809|gb|AAK64374.1|AF361371_9 Wzx [Escherichia coli]431 1 0 99.77% agreement
stx2.fa 280 Reference Reference stx2A 319 0 0 100.00% agreement
stx2.fa 454 Junior (1) Newbler stx2A 319 0 0 100.00% agreement
stx2.fa 454 Junior (1) MIRA stx2A 206 1 0 64.26% disagreement
stx2.fa 454 Junior (1+2) Newbler stx2A 319 0 0 100.00% agreement
stx2.fa 454 Junior (1+2) MIRA stx2A 319 0 0 100.00% agreement
stx2.fa 454 Junior (2) Newbler stx2A 319 0 0 100.00% agreement
stx2.fa 454 Junior (2) MIRA stx2A 292 0 0 91.54% disagreement
stx2.fa C236-11 Reference stx2A 319 0 0 100.00% agreement
stx2.fa Ion Torrent (1) Newbler stx2A 319 0 0 100.00% agreement
stx2.fa Ion Torrent (1) MIRA stx2A 319 0 0 100.00% agreement
stx2.fa Ion Torrent (1+2) Newbler stx2A 198 6 3 60.19% disagreement
stx2.fa Ion Torrent (1+2) MIRA stx2A 319 0 0 100.00% agreement
stx2.fa Ion Torrent (2) Newbler stx2A 319 0 0 100.00% agreement
stx2.fa Ion Torrent (2) MIRA stx2A 198 6 3 60.19% disagreement
stx2.fa MiSeq (contigs) MIRA stx2A 319 0 0 100.00% agreement
stx2.fa MiSeq (contigs) Velvet stx2A 319 0 0 100.00% agreement
stx2.fa MiSeq (contigs) CLC stx2A 319 0 0 100.00% agreement
stx2.fa MiSeq (scaffolds) Velvet stx2A 319 0 0 100.00% agreement
stx2.fa MiSeq (scaffolds) CLC stx2A 319 0 0 100.00% agreement
stx2.fa 280 Reference Reference stx2B 89 0 0 100.00% agreement
stx2.fa 454 Junior (1) Newbler stx2B 89 0 0 100.00% agreement
stx2.fa 454 Junior (1) MIRA stx2B 89 0 0 100.00% agreement
stx2.fa 454 Junior (1+2) Newbler stx2B 89 0 0 100.00% agreement
stx2.fa 454 Junior (1+2) MIRA stx2B 89 0 0 100.00% agreement
stx2.fa 454 Junior (2) Newbler stx2B 89 0 0 100.00% agreement
stx2.fa 454 Junior (2) MIRA stx2B 77 0 0 86.52% disagreement
stx2.fa C236-11 Reference stx2B 89 0 0 100.00% agreement
stx2.fa Ion Torrent (1) Newbler stx2B 89 0 0 100.00% agreement
stx2.fa Ion Torrent (1) MIRA stx2B 89 0 0 100.00% agreement
stx2.fa Ion Torrent (1+2) Newbler stx2B 89 0 0 100.00% agreement
stx2.fa Ion Torrent (1+2) MIRA stx2B 89 0 0 100.00% agreement
stx2.fa Ion Torrent (2) Newbler stx2B 89 0 0 100.00% agreement
stx2.fa Ion Torrent (2) MIRA stx2B 89 0 0 100.00% agreement
stx2.fa MiSeq (contigs) MIRA stx2B 89 0 0 100.00% agreement
stx2.fa MiSeq (contigs) Velvet stx2B 89 0 0 100.00% agreement
stx2.fa MiSeq (contigs) CLC stx2B 89 0 0 100.00% agreement
stx2.fa MiSeq (scaffolds) Velvet stx2B 89 0 0 100.00% agreement
stx2.fa MiSeq (scaffolds) CLC stx2B 89 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerA 385 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerA 385 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerA 385 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) Newbler TerA 385 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerA 385 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerA 385 0 0 100.00% agreement
tellerium.fa 454 Junior (2) MIRA TerA 385 0 0 100.00% agreement
tellerium.fa C236-11 Reference TerA 385 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerA 287 0 0 74.55% disagreement
tellerium.fa Ion Torrent (1) MIRA TerA 379 2 0 97.92% disagreement
tellerium.fa Ion Torrent (1+2) Newbler TerA 287 0 0 74.55% disagreement
tellerium.fa Ion Torrent (1+2) MIRA TerA 380 2 0 98.18% disagreement
tellerium.fa Ion Torrent (2) Newbler TerA 385 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) MIRA TerA 380 2 0 98.18% disagreement
tellerium.fa MiSeq (contigs) MIRA TerA 385 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerA 385 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerA 385 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerA 385 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerA 385 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerB 151 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerB 151 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerB 151 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) Newbler TerB 151 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerB 151 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerB 151 0 0 100.00% agreement
tellerium.fa 454 Junior (2) MIRA TerB 151 0 0 100.00% agreement
tellerium.fa C236-11 Reference TerB 151 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerB 151 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) MIRA TerB 151 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) Newbler TerB 151 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) MIRA TerB 151 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) Newbler TerB 151 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) MIRA TerB 151 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) MIRA TerB 151 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerB 151 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerB 151 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerB 151 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerB 151 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerC 346 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerC 346 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerC 346 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) Newbler TerC 346 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerC 346 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerC 346 0 0 100.00% agreement
tellerium.fa 454 Junior (2) MIRA TerC 346 0 0 100.00% agreement
tellerium.fa C236-11 Reference TerC 346 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerC 346 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) MIRA TerC 346 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) Newbler TerC 346 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) MIRA TerC 346 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) Newbler TerC 346 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) MIRA TerC 346 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) MIRA TerC 346 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerC 346 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerC 346 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerC 346 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerC 346 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerD 192 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerD 192 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerD 192 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) Newbler TerD 192 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerD 192 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerD 192 0 0 100.00% agreement
tellerium.fa 454 Junior (2) MIRA TerD 192 0 0 100.00% agreement
tellerium.fa C236-11 Reference TerD 192 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerD 154 0 0 80.21% disagreement
tellerium.fa Ion Torrent (1) MIRA TerD 154 0 0 80.21% disagreement
tellerium.fa Ion Torrent (1+2) Newbler TerD 192 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) MIRA TerD 154 0 0 80.21% disagreement
tellerium.fa Ion Torrent (2) Newbler TerD 154 0 0 80.21% disagreement
tellerium.fa Ion Torrent (2) MIRA TerD 154 0 0 80.21% disagreement
tellerium.fa MiSeq (contigs) MIRA TerD 192 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerD 192 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerD 192 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerD 192 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerD 192 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerE 191 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerE 191 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerE 191 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) Newbler TerE 191 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerE 191 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerE 191 0 0 100.00% agreement
tellerium.fa 454 Junior (2) MIRA TerE 150 0 0 78.53% disagreement
tellerium.fa C236-11 Reference TerE 191 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerE 191 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) MIRA TerE 132 7 0 65.45% disagreement
tellerium.fa Ion Torrent (1+2) Newbler TerE 132 7 0 65.45% disagreement
tellerium.fa Ion Torrent (1+2) MIRA TerE 191 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) Newbler TerE 132 7 0 65.45% disagreement
tellerium.fa Ion Torrent (2) MIRA TerE 191 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) MIRA TerE 191 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerE 191 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerE 191 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerE 191 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerE 191 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerF 413 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerF 413 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerF 210 122 12 21.31% disagreement
tellerium.fa 454 Junior (1+2) Newbler TerF 413 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerF 413 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerF 413 0 0 100.00% agreement
tellerium.fa 454 Junior (2) MIRA TerF 210 122 12 21.31% disagreement
tellerium.fa C236-11 Reference TerF 413 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerF 291 0 0 70.46% disagreement
tellerium.fa Ion Torrent (1) MIRA TerF 291 0 0 70.46% disagreement
tellerium.fa Ion Torrent (1+2) Newbler TerF 291 0 0 70.46% disagreement
tellerium.fa Ion Torrent (1+2) MIRA TerF 291 0 0 70.46% disagreement
tellerium.fa Ion Torrent (2) Newbler TerF 291 0 0 70.46% disagreement
tellerium.fa Ion Torrent (2) MIRA TerF 291 0 0 70.46% disagreement
tellerium.fa MiSeq (contigs) MIRA TerF 413 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerF 413 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerF 413 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerF 413 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerF 413 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerW 77 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerW 77 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerW 42 0 0 54.55% disagreement
tellerium.fa 454 Junior (1+2) Newbler TerW 77 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerW 77 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerW 42 0 0 54.55% disagreement
tellerium.fa 454 Junior (2) MIRA TerW 77 0 0 100.00% agreement
tellerium.fa C236-11 Reference TerW 77 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerW 77 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) MIRA TerW 51 0 0 66.23% disagreement
tellerium.fa Ion Torrent (1+2) Newbler TerW 77 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) MIRA TerW 77 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) Newbler TerW 77 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) MIRA TerW 77 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) MIRA TerW 77 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerW 77 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerW 77 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerW 77 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerW 77 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerX 212 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerX 212 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerX 212 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) Newbler TerX 212 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerX 212 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerX 212 0 0 100.00% agreement
tellerium.fa 454 Junior (2) MIRA TerX 212 0 0 100.00% agreement
tellerium.fa C236-11 Reference TerX 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerX 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) MIRA TerX 203 4 0 93.87% disagreement
tellerium.fa Ion Torrent (1+2) Newbler TerX 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) MIRA TerX 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) Newbler TerX 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) MIRA TerX 203 0 0 95.75% disagreement
tellerium.fa MiSeq (contigs) MIRA TerX 212 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerX 212 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerX 212 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerX 212 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerX 212 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerY1 197 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerY1 197 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerY1 197 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) Newbler TerY1 197 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerY1 197 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerY1 197 0 0 100.00% agreement
tellerium.fa 454 Junior (2) MIRA TerY1 197 0 0 100.00% agreement
tellerium.fa C236-11 Reference TerY1 197 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerY1 197 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) MIRA TerY1 197 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) Newbler TerY1 197 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) MIRA TerY1 197 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) Newbler TerY1 197 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) MIRA TerY1 197 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) MIRA TerY1 197 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerY1 197 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerY1 197 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerY1 197 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerY1 197 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerY2 212 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerY2 212 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerY2 212 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) Newbler TerY2 212 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerY2 212 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerY2 212 0 0 100.00% agreement
tellerium.fa 454 Junior (2) MIRA TerY2 212 0 0 100.00% agreement
tellerium.fa C236-11 Reference TerY2 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerY2 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) MIRA TerY2 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) Newbler TerY2 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) MIRA TerY2 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) Newbler TerY2 212 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) MIRA TerY2 212 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) MIRA TerY2 212 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerY2 212 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerY2 212 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerY2 212 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerY2 212 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerY3 346 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerY3 346 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerY3 343 4 0 97.98% disagreement
tellerium.fa 454 Junior (1+2) Newbler TerY3 346 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerY3 346 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerY3 326 1 0 93.93% disagreement
tellerium.fa 454 Junior (2) MIRA TerY3 346 0 0 100.00% agreement
tellerium.fa C236-11 Reference TerY3 346 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerY3 346 1 0 99.71% disagreement
tellerium.fa Ion Torrent (1) MIRA TerY3 346 1 0 99.71% disagreement
tellerium.fa Ion Torrent (1+2) Newbler TerY3 346 1 0 99.71% disagreement
tellerium.fa Ion Torrent (1+2) MIRA TerY3 346 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) Newbler TerY3 343 1 0 98.84% disagreement
tellerium.fa Ion Torrent (2) MIRA TerY3 346 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) MIRA TerY3 346 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerY3 346 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerY3 346 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerY3 346 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerY3 346 0 0 100.00% agreement
tellerium.fa 280 Reference Reference TerZ 193 0 0 100.00% agreement
tellerium.fa 454 Junior (1) Newbler TerZ 193 0 0 100.00% agreement
tellerium.fa 454 Junior (1) MIRA TerZ 193 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) Newbler TerZ 193 0 0 100.00% agreement
tellerium.fa 454 Junior (1+2) MIRA TerZ 193 0 0 100.00% agreement
tellerium.fa 454 Junior (2) Newbler TerZ 193 0 0 100.00% agreement
tellerium.fa 454 Junior (2) MIRA TerZ 193 0 0 100.00% agreement
tellerium.fa C236-11 Reference TerZ 193 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) Newbler TerZ 193 0 0 100.00% agreement
tellerium.fa Ion Torrent (1) MIRA TerZ 193 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) Newbler TerZ 193 0 0 100.00% agreement
tellerium.fa Ion Torrent (1+2) MIRA TerZ 193 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) Newbler TerZ 193 0 0 100.00% agreement
tellerium.fa Ion Torrent (2) MIRA TerZ 193 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) MIRA TerZ 193 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) Velvet TerZ 193 0 0 100.00% agreement
tellerium.fa MiSeq (contigs) CLC TerZ 193 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) Velvet TerZ 193 0 0 100.00% agreement
tellerium.fa MiSeq (scaffolds) CLC TerZ 193 0 0 100.00% agreement
antibiotics.fa 280 Reference Reference TetA 424 0 0 100.00% agreement
antibiotics.fa 454 Junior (1) Newbler TetA 424 0 0 100.00% agreement
antibiotics.fa 454 Junior (1) MIRA TetA 424 0 0 100.00% agreement
antibiotics.fa 454 Junior (1+2) Newbler TetA 424 0 0 100.00% agreement
antibiotics.fa 454 Junior (1+2) MIRA TetA 424 0 0 100.00% agreement
antibiotics.fa 454 Junior (2) Newbler TetA 424 0 0 100.00% agreement
antibiotics.fa 454 Junior (2) MIRA TetA 424 0 0 100.00% agreement
antibiotics.fa C236-11 Reference TetA 424 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1) Newbler TetA 424 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1) MIRA TetA 424 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1+2) Newbler TetA 424 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1+2) MIRA TetA 424 0 0 100.00% agreement
antibiotics.fa Ion Torrent (2) Newbler TetA 259 3 0 60.38% disagreement
antibiotics.fa Ion Torrent (2) MIRA TetA 261 0 0 61.56% disagreement
antibiotics.fa MiSeq (contigs) MIRA TetA 424 0 0 100.00% agreement
antibiotics.fa MiSeq (contigs) Velvet TetA 424 0 0 100.00% agreement
antibiotics.fa MiSeq (contigs) CLC TetA 424 0 0 100.00% agreement
antibiotics.fa MiSeq (scaffolds) Velvet TetA 424 0 0 100.00% agreement
antibiotics.fa MiSeq (scaffolds) CLC TetA 424 0 0 100.00% agreement
antibiotics.fa 280 Reference Reference blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa 454 Junior (1) Newbler blaCTX-M-15 262 161 4 36.07% disagreement
antibiotics.fa 454 Junior (1) MIRA blaCTX-M-15 262 161 4 36.07% disagreement
antibiotics.fa 454 Junior (1+2) Newbler blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa 454 Junior (1+2) MIRA blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa 454 Junior (2) Newbler blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa 454 Junior (2) MIRA blaCTX-M-15 87 61 17 9.29% disagreement
antibiotics.fa C236-11 Reference blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1) Newbler blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1) MIRA blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1+2) Newbler blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1+2) MIRA blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa Ion Torrent (2) Newbler blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa Ion Torrent (2) MIRA blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa MiSeq (contigs) MIRA blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa MiSeq (contigs) Velvet blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa MiSeq (contigs) CLC blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa MiSeq (scaffolds) Velvet blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa MiSeq (scaffolds) CLC blaCTX-M-15 280 0 0 100.00% agreement
antibiotics.fa 280 Reference Reference blaT 52 1 0 85.00% agreement
antibiotics.fa 454 Junior (1) Newbler blaT 52 1 0 85.00% agreement
antibiotics.fa 454 Junior (1) MIRA blaT 52 1 0 85.00% agreement
antibiotics.fa 454 Junior (1+2) Newbler blaT 52 1 0 85.00% agreement
antibiotics.fa 454 Junior (1+2) MIRA blaT 52 1 0 85.00% agreement
antibiotics.fa 454 Junior (2) Newbler blaT 52 1 0 85.00% agreement
antibiotics.fa 454 Junior (2) MIRA blaT 39 24 0 25.00% disagreement
antibiotics.fa C236-11 Reference blaT 52 1 0 85.00% agreement
antibiotics.fa Ion Torrent (1) Newbler blaT 52 1 0 85.00% agreement
antibiotics.fa Ion Torrent (1) MIRA blaT 52 1 0 85.00% agreement
antibiotics.fa Ion Torrent (1+2) Newbler blaT 52 1 0 85.00% agreement
antibiotics.fa Ion Torrent (1+2) MIRA blaT 52 1 0 85.00% agreement
antibiotics.fa Ion Torrent (2) Newbler blaT 52 1 0 85.00% agreement
antibiotics.fa Ion Torrent (2) MIRA blaT 52 1 0 85.00% agreement
antibiotics.fa MiSeq (contigs) MIRA blaT 52 1 0 85.00% agreement
antibiotics.fa MiSeq (contigs) Velvet blaT 52 1 0 85.00% agreement
antibiotics.fa MiSeq (contigs) CLC blaT 52 1 0 85.00% agreement
antibiotics.fa MiSeq (scaffolds) Velvet blaT 52 1 0 85.00% agreement
antibiotics.fa MiSeq (scaffolds) CLC blaT 52 1 0 85.00% agreement
antibiotics.fa 280 Reference Reference blaTEM 286 0 0 100.00% agreement
antibiotics.fa 454 Junior (1) Newbler blaTEM 286 0 0 100.00% agreement
antibiotics.fa 454 Junior (1) MIRA blaTEM 286 0 0 100.00% agreement
antibiotics.fa 454 Junior (1+2) Newbler blaTEM 286 0 0 100.00% agreement
antibiotics.fa 454 Junior (1+2) MIRA blaTEM 286 0 0 100.00% agreement
antibiotics.fa 454 Junior (2) Newbler blaTEM 286 0 0 100.00% agreement
antibiotics.fa 454 Junior (2) MIRA blaTEM 42 28 2 4.90% disagreement
antibiotics.fa C236-11 Reference blaTEM 286 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1) Newbler blaTEM 286 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1) MIRA blaTEM 178 0 0 62.24% disagreement
antibiotics.fa Ion Torrent (1+2) Newbler blaTEM 286 0 0 100.00% agreement
antibiotics.fa Ion Torrent (1+2) MIRA blaTEM 178 0 0 62.24% disagreement
antibiotics.fa Ion Torrent (2) Newbler blaTEM 286 0 0 100.00% agreement
antibiotics.fa Ion Torrent (2) MIRA blaTEM 178 0 0 62.24% disagreement
antibiotics.fa MiSeq (contigs) MIRA blaTEM 286 0 0 100.00% agreement
antibiotics.fa MiSeq (contigs) Velvet blaTEM 286 0 0 100.00% agreement
antibiotics.fa MiSeq (contigs) CLC blaTEM 286 0 0 100.00% agreement
antibiotics.fa MiSeq (scaffolds) Velvet blaTEM 286 0 0 100.00% agreement
antibiotics.fa MiSeq (scaffolds) CLC blaTEM 286 0 0 100.00% agreement
antibiotics.fa 280 Reference Reference irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa 454 Junior (1) Newbler irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa 454 Junior (1) MIRA irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa 454 Junior (1+2) Newbler irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa 454 Junior (1+2) MIRA irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa 454 Junior (2) Newbler irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa 454 Junior (2) MIRA irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase54 38 2 7.66% disagreem nt
antibiotics.fa C236-11 Reference irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa Ion Torrent (1) Newbler irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa Ion Torrent (1) MIRA irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa Ion Torrent (1+2) Newbler irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa Ion Torrent (1+2) MIRA irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa Ion Torrent (2) Newbler irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa Ion Torrent (2) MIRA irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa MiSeq (contigs) MIRA irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa MiSeq (contigs) Velvet irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa MiSeq (contigs) CLC irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa MiSeq (scaffolds) Velvet irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa MiSeq (scaffolds) CLC irod7_orf00018 aminoglycoside/hydroxyurea antibiotic resistance kinase209 0 0 100.00% greement
antibiotics.fa 280 Reference Reference lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa 454 Junior (1) Newbler lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa 454 Junior (1) MIRA lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa 454 Junior (1+2) Newbler lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa 454 Junior (1+2) MIRA lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa 454 Junior (2) Newbler lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa 454 Junior (2) MIRA lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB54 38 2 8.00% disagreement
antibiotics.fa C236-11 Reference lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa Ion Torrent (1) Newbler lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa Ion Torrent (1) MIRA lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa Ion Torrent (1+2) Newbler lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa Ion Torrent (1+2) MIRA lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa Ion Torrent (2) Newbler lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa Ion Torrent (2) MIRA lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa MiSeq (contigs) MIRA lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa MiSeq (contigs) Velvet lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa MiSeq (contigs) CLC lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa MiSeq (scaffolds) Velvet lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
antibiotics.fa MiSeq (scaffolds) CLC lcl||EcE24377A_B0003||56303349 streptomycin resistance protein, StrB2 0 1 0 99.50% agreement
microcins.fa 280 Reference Reference microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa 454 Junior (1) Newbler microcin H47 secretion protein206 0 0 53.79% disagreement
microcins.fa 454 Junior (1) MIRA microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa 454 Junior (1+2) Newbler microcin H47 secretion protein291 0 0 75.98% disagreement
microcins.fa 454 Junior (1+2) MIRA microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa 454 Junior (2) Newbler microcin H47 secretion protein291 0 0 75.98% disagreement
microcins.fa 454 Junior (2) MIRA microcin H47 secretion protein277 221 62 14.62% disagreement
microcins.fa C236-11 Reference microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa Ion Torrent (1) Newbler microcin H47 secretion protein256 11 0 63.97% disagreement
microcins.fa Ion Torrent (1) MIRA microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa Ion Torrent (1+2) Newbler microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa Ion Torrent (1+2) MIRA microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa Ion Torrent (2) Newbler microcin H47 secretion protein351 9 0 89.30% disagreement
microcins.fa Ion Torrent (2) MIRA microcin H47 secretion protein291 0 0 75.98% disagreement
microcins.fa MiSeq (contigs) MIRA microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa MiSeq (contigs) Velvet microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa MiSeq (contigs) CLC microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa MiSeq (scaffolds) Velvet microcin H47 secretion protein383 0 0 100.00% agreement
microcins.fa MiSeq (scaffolds) CLC microcin H47 secretion protein383 0 0 100.00% agreement
adhesins.fa 280 Reference Reference AggA 167 0 0 100.00% agreement
adhesins.fa 454 Junior (1) Newbler AggA 105 0 0 62.87% disagreement
adhesins.fa 454 Junior (1) MIRA AggA 35 26 0 5.39% disagreement
adhesins.fa 454 Junior (1+2) Newbler AggA 167 0 0 100.00% agreement
adhesins.fa 454 Junior (1+2) MIRA AggA 167 0 0 100.00% agreement
adhesins.fa 454 Junior (2) Newbler AggA 167 0 0 100.00% agreement
adhesins.fa 454 Junior (2) MIRA AggA 172 27 10 86.83% disagreement
adhesins.fa C236-11 Reference AggA 167 0 0 100.00% agreement
adhesins.fa Ion Torrent (1) Newbler AggA 167 0 0 100.00% agreement
adhesins.fa Ion Torrent (1) MIRA AggA 167 0 0 100.00% agreement
adhesins.fa Ion Torrent (1+2) Newbler AggA 167 0 0 100.00% agreement
adhesins.fa Ion Torrent (1+2) MIRA AggA 167 0 0 100.00% agreement
adhesins.fa Ion Torrent (2) Newbler AggA 167 0 0 100.00% agreement
adhesins.fa Ion Torrent (2) MIRA AggA 167 0 0 100.00% agreement
adhesins.fa MiSeq (contigs) MIRA AggA 167 0 0 100.00% agreement
adhesins.fa MiSeq (contigs) Velvet AggA 167 0 0 100.00% agreement
adhesins.fa MiSeq (contigs) CLC AggA 167 0 0 100.00% agreement
adhesins.fa MiSeq (scaffolds) Velvet AggA 167 0 0 100.00% agreement
adhesins.fa MiSeq (scaffolds) CLC AggA 167 0 0 100.00% agreement
adhesins.fa 280 Reference Reference AggB 81 0 0 75.70% agreement
adhesins.fa 454 Junior (1) Newbler AggB 117 11 10 99.07% disagreement
adhesins.fa 454 Junior (1) MIRA AggB 28 18 6 9.35% disagreement
adhesins.fa 454 Junior (1+2) Newbler AggB 81 0 0 75.70% agreement
adhesins.fa 454 Junior (1+2) MIRA AggB 117 11 10 99.07% disagreement
adhesins.fa 454 Junior (2) Newbler AggB 81 0 0 75.70% agreement
adhesins.fa 454 Junior (2) MIRA AggB 117 11 10 99.07% disagreement
adhesins.fa C236-11 Reference AggB 81 0 0 75.70% agreement
adhesins.fa Ion Torrent (1) Newbler AggB 116 9 9 100.00% disagreement
adhesins.fa Ion Torrent (1) MIRA AggB 116 9 9 100.00% disagreement
adhesins.fa Ion Torrent (1+2) Newbler AggB 116 9 9 100.00% disagreement
adhesins.fa Ion Torrent (1+2) MIRA AggB 81 0 0 75.70% agreement
adhesins.fa Ion Torrent (2) Newbler AggB 116 9 9 100.00% disagreement
adhesins.fa Ion Torrent (2) MIRA AggB 116 9 9 100.00% disagreement
adhesins.fa MiSeq (contigs) MIRA AggB 81 0 0 75.70% agreement
adhesins.fa MiSeq (contigs) Velvet AggB 81 0 0 75.70% agreement
adhesins.fa MiSeq (contigs) CLC AggB 81 0 0 75.70% agreement
adhesins.fa MiSeq (scaffolds) Velvet AggB 81 0 0 75.70% agreement
adhesins.fa MiSeq (scaffolds) CLC AggB 81 0 0 75.70% agreement
adhesins.fa 280 Reference Reference AggC 860 0 0 100.00% agreement
adhesins.fa 454 Junior (1) Newbler AggC 769 0 0 89.42% disagreement
adhesins.fa 454 Junior (1) MIRA AggC 853 571 48 32.79% disagreement
adhesins.fa 454 Junior (1+2) Newbler AggC 769 0 0 89.42% disagreement
adhesins.fa 454 Junior (1+2) MIRA AggC 471 7 0 53.95% disagreement
adhesins.fa 454 Junior (2) Newbler AggC 772 2 0 89.53% disagreement
adhesins.fa 454 Junior (2) MIRA AggC 738 7 0 85.00% disagreement
adhesins.fa C236-11 Reference AggC 860 0 0 100.00% agreement
adhesins.fa Ion Torrent (1) Newbler AggC 737 1 0 85.58% disagreement
adhesins.fa Ion Torrent (1) MIRA AggC 404 0 0 46.98% disagreement
adhesins.fa Ion Torrent (1+2) Newbler AggC 731 0 0 85.00% disagreement
adhesins.fa Ion Torrent (1+2) MIRA AggC 769 0 0 89.42% disagreement
adhesins.fa Ion Torrent (2) Newbler AggC 737 1 0 85.58% disagreement
adhesins.fa Ion Torrent (2) MIRA AggC 731 0 0 85.00% disagreement
adhesins.fa MiSeq (contigs) MIRA AggC 860 0 0 100.00% agreement
adhesins.fa MiSeq (contigs) Velvet AggC 550 0 0 63.95% disagreement
adhesins.fa MiSeq (contigs) CLC AggC 860 0 0 100.00% agreement
adhesins.fa MiSeq (scaffolds) Velvet AggC 550 0 0 63.95% disagreement
adhesins.fa MiSeq (scaffolds) CLC AggC 860 0 0 100.00% agreement
adhesins.fa 280 Reference Reference AggD 254 0 0 39.20% agreement
adhesins.fa 454 Junior (1) Newbler AggD 254 0 0 39.20% agreement
adhesins.fa 454 Junior (1) MIRA AggD 225 17 0 32.10% disagreement
adhesins.fa 454 Junior (1+2) Newbler AggD 254 0 0 39.20% agreement
adhesins.fa 454 Junior (1+2) MIRA AggD 254 0 0 39.20% agreement
adhesins.fa 454 Junior (2) Newbler AggD 241 7 2 36.11% disagreement
adhesins.fa 454 Junior (2) MIRA AggD 254 0 0 39.20% agreement
adhesins.fa C236-11 Reference AggD 254 0 0 39.20% agreement
adhesins.fa Ion Torrent (1) Newbler AggD 241 7 2 36.11% disagreement
adhesins.fa Ion Torrent (1) MIRA AggD 141 0 0 21.76% disagreement
adhesins.fa Ion Torrent (1+2) Newbler AggD 241 7 2 36.11% disagreement
adhesins.fa Ion Torrent (1+2) MIRA AggD 141 0 0 21.76% disagreement
adhesins.fa Ion Torrent (2) Newbler AggD 241 7 2 36.11% disagreement
adhesins.fa Ion Torrent (2) MIRA AggD 101 7 2 14.51% disagreement
adhesins.fa MiSeq (contigs) MIRA AggD 254 0 0 39.20% agreement
adhesins.fa MiSeq (contigs) Velvet AggD 231 0 0 35.65% disagreement
adhesins.fa MiSeq (contigs) CLC AggD 254 0 0 39.20% agreement
adhesins.fa MiSeq (scaffolds) Velvet AggD 231 0 0 35.65% disagreement
adhesins.fa MiSeq (scaffolds) CLC AggD 254 0 0 39.20% agreement
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